Citations

Citations to this article as recorded by  

• Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
  Shang-Chin Huang, Jia-Horng Kao
  Clinical and Molecular Hepatology.2026; 32(1): e117.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
  Rui Huang, Mindie H. Nguyen
  Clinical and Molecular Hepatology.2026; 32(1): e85.     CrossRef

Citations

Citations to this article as recorded by  

• Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
  Shang-Chin Huang, Jia-Horng Kao
  Clinical and Molecular Hepatology.2026; 32(1): e117.     CrossRef
• Correspondence to editorial 1 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
  Rui Huang, Mindie H. Nguyen
  Clinical and Molecular Hepatology.2026; 32(1): e83.     CrossRef
• Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus
  Shang-Chin Huang, Jia-Horng Kao
  Biomedical Journal.2026; 49(3): 100969.     CrossRef
• The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
  Shang-Chin Huang, Tai-Chung Tseng
  Gut and Liver.2026; 20(3): 350.     CrossRef
• Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy
  Dong Hyun Sinn, Kyung-Ah Kim, Jung Il Lee, Geum-Youn Gwak
  Journal of Korean Medical Science.2026;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Comparison of the identification and practicability of non-invasive diagnostic indicators under NAFLD, MAFLD and MASLD in China: a cross-sectional study
  Xin-Yun Tan, Hui-Hui Zou, Xinjuan Huang, Man-Jie Guo, Ruo-Ling Yu, Xue-Lian Liu, Ting Peng, Xuan Yang, Chun-Xiang Qin
  BMJ Open.2026; 16(4): e094809.     CrossRef

Citations

Citations to this article as recorded by  

• Sex and gender differences in metabolic dysfunction-associated liver disease
  Rishitha Penmetsa, Sasha Kapil, Lisa B. VanWagner
  Indian Journal of Gastroenterology.2026; 45(2): 192.     CrossRef
• New Definition, New Point of View: Sex and Gender Interpretation of MASLD—Interpretation of Guidelines and Review of the Literature
  Massimo De Luca, Rita Verdoliva, Anna Lombardi, Antonio Giorgio
  Gastroenterology Insights.2026; 17(1): 7.     CrossRef
• The Gut–Liver Axis in MASLD: From Host–Microbiome Crosstalk to Precision Therapeutics
  Ji Zhou, Bowen Zhu, Ziqian Bing, Tingting Wang, Yue Zhao
  Microorganisms.2026; 14(2): 471.     CrossRef
• Sex-specific dynamics of MASLD reveal early hepatic and extrahepatic metabolic deterioration in females despite long-term protection
  Maria Repollés-de-Dalmau, Anna Marsal-Beltran, Catalina Núñez-Roa, Joan Vendrell, Victòria Ceperuelo-Mallafré, Sonia Fernández-Veledo
  Biology of Sex Differences.2026;[Epub]     CrossRef
• Sex-specific cardiometabolic phenotypes in MASLD: 3PM-centric stratification and trajectory mapping for proactive risk assessment
  Carlos José Pirola, Luis Diambra, Tomas Fernández Gianotti, Silvia Sookoian
  EPMA Journal.2026; 17(2): 387.     CrossRef
• Dysregulation of the Gut-Adipose Tissue-Liver Axis: a Possible Mechanism Behind the Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes
  Susanna Longo, Tommaso Giovanni Rinaldi, Jose Manuel Fernández-Real, Massimo Federici
  Current Diabetes Reports.2026;[Epub]     CrossRef
• Correspondence to letter to the editor on “Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease”
  Eiji Kakazu, Masaaki Mino, Tatsuya Kanto
  Clinical and Molecular Hepatology.2026; 32(2): e235.     CrossRef
• MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
  Ilaria Milani, Marianna Chinucci, Frida Leonetti, Danila Capoccia
  Biomedicines.2025; 13(4): 855.     CrossRef
• Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease
  Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou
  BMC Gastroenterology.2025;[Epub]     CrossRef
• Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
  Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang
  Gut and Liver.2025; 19(4): 479.     CrossRef
• Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease
  Bryan Adrian Priego-Parra, Berenice M Román-Calleja, Rocio Gallego-Duran, Jordi Gracia-Sancho, Jose Antonio Velarde Ruiz-Velasco, Jose Maria Remes-Troche
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery
  Stavros P. Papadakos, Chara Georgiadou, Eva Kassi, Rallia-Iliana Velliou, Antonios Chatzigeorgiou
  Expert Opinion on Drug Discovery.2025; 20(12): 1683.     CrossRef

Citations

Citations to this article as recorded by  

• Early burden, enduring risk: The alarming outcomes of pediatric MASLD
  Marialena Mouzaki
  Hepatology.2026; 83(3): 445.     CrossRef
• Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
  Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
  Journal of Advanced Research.2026; 80: 893.     CrossRef
• Population perspectives on benefits and harms of screening for metabolic dysfunction–associated steatotic liver disease
  Alina M. Allen, W. Ray Kim, Patrizia Carrieri, Rachel Canning, Fang-Shu Ou, Joanne Benson, Jessica L. Olson, Sudhakar K. Venkatesh, Jiahui Li, Meng Yin, Maysa Eslami, Richard L. Ehman, Jennifer Hunter Berg, Jeffrey V. Lazarus
  Hepatology.2026; 83(2): 362.     CrossRef
• A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study
  Ho Soo Chun, Minjong Lee, Hye Ah Lee, Eun Seo Park, Jeong Yoon Choi, Hyo Song Baek, Tae Hun Kim, Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jé
  Clinical Gastroenterology and Hepatology.2026; 24(3): 688.     CrossRef
• The OGT–TFF2 axis mediates intrahepatic crosstalk and MASH pathogenesis
  Lei Zhang, Cuijuan Han, Man Mohan Shrestha, Jiamei Le, Wilhelm K. Berger, Yiheng Huang, Reina Desrouleaux, Eric Wang, Laszlo Nagy, Xiaoyong Yang
  Hepatology.2026; 83(5): 1215.     CrossRef
• Socioeconomic Factors Impact the Perception of Healthcare Experiences in Patients with Cirrhosis
  Nicole Ng, Subhanik Purkayastha, Xiaohan Ying, Arun Jesudian, Russell Rosenblatt
  Digestive Diseases and Sciences.2026; 71(2): 486.     CrossRef
• Intersections of vitamin D deficiency, HIV and chronic liver diseases
  Francesca Farina, Aurgho Datta, Suzanne N. Morin, Sahar Saeed, Bertrand Lebouche, Giovanni Guaraldi, Salvatore Petta, Giada Sebastiani
  HIV Medicine.2026; 27(1): 4.     CrossRef
• Hepatocellular carcinoma arising from ectopic liver tissue: a systematic review of the literature
  Sami Akbulut, Tevfik Tolga Sahin
  European Journal of Gastroenterology & Hepatology.2026; 38(3): 243.     CrossRef
• Pubertal exposure to glyphosate-based herbicide aggravates diet-induced steatosis and hormonal dysregulation in adult mice
  Jakeline Liara Teleken, Ana Paula Farina Rosolen, Joseane Morari, Sandra Lucinei Balbo, Rosane Aparecida Ribeiro, Maria Lúcia Bonfleur
  Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(3): 3589.     CrossRef
• Reliable Monitoring of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Using Imaging: A Systematic Literature Review and Meta-Analysis on Measurement Repeatability
  Michael Ndaa, Prashant K. Pandya, Jordan Swensson, Niharika Samala, Saima Ajaz, Deepak Joshi, Walid S. Ayoub, Fatih Akisik
  Endocrine Practice.2026; 32(2): 258.     CrossRef
• Semaglutide, the first approved GLP-1 receptor agonist for the management of metabolic dysfunction-associated steatohepatitis
  Chrysoula Boutari, Michael A. Hill, Christos S. Mantzoros
  Metabolism.2026; 174: 156397.     CrossRef
• NSD2 exacerbates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway
  Yuan Qiao, Yijia Zhang, Cuiting Sun, Qi Jin, Peng Qu, Zecheng Li, Yang Qiu, Hua Meng, Dantao Peng, Liang Peng
  Metabolism.2026; 174: 156416.     CrossRef
• The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD
  Noritaka Wakui, Yu Ogino, Naohisa Kamiyama, Takuma Oguri, Tomoya Uchimura, Takahide Kudo, Kenichi Maruyama, Hideki Nagumo, Naoyuki Yoshimine, Kunihide Mouri, Kojiro Kobayashi, Takanori Mukozu, Teppei Matsui, Hidenari Nagai, Yoshinori Igarashi, Takahisa Ma
  Ultrasound in Medicine & Biology.2026; 52(1): 237.     CrossRef
• Outcome-Specific Cardiovascular and Hypertensive Risk Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights From a Competing Risk Cohort Analysis
  Masashi Hirooka, Teruki Miyake, Ryo Yano, Yoshiko Nakamura, Yuki Okazaki, Toyoki Shimamoto, Atsushi Yukimoto, Yasunori Yamamoto, Takao Watanabe, Osamu Yoshida, Kana Hirooka, Yoshio Tokumoto, Masanori Abe, Takeru Iwata, Yoichi Hiasa
  Gastro Hep Advances.2026; 5(1): 100806.     CrossRef
• Diabetes and the liver
  Ebo Dadey, Tiong Yeng Lim, Janine Makaronidis
  Clinical Medicine.2026; 26(1): 100528.     CrossRef
• Valproic Acid Exacerbates Lipid Accumulation in High‐Fat Hepatocytes Induced by Oleic Acid: Insights From Lipidomic Analysis
  Shansen Xu, Xianglei Ma, Lingli Huang, Tingting Yue, Ya'nan Chen
  Lipids.2026; 61(1): 163.     CrossRef
• Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
  Herbert Tilg, Salvatore Petta, Norbert Stefan, Giovanni Targher
  JAMA.2026; 335(2): 163.     CrossRef
• Recognizing the Burden of Metabolic Liver Disease in IBD
  Raseen Tariq, Richard K Sterling
  Inflammatory Bowel Diseases.2026; 32(3): 584.     CrossRef
• Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis
  Joyce Lui, Yesung Kweon, Mohamed I. Elsaid
  Alimentary Pharmacology & Therapeutics.2026; 63(5): 750.     CrossRef
• Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
  Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu
  Clinical Pharmacology & Therapeutics.2026; 119(2): 336.     CrossRef
• Protective effect of vitamin D on high-fat-diet-induced metabolic dysfunction-associated steatotic liver disease in mice
  Amal A. Mohamed, Wael Hafez, Said El-Feky, Mona G. Khalil, Amina S. Soliman, Karima Nasraldin, Ingy M. Ibrahim, Hanan A. Hegazy, Weam Shaheen, Abbas M. Abbas, Hager Shaheen, Marian FL. Abdelmalak, Hany N. Azzam, Omnia Ezzat, Noheir Ashraf Ibrahem Fathy Ha
  Steroids.2026; 225: 109718.     CrossRef
• The adipokine Isthmin-1 in obesity and its complications: recent research advances
  Yuting Zhuang, Jialuo Liu, Yanling Sui, Jiamin Song, Guoyue Yuan, Li Zhao
  Life Sciences.2026; 384: 124092.     CrossRef
• Integrated network toxicology, molecular docking and transcriptomics reveal the mechanistic role of phthalate esters in metabolic disease pathogenesis
  Yuancheng Shao, Qi Liu, Yicheng Jiang, Gang Zhou, Xihan Gu, Shufan Zhang, Shuai Chen, Jiaming Xue, Liming Tang
  Food and Chemical Toxicology.2026; 207: 115855.     CrossRef
• Commercial glyphosate formulations exceed active ingredient toxicity via mitochondrial ROS and transcriptomic disruption
  Jakeline Liara Teleken, Leticia Prates Roma, Rosane Aparecida Ribeiro, Alex Rafacho, Maria Lúcia Bonfleur
  Toxicology in Vitro.2026; 111: 106178.     CrossRef
• Effects of bariatric surgery on neurological disturbances and quality of life in patients with metabolic dysfunction-associated steatotic liver disease and obesity: a prospective longitudinal study
  Concepción Gómez, Juan José Gallego Roig, María Lapeña, Clara Alfaro-Cervelló, Alessandra Fiorillo, Adrià López-Gramaje, Raquel Alfonso Ballester, Norberto Casinello, María Capilla Lozano, María Desamparados Escudero-García, Cristina Montón, Amparo Urios
  Surgery for Obesity and Related Diseases.2026; 22(1): 113.     CrossRef
• Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases
  Nicola Pugliese, Matteo Spertino, Miriana Mercurio, Stefano Ciardullo, Gianluca Perseghin, Cesare Hassan, Roberto Vettor, Salvatore Petta, Alessio Aghemo
  Clinical Gastroenterology and Hepatology.2026; 24(3): 583.     CrossRef
• Novel dual AMPK/NRF2 activation by leucocyanidin from Hawthorn (Crataegus) for mitochondria repair-Targeted therapy of hepatic steatosis
  Yunheng Li, Minghua Ye, Qiaojun He, Bo Yang, Peihua Luo, Xiaochun Yang
  Phytomedicine.2026; 150: 157614.     CrossRef
• The role of liver sinusoidal endothelial cells in liver diseases: Key players in health and pathology
  Eric Felli, Yeldos Nulan, Martí Ortega-Ribera, Anabel Fernández-Iglesias, Jordi Gracia-Sancho
  Journal of Hepatology.2026; 84(3): 655.     CrossRef
• A comparative study between ultrasound-guided-attenuation-parameter (UGAP), controlled attenuation parameter (CAP), and proton density fat fraction (PDFF) for assessment of hepatic steatosis
  Marie Byenfeldt, Christer Grönlund, Patrik Nasr, Anna Lindam, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg
  Scandinavian Journal of Gastroenterology.2026; 61(1): 124.     CrossRef
• Hepatic steatosis can accurately be measured during free breathing using ultrasound-guided attenuation parameter (UGAP) technology. Technical note
  Marie Byenfeldt, Patrik Nasr, Anna Lindam, Christer Grönlund, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg
  European Journal of Radiology.2026; 195: 112602.     CrossRef
• Platelet Proteomics: A Glimpse Into Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis
  Iulia Minciuna, Maria Iacobescu, Ioana Rusu, Oana Nicoara‐Farcau, Petra Fischer, Andreea Maria Soporan, Ioana Ecaterina Pralea, Horia Stefanescu, Cristina Adela Iuga, Bogdan Procopet
  Hepatology Research.2026; 56(4): 446.     CrossRef
• The nexus of environmental endocrine-disrupting chemical exposure and metabolic dysfunction-associated steatotic liver disease: An emerging public health challenge
  Hongxia Chen, Hong Cui, Zhongji Meng
  Ecotoxicology and Environmental Safety.2026; 309: 119513.     CrossRef
• Transient elastography during pregnancy: a glimpse into maternal liver health
  Seung Mi Lee, Won Kim
  The Lancet Obstetrics, Gynaecology, & Women's Health.2026; 2(1): e2.     CrossRef
• Elevated adipose inflammation, but reduced hepatic triacylglycerol storage in diet-induced obese Plin4−/− mice
  Atanaska Ivanova Doncheva, Ryoko Higa, Prabhat Khanal, Martine Villemo Øksenvåg Ingebrigtsen, Yuchuan Li, Shrikant Kolan, Pratibha Kolan, Ales Kvasnicka, Ingunn Jermstad, Shaista Khan, Bjørn Steen Skålhegg, Svein Olav Kolset, Hilde Nebb, Marit Hjorth, Fro
  Journal of Biological Chemistry.2026; 302(2): 111043.     CrossRef
• Endohepatology: Evolving Indications, Challenges, Unmet Needs and Opportunities
  Akash Roy, Mithun Sharma, Anand V. Kulkarni, Sundeep Lakhtakia, Aniruddha Pratap Singh, Rakesh Kalapala, Gregory G. Ginsberg, D.Nageshwar Reddy, K. Rajender Reddy
  Gastro Hep Advances.2026; 5(2): 100838.     CrossRef
• Effectiveness and safety of saroglitazar in managing dyslipidaemia and liver enzymes in patients with type 2 diabetes, MASLD, and Stage 3 chronic kidney disease: A 12‐month observational study
  Gaurab Bhaduri, Shambo S. Samajdar, Sanjay Bandyopadhyay, Shatavisa Mukherjee, Shashank R. Joshi
  Diabetes, Obesity and Metabolism.2026; 28(3): 2449.     CrossRef
• Association of Liver Fibrosis Fibrosis-4 Score with Perioperative Complications and Mortality: A Retrospective Multicenter Analysis
  Shira Zelber-Sagi, Vikas N. O’Reilly-Shah, Ashish K. Khanna, Peter Rock, Itay Bentov
  Anesthesiology.2026; 144(2): 365.     CrossRef
• Distinct and complementary metabolic effects of GLP-1 and glucagon receptor agonism in diet-induced obese mice
  Marie Winther-Sørensen, Christine Rasmussen, Samuel A.J. Trammell, Caroline Hansen, Mogens Vyberg, Reza Serizawa, Erik A. Richter, Trisha J. Grevengoed, Lise Lotte Gluud, Rune E. Kuhre, Nicolai J. Wewer Albrechtsen
  Peptides.2026; 195: 171462.     CrossRef
• Nutrition in MASLD: a patient focused, evidence-based clinician’s guide
  Katrina Pekarska, Paul N Brennan, Dana Ivancovsky Wajcman, Jennifer Towey, Leah Cox, Katie Weatherby, Stuart McPherson, Jonathan Stine, Jose Willemse, Wenhao Li, William Alazawi, Jeffrey V Lazarus, Richard Parker
  Frontline Gastroenterology.2026; 17(3): 262.     CrossRef
• Noninvasive Assessment of Hepatic Steatosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease Patients by Using Ultrasound Attenuation Imaging
  Kun Wang, Qun Liu, Jing Wang, Minghui Wang, Jinqiao Zhang, Yanjie Yu, Ling Liu, Hairong Liu
  Journal of Ultrasound in Medicine.2026; 45(6): 1209.     CrossRef
• Hepatic adaptation to chronic metabolic stress primes tumorigenesis
  Constantine N. Tzouanas, Jessica E.S. Shay, Marc S. Sherman, Adam J. Rubin, Benjamin E. Mead, Tyler T. Dao, Junyan Tao, Brandon M. Lehrich, George Eng, Jeffrey Patterson-Fortin, Titus Butzlaff, Miyeko D. Mana, Kellie E. Kolb, Chad Walesky, Brian J. Pepe-M
  Cell.2026; 189(2): 435.     CrossRef
• Two‐Step Machine Learning Model Enhances Identification of High‐Risk Metabolic Dysfunction‐Associated Steatotic Liver Disease
  Zheng'ao Xu, Yongfen Zhu, Fengjuan Chen, Qiongyue Fan, Ruiqi Wang, Yilong Fu, Xunxun Wu, Li Zhu, Fushuang Ha, Qing Ye, Chunyan Ye, Xiaoming Chen, Meijie Chen, Jiale Niu, Yangyang Xie, Kaixin Chang, Jiakun Miao, Weili Liu, Junping Shi, Zhongjie Hu, Minghua
  Liver International.2026;[Epub]     CrossRef
• Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study
  Semiu O. Gbadamosi, David Shi, Abdalla Aly, Caichen K. Zhong, Husam Albarmawi, Aidan McGovern, Anthony Hoovler, Carlos Campos
  Diabetes Therapy.2026; 17(2): 251.     CrossRef
• Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic
  Ho Soo Chun, Minjong Lee
  Clinical and Molecular Hepatology.2026; 32(1): 368.     CrossRef
• Linked Intronic Polymorphisms of the PNPLA3 Gene Are Associated with Serum Markers of Liver Injury in Patients with Spontaneous HCV Clearance
  Karina Gonzalez-Aldaco, Luis A. Torres-Reyes, Arturo Panduro, Sonia Roman
  International Journal of Molecular Sciences.2026; 27(1): 473.     CrossRef
• Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction
  Juan Ma, Ning Xie, Ziwei Wang, Xiru Liang, Yulong Han, Qiang Zhao, Ming Wang, Hongwei Lu, Wanyi Kou, William Alazawi, Jinhai Wang, Lu Li, Ning Liu, Na Liu, Haitao Shi, Feng Xu
  Advanced Science.2026;[Epub]     CrossRef
• A sex-specific brake on liver oestrogen signalling
  Pamela Kakimoto, Natalie Krahmer
  Nature Metabolism.2026; 8(1): 8.     CrossRef
• Mesenchymal Stromal/Stem Cell-Based Therapies for Liver Regeneration: Current Status and Future Directions
  Seohyun Choi, Jaemin Jeong
  International Journal of Molecular Sciences.2026; 27(2): 619.     CrossRef
• The burden and mortality impact of cardiovascular disease–metabolic dysfunction–associated steatotic liver disease comorbidity
  Siyuan Tan, Ting Huang, Zixi Zhang, Jiabao Zhou, Hao Chen, Tao Tu, Qiuzhen Lin, Yichao Xiao, Qiming Liu
  Diabetes Research and Clinical Practice.2026; 232: 113092.     CrossRef
• Non-alcoholic fatty liver disease in Northeast India: a narrative review of rising metabolic syndrome
  Shiludi Longkumer, Maitrayee Dutta Swargiary
  Egyptian Liver Journal.2026;[Epub]     CrossRef
• Dose‒response relationship between exercise and hepatic steatosis: A systematic review with Bayesian network meta-analysis of randomized controlled trials
  Xinyun Tan, Huihui Zou, Manjie Guo, Jiayu Liu, Xinjuan Huang, Ruoling Yu, Xuelian Liu, Chunxiang Qin
  Journal of Sport and Health Science.2026; 15: 101125.     CrossRef
• Kefiran, a polysaccharide from kefir grain, modulates gut microbiota and hepatic metabolism to mitigate metabolic dysfunction-associated steatotic liver disease
  Yuanyuan Cui, Jiajia Zhu, Jun Xi, Changhe Ding, Jun Meng
  International Journal of Biological Macromolecules.2026; 341: 150147.     CrossRef
• Assessment of the Diagnostic Performance and Clinical Impact of AI in Hepatic Steatosis: Systematic Review and Meta-Analysis
  Jiamei Song, Dan Liu, Jitong Li, Haoru Cong, Ruixue Deng, Yihan Lu, Jiayi Sun, Jingzhou Zhang
  Journal of Medical Internet Research.2026; 28: e78310.     CrossRef
• Multi-Omics Evidence Linking Depression to MASLD Risk via Inflammatory Immune Signaling
  Keye Lin, Yiwei Liu, Xitong Liang, Yiming Zhang, Zijie Luo, Fei Chen, Runhua Zhang, Peiyu Ma, Xiang Chen
  Biomedicines.2026; 14(1): 174.     CrossRef
• Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Dise
  Savvoula Savvidou, Elektra Augousti-Varela, Aikaterini Damianakou, Miltiadis Chalkias, Ioannis Stergiou
  Metabolic Syndrome and Related Disorders.2026; 24(3): 121.     CrossRef
• Oxidative stress in metabolic dysfunction-associated steatohepatitis: Mechanisms and emerging therapeutic strategies
  Yidan Chen, Hui Yu, Xinyu Kai, Runting Yin, Zhen Ouyang, Yuan Wei, Cai Zhang
  Biochemical Pharmacology.2026; 246: 117702.     CrossRef
• Diet intervention altered DNA methylation of potassium voltage-gated channel subfamily Q member 1 in metabolic dysfunction-associated steatohepatitis
  Xinyu Shi, Hualing Song, Xinying Xiong, Shuang Wei, Lei Zhang, Shengfu You, Wenjun Zhou, Guang Ji, Baocheng Liu, Na Wu
  Clinical Epigenetics.2026;[Epub]     CrossRef
• Mechanisms of scramblases in regulating hepatic lipoprotein secretion and autophagy
  Allen Chen, Chen Zhang, Wen-Xing Ding, Hong-Min Ni
  Journal of Lipid Research.2026; 67(2): 100979.     CrossRef
• Artificial Intelligence for Fibrosis Diagnosis in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review
  Neilson Silveira de Souza, Théo Cordeiro Veiga Vitório, Raphael Augusto de Souza, Marcos Antônio Dórea Machado, Helma Pinchemel Cotrim
  Diagnostics.2026; 16(2): 261.     CrossRef
• Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study
  Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai
  Hepatology International.2026; 20(2): 292.     CrossRef
• Diagnostic Utility of Serum Activating Transcription Factor 4 and Toll-like Receptor 4 as Early Biomarkers of Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease
  Isa Yalcinkaya, Iskender Ekinci, Seyma Dumur, Eda Nur Duran, Hafize Uzun, Melda Yalcinkaya, Elif Kadioglu Yeniyurt, Omer Vehbi Alpaydin, Gulden Anataca, Omur Tabak
  Journal of Clinical Medicine.2026; 15(2): 559.     CrossRef
• Use of Artificial Intelligence-Assisted Histopathology for Evaluation of Sex-Specific Progression and Regression of Hepatocellular Carcinoma Related to Metabolic Dysfunction-Associated Fatty Liver Disease
  Ke Yin, Yuyun Song, Ran Fei, Xu Cong, Baiyi Liu, Zilong Wang, Xin Ai, Minjun Liao, Yayun Ren, Kutbuddin Akbary, Wei Wang, Qiang Yang, Xiao Teng, Nan Wu, Huiying Rao, Xiaoxiao Wang, Feng Liu
  Diagnostics.2026; 16(2): 234.     CrossRef
• Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs
  Lei Yang, Jiale Ruan, Yingying Fang, Anyi Xu
  Frontiers in Medicine.2026;[Epub]     CrossRef
• Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation
  Senping Xu, Zhaoshan Zhang, Zhongquan Zhou, Jiawei Guo
  Biology.2026; 15(2): 148.     CrossRef
• Phosphatidylserine Supplementation Improves Metabolic Liver Disease and Glycemic Control in the Presence of Suppressed Oxidative Glucose Metabolism
  Li Dong, Sihan Lin, John Slavin, Satya Gunnam, Zhili Cheng, Shuai Nie, Michael G. Leeming, Nicholas A. Williamson, Magdalene K. Montgomery
  Diabetes.2026; 75(2): 273.     CrossRef
• Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH
  Weiheng Wen, Zenghui Liu, Wenliang Tan, Yingzheng Tan, Wei Li, Jian Wan, Hongsai Hu, Zhengwu Jiang, Xing Tang, Jing Yang, Jiao Xiao, Xiongjin Tan, Xun Chen, Peili Wu, Yukun Li
  npj Digital Medicine.2026;[Epub]     CrossRef
• Morphological characterization of a novel model of steatohepatitis in the FAH -/- pig
  Silvana N. Wilken, Philipp Felgendreff, Anna Minshew, Boyukkhanim Ahmadzada, Seyed M. Hosseiniasl, Sara Kazeminia, Kachi Ezenekwe, Ameya Patil, Byoung U. Park, Ahmer Sultan, Lindsey Smith, Julio Cisneros Correa, Kamal Hussein, Harmeet Malhi, Roger K. More
  Veterinary Pathology.2026; 63(4): 746.     CrossRef
• Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts
  Huangxin Zhu, Lihua Liu, Sicheng Yang, Yunfeng Fu, Yating Pan, Qingan Fu, Fan Du, Xiaodong Zhou
  Cardiovascular Diabetology.2026;[Epub]     CrossRef
• Stemness CD24 activation promotes hepatocellular carcinoma progression via an immune escape mechanism
  Yin Cai, Lu-Yin Liu, Xiao-Xiao Xia, Hao Tang, Min Xu, Wen-Li Sai, Deng-Fu Yao, Min Yao
  World Journal of Gastroenterology.2026;[Epub]     CrossRef
• Targeting the 4-HNE–H₂S pathway as a therapeutic strategy for placental injury in pregnancy with MAFLD
  Tianxiao Hu, Jiayu Qi, Yinuo Xu, Jia He, Qingying Tan, Jie Hao, Jing Wang, Jiewei Hong, Jianwei Wang, Lin Chen, Xiaobing Dou
  International Immunopharmacology.2026; 172: 116245.     CrossRef
• Association of the Triglyceride-Glucose Index With Established Cardiovascular Disease in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study
  Soumayan Mondal, Sidharth S Pattnaik, Nihar Ranjan Mohanty, Sailendra Nayak, Ambika Mohanty, Shubhransu Patro
  Cureus.2026;[Epub]     CrossRef
• Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk
  Qiqi Zhao, Shengwen Lu, Yu Guan, Zhiwen Sun, Shi Qiu, Aihua Zhang
  Lipids in Health and Disease.2026;[Epub]     CrossRef
• Prognostic value of non-invasive fibrosis assessment scores in predicting mortality among individuals with metabolic dysfunction-associated steatotic liver disease
  Lingjie Wu, Shunling Cai, Zhongbin Lin, Ruilie Chen, Yuanfeng Zhang, Xiaobing Gong
  BMC Public Health.2026;[Epub]     CrossRef
• Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes
  Anna V. Naumova, Guilherme Moura Cunha, Nicole J. Kim, Jie Lu, Daniel Isquith, Baocheng Chu, Charles Maynard, Arash Mahdavi, Negar Firoozeh, Karen Ordovas, Xue‐Qiao Zhao, Francis Kim
  Obesity.2026; 34(3): 622.     CrossRef
• Association Between Metabolically Associated Steatotic Liver Disease (MASLD) and Cardiovascular Risk Scores in Urban Adults
  FARIS HUSSAIN, KELVIN KANAYO NWABUEZE, FATIMA IJAZ, SONIA OUTALEB, MAHMUDUL HASAN NAHID, SYED ABID, MARIAM SALEEM, KHANT NYI ZAYA, SAIFULLAH SYED, HUMAIRA JANANTH, MANAHIL ZARIEF
  Juntendo Medical Journal.2026; 72(1): 54.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in Tanzania: prevalence and predictors
  Evangelista Malindisa, Illuminata Kafumu, Allen Rweyendera, Elisha Mkemangwa, David Majinge, Igembe Nkandala, Paulina Manyiri, Semvua Kilonzo
  BMC Endocrine Disorders.2026;[Epub]     CrossRef
• Body mass index and metabolic dysfunction associated steatotic liver disease remission among Chinese adults in a retrospective cohort study
  Jiwen Zhang, Yuyin Guo, Bi’e Li, Jiaqian Zhu, Chuang Gao, Qiongdan Zhang, Yong Han, Chuxuan Gu
  Scientific Reports.2026;[Epub]     CrossRef
• 12,13-diHOME ameliorates MASLD by regulating Sestrin2-mediated AMPK/ULK1/Lipophagy in obese mice
  Kexin Zhang, Chengxia Kan, Hongyan Qiu, Junfeng Shi, Jian Chen, Tianpeng Zheng, Jingwen Zhang, Yujie Ma, Sufang Sheng, Ningning Hou, Fang Han, Xiaodong Sun
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026; 1872(4): 168186.     CrossRef
• Burden of MASLD and liver fibrosis: evidence from Phenome India cohort
  Meghana Arvind, Anshul Verma, Sreeshma Raj K, Satyartha Prakash, Vignesh S. Kumar, Mohammad Azhar Uddin, Ayushi Narayan, Mamta Rathore, Nancy Rawat, Ankita Sahu, Yogesh Kumar, Pulkit Hasmukhbhai Leuva, Monika Sharma, Rajesh S, Dwaipayan Saha, Ankita Mridh
  The Lancet Regional Health - Southeast Asia.2026; 45: 100723.     CrossRef
• Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment
  Ina Bergheim, Jean Francois Cadranel, Jianguo Chen, Wenxing Ding, Robert Eferl, Carmen Garcia-Ruiz, Hartmut Jaeschke, Firouzeh Kazerouni, Amedeo Lonardo, Derek A. Mann, Nahum Méndez-Sánchez, Camelia Mokhtari, Han Moshage, Chiara Raggi, Pavel Strnad, Oren
  Exploration of Digestive Diseases.2026;[Epub]     CrossRef
• Prevalence and risk factors for metabolic dysfunction–associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort
  Oumarou Nabi, Jonas Spaak, Göran Bergström, Gunnar Engström, Carl Johan Östgren, Andrei Malinovschi, Joel Kullberg, Anders Blomberg, Tomas Jernberg, Daniel P. Andersson, Hannes Hagström
  Journal of Internal Medicine.2026; 299(4): 481.     CrossRef
• Interactions Between the Gut Microbiome and Genetic and Clinical Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus from Different Geographical Regions of Argentina
  Bárbara Suarez, Adriana Mabel Álvarez, María Florencia Mascardi, Ana Laura Manzano Ramos, Dong Hoon Woo, María Mercedes Gutiérrez, Guillermo Alzueta, María del Carmen Basbus, Santiago Bruzone, Patricia Cuart, Guillermo Dieuzeide, Teresita García, Olga Esc
  Life.2026; 16(2): 283.     CrossRef
• Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
  Abdulrahman Ismaiel, Vera Ciornolutchii, Stefan‐Lucian Popa, Dan L. Dumitrascu
  European Journal of Clinical Investigation.2026;[Epub]     CrossRef
• Predictive factors of metabolic dysfunction associated steatotic liver disease (MASLD) among individuals with cardio-metabolic risk factors, multicenter cross-sectional study, North East Ethiopia
  Getachew Bizuneh Aydagnuhm, Aklile Semu Tefera, Gebru Tesfaw Getahun, Ermiyas Endewunet Melaku
  BMC Gastroenterology.2026;[Epub]     CrossRef
• Temporal trends and racial/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022
  Wenzhan Jing, Hang Pham, Samuel So
  JHEP Reports.2026; 8(4): 101754.     CrossRef
• Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence
  Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Jorge L. Poo, Nahum Méndez-Sánchez
  Archives of Medical Research.2026; 57(4): 103387.     CrossRef
• Long-term dementia risk in metabolic dysfunction-associated steatotic liver disease: a population-based study
  Andreas Bartholdy, Kristine Frøsig Moseholm, Pernille Yde Nielsen, Nicolai J. Wewer Albrechtsen, Lise Lotte Gluud, Majken Karoline Jensen
  Metabolic Brain Disease.2026;[Epub]     CrossRef
• Outils diagnostiques de la fibrose hépatique dans la stéatohépatite dysmétabolique
  Candice Gea, Guillaume Feugray, Valéry Brunel
  Revue Francophone des Laboratoires.2026; 2026(579): 36.     CrossRef
• Mitochondrial dysfunction in MASH: Focusing on chronic inflammation and intercellular communication
  Wanyi Luo, Muxin Yu, Chuwei Zheng, Xiaowen Li, Xiaotian Ma, Guocheng Zeng, Jinming Zhang, Xia Ji, Liyan Sun
  Biochemical and Biophysical Research Communications.2026; 804: 153356.     CrossRef
• Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
  Markos Kalligeros, Laurent Castera, Emmanuel A. Tsochatzis, Naim Alkhouri
  Clinics in Liver Disease.2026; 30(2): 323.     CrossRef
• La ballonisation hépatocytaire : une nouvelle cible thérapeutique dans la Physiopathologie de la MASH
  Arthur Cens, Bart Staels, Réjane Paumelle
  Revue Francophone des Laboratoires.2026; 2026(579): 28.     CrossRef
• Febuxostat Improves MASLD in Male Rats: Roles of XOR Inhibition and Associated JNK/NRF2/HO-1 Pathway Changes
  Zhiyu Pu, Yangyang Cen, Bowen Yang, Kaijun Xing, Linxi Lian, Xi Chi, Jianjun Yang, Yannan Zhang
  International Journal of Molecular Sciences.2026; 27(2): 1069.     CrossRef
• Association between blood heavy metal levels and subtypes of steatotic liver disease: A nationally representative cross-sectional analysis in South Korea
  Ji Hye Choi, Juyeong Kim, Yesol Yim, Hyunjee Kim, Jiyoung Hwang, Ho Geol Woo, Sang Youl Rhee, Yerin Hwang, Dong Keon Yon
  Medicine.2026; 105(4): e47365.     CrossRef
• Biological aging across the metabolic dysfunction–associated steatotic liver disease spectrum: A systematic review
  Chukwuemeka E. Ogbu, Stella C. Ogbu, Chidera P. Ogbu, Chinazor Umerah
  iLIVER.2026; 5(1): 100222.     CrossRef
• Fermented Foods and the Gut–Liver Axis: Modulation of MASLD Through Gut Microbiota
  Agnieszka Wesołek-Leszczyńska, Dawid Rosiejka, Kalina Bogdańska, Paweł Bogdański
  Nutrients.2026; 18(3): 542.     CrossRef
• Association of four insulin resistance indices with liver‐related adverse outcomes: A prospective cohort study
  Xiao‐Meng Wang, Hao Yan, Wen‐Fang Zhong, Jia‐Hao Xie, Huan Chen, Jun‐Jie Wang, Wei‐Qi Song, Dong Shen, Pei‐Dong Zhang, Xi‐Ru Zhang, Jiao‐Jiao Ren, Dan Liu, Zhi‐Hao Li, Chen Mao
  Diabetes, Obesity and Metabolism.2026; 28(5): 3598.     CrossRef
• Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials
  Khalid I. AlHussaini
  Frontiers in Medicine.2026;[Epub]     CrossRef
• Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia
  Yusuf Yilmaz, Alina M. Allen, Jérôme Boursier, Juan P. Arab
  Clinics in Liver Disease.2026; 30(2): 289.     CrossRef
• Associations of relative fat mass with metabolic dysfunction–associated steatotic liver disease and liver fibrosis: evidence from the U.S. NHANES 2017–2023
  Hai-Yuan Zhong, Ling-Dan Ma, Jin-Cheng Li, Dan Jiang, Yu-Mei Qin, Ming-Yu Lai, Guang Xiong
  BMC Gastroenterology.2026;[Epub]     CrossRef
• Gut microbiota, liver disease, and perioperative anesthesia: interactions, risks, and therapeutic opportunities
  Lei Shi, Ye Yu, Zihan Ma, Weiyi Jiang
  Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
• Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease
  Jeffrey V. Lazarus, Christopher J. Kopka, Aina Nicolàs, Safura Abdool Karim, Meena B. Bansal, Michael Betel, John F. Dillon, Pere Gines, Aleksander Krag, Veronica Miller, Cynthia A. Moylan, Alisa Pedrana, Paula Petrone, Jörn M. Schattenberg, Sunil S. Solo
  Nature Reviews Gastroenterology & Hepatology.2026; 23(4): 355.     CrossRef
• SIRT3 ameliorates hepatic inflammation, oxidative stress, and fibrosis in HFD- or MCD diet-fed mice
  Huifang Lv, Wenyue Sun, Cuixia Tian, Chunyong Bian, Zhongting Lu, Xin Guo
  The Journal of Nutritional Biochemistry.2026; 152: 110276.     CrossRef
• Paulobutalipin, a Lipid Accumulation Inhibitor from a Streptomyces sp.
  Thanh-Hau Huynh, Hoseo Lee, Sangwook Kang, Jeong-Hyeon Kim, Huiyeong Ju, Ki-Bong Oh, Sang-Jip Nam, Ja Hyun Koo, Dong-Chan Oh
  Journal of Natural Products.2026; 89(2): 682.     CrossRef
• MASLD, MASH, and the CKM Spectrum
  Faiez Zannad, Muhammad Shahzeb Khan, Nisha Bansal, Michael Böhm, Sven M. Francque, Nicolas Girerd, James L. Januzzi, Veronica Miller, Marie-Eve Piché, Vlad Ratziu, Bart Staels, Harriette G.C. Van Spall, Arun J. Sanyal, Javed Butler
  JACC.2026; 87(15): 2006.     CrossRef
• Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction–associated steatotic liver disease and its progression to hepatocellular carcinoma
  Thomai Kouti, Panayiota Christodoulou, Stephanos Christodoulides, Foula Protopapa, Charalambos Michaeloudes, Paraskevi A. Farazi
  Frontiers in Nutrition.2026;[Epub]     CrossRef
• Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and inter
  Lanlan Chen, Paul Horn, Frank Tacke
  Diabetes, Obesity and Metabolism.2026; 28(S2): 46.     CrossRef
• MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review
  Adela Gabriela Ştefan, Adina Mitrea, Diana Clenciu, Ionela Mihaela Vladu, Maria Magdalena Roşu, Diana Cristina Protasiewicz-Timofticiuc, Theodora Claudia Radu-Gheonea, Ion-Cristian Efrem, Anca Maria Amzolini, Beatrice Elena Vladu, Ana-Maria Efrem, Delia-V
  Medicina.2026; 62(2): 325.     CrossRef
• The active components of the Danshen-Shanzha herb-pair exert a protective effect on MASLD by synergistically promoting fatty acid oxidation via the activation of PPARα, Plin-5 and Plin-2
  Ying Yang, Yaxing Li, Zirong Zhou, Hui Li, Yihan Ma, Wenjie Bi, Mengjiao Li, Xiaoli Liu, Qiang Jia, Liwen Han, Songsong Wang
  Journal of Ethnopharmacology.2026; 362: 121374.     CrossRef
• Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases
  I. Commins, D. Clayton-Chubb, N. Janko, A. Majeed, W. Kemp, S. K. Roberts
  Medical Sciences.2026; 14(1): 84.     CrossRef
• Detection of hepatic steatosis with ultrasound-guided attenuation parameter (UGAP) in metabolic dysfunction-associated steatotic liver disease (MASLD) compared with proton density fat fraction (PDFF): Impact of measurement number and region of interest (R
  Marie Byenfeldt, Christer Grönlund, Patrik Nasr, Anna Lindam, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg
  Ultrasound.2026;[Epub]     CrossRef
• Artificial intelligence and digital transformation of gastroenterology and hepatology: A critical review of clinical applications and future challenges
  Miguel Suarez, Raquel Martínez, Félix González-Martínez, Ana María Torres, Jorge Mateo
  World Journal of Hepatology.2026;[Epub]     CrossRef
• Efficacy of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease: an umbrella review of meta-analyses on liver enzymes
  Alsu R. Khurmatullina, Dmitrii N. Andreev, Igor V. Maev, Andrey V. Zaborovsky, Yury A. Kucheryavyy, Petr A. Beliy, Philipp S. Sokolov
  Frontiers in Medicine.2026;[Epub]     CrossRef
• Panax notoginseng Saponins Ameliorate High‐Fat Diet‐Induced Liver Injury via Mechanisms Involving TLR4‐Mediated Signaling and Lipid Metabolism
  Rong Li, Junyu Ma, Mengyao Li, Bangzhao Zeng, Xuexun Li, Xiaoyan Bi, Xin Zhao, Qin Gao, Yanling Yao, Yang Jiang, Chunmei Zhang, Fuli Ya
  Food Science & Nutrition.2026;[Epub]     CrossRef
• MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5
  Morgan C. Nelson, Liam C. O’Malley, Soh-Hyun Lee, Kaylyn M. Bauer, Arevik Ghazaryan, William W. Tang, Chad VanSant-Webb, Van B. Tran, Colton Hernandez, Ben Battistone, Amber Thibeaux, June L. Round, Micah J. Drummond, H. Atakan Ekiz, Kimberley J. Evason,
  Cancer Research Communications.2026; 6(2): 359.     CrossRef
• Imaging in MASLD
  Sudhakar K. Venkatesh
  Expert Review of Gastroenterology & Hepatology.2026; 20(3): 257.     CrossRef
• Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors
  Júlia Mayumi Tomaru, Iara Ribeiro Nunes, Caroline Fernandes de Souza Santiago, Alda Maria Machado Bueno Otoboni, Claudemir Gregorio Mendes, Adriana Maria Ragassi Fiorini, Elen Landgraf Guiguer, Claudia Cristina Teixeira Nicolau, Antonelly Cassio Alves Car
  Nutrients.2026; 18(4): 636.     CrossRef
• Occurrence and prognosis of metabolic dysfunction-associated steatosis liver disease and gastrointestinal tumors: a systematic review and meta-analysis
  Siyu Duan, Yiyi Wei, Zhuoyu Ding, Chaomin Pan, Li Yang, Yan Gu, Xinke Wang
  PeerJ.2026; 14: e20616.     CrossRef
• Liver involvement in dengue virus infection: a narrative review
  Madunil Anuk Niriella, Ravini Amila Premaratna, Shashini Hathurusinghe, Ranjan Premaratna, Anuradha Supun Dassanayake, Hithanadura Janaka de Silva
  Journal of Clinical Virology Plus.2026; 6(2): 100247.     CrossRef
• Toll Like Receptor 4: A Potential Link Between Obesity and Metabolic Diseases
  Ghadeer Alhamar, Joanna Razafiarison, Fawaz Alzaid, Fahd Al‐Mulla, Rasheed Ahmad
  Obesity Reviews.2026;[Epub]     CrossRef
• Editorial: Pharmacological and nutritional approaches to metabolic associated fatty liver disease: a step towards achieving SDG 3
  Mahmut Bodur, Bojana Vidović, Anastasios Nikolaou, Birsen Yilmaz
  Frontiers in Pharmacology.2026;[Epub]     CrossRef
• Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus
  Jiwon Yang, Yeongseok Hwang, Jin-Sung Ju, Seungbong Han, Jihyun An, Ju Hyun Shim
  Hepatology.2026;[Epub]     CrossRef
• A novel C/EBPα–miR-335-5p–PRKAA2 regulatory axis drives hepatic lipid accumulation in MASLD
  Xiying Zeng, Yajing Xu, Sufang You, Honghong Duan, Qingyan Cai, Huibin Huang
  Scientific Reports.2026;[Epub]     CrossRef
• Altered Tryptophan–Kynurenine Pathway and Low-Grade Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Insights from LC–MS/MS–Based Metabolite Profiling
  Kübranur Ünal, Leyla İbrahimkhanlı, Mehmet Emre Erol, Nemat İbrahimkhanlı, Sabri Engin Altıntop, Mahi Nur Cerit, Ethem Turgay Cerit, Halit Nahit Şendur
  International Journal of Tryptophan Research.2026;[Epub]     CrossRef
• Modulation of metabolic, inflammatory, fibrotic, and cell death pathways by resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a transcriptomic profiling study
  Chen-yang He, Zhi-hua Wang, Jian-ping Weng, Hans Strijdom, Suo-wen Xu
  Acta Pharmacologica Sinica.2026; 47(4): 1070.     CrossRef
• From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies
  Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang
  Portal Hypertension & Cirrhosis.2026; 5(2): 170.     CrossRef
• Inflammation burden index as a complementary marker for the assessment of hepatic steatosis and fibrosis: evidence from NHANES 2017–2018
  Shaoguang Chen, Lixiao Zhu, Yulou Jiang
  Abdominal Radiology.2026;[Epub]     CrossRef
• Deubiquitinase USP2 promotes hepatic stellate cell activation via p300 stabilization
  Seunghee Byun, Hyunsik Kim, Sun‐Ho Lee, Jae‐Hwan Kwon, Hyunseung Kim, Jung‐Yoon Yoo, Soo‐Yeon Park, Ho‐Geun Yoon
  FEBS Letters.2026; 600(9): 1318.     CrossRef
• Epidemiological Trajectories and Quality of Care Disparities of MASLD in Asia, 1990–2023
  Kexin Zhang, Wei Xu, Chengxia Kan, Sufang Sheng, Fang Han, Jian Chen, Xuan Li, Ningning Hou, Xiaodong Sun, Ying Xue
  Digestive Diseases and Sciences.2026;[Epub]     CrossRef
• Impact of different subtypes of steatotic liver disease on immune checkpoint inhibitor-related drug-induced liver injury: a retrospective study
  Tianyi Ma, Zhanfang Guo, Haijia Bi, Huawei Yuan, Yu Li, Mei Sun
  European Journal of Gastroenterology & Hepatology.2026; 38(3): 351.     CrossRef
• Triglyceride glucose index—a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging
  Guodong Yang, Wenli He, Xin Qiu, Shuang Shen, Peishu Li, Yifei Feng, Jiayuan Zhang, Bangde Xiang
  Cardiovascular Diabetology.2026;[Epub]     CrossRef
• The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging
  Tugce Apaydin, Haluk Tarik Kani, Caglayan Keklikkiran, Yusuf Yilmaz, Dilek Gogas Yavuz
  Journal of Endocrinological Investigation.2026; 49(5): 1029.     CrossRef
• From Childhood to Old Age: Current Knowledge and Practical Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease
  Iwona Gorczyca-Głowacka, Michał Tarnowski, Anna Zmelonek-Znamirowska, Przemysław Wolak
  Journal of Clinical Medicine.2026; 15(4): 1536.     CrossRef
• Development of a Lipidomics-Based Cell Screening Platform for Indirect Antioxidants Targeting Oxidized Lipid Droplet Formation and Mitochondrial Membrane Abnormality
  Yuzu Shibata, Toshihiro Sakurai, Akiko Sakurai, Misuzu Sato, Shu-Ping Hui
  Nutrients.2026; 18(5): 719.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications
  Menatalla M. A. Mohamed, Maha M. M. I. Taha, Mohnd M. M. R. Ibrahim
  ASIDE Gastroenterology.2026; 2(2): 15.     CrossRef
• Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography
  Hidenao Noritake, Takafumi Inoue, Takashi Yonekura, Hiroki Tamakoshi, Yuya Ida, Moe Matsumoto, Tomohiko Hanaoka, Maho Yamashita, Masahiro Umemura, Kazuyoshi Ohta, Takeshi Chida, Kazuhito Kawata
  Journal of Clinical Lipidology.2026; 20(5): 947.     CrossRef
• Fecal microbiota transplantation alleviates steatosis and inflammation in high-fat and high-sugar diet-induced fatty liver in mice
  Fangxia Mi, Jinglu Guo, Wentao Zheng, Jianwei Shen, Hua Ye
  Frontiers in Cell and Developmental Biology.2026;[Epub]     CrossRef
• Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4α
  Xinru Chen, Nga Nguyen, Susan E. Turner, Albert K. Tai, Manal F. Abdelmalek, Lidija Covic, Athan Kuliopulos
  JHEP Reports.2026; 8(6): 101796.     CrossRef
• Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease
  Jason N. Chen, Bulent Tolga Delibasi, James Wang, Thomas Tran, Connie Hu, Charles W. Randall
  BMC Gastroenterology.2026;[Epub]     CrossRef
• Rab5 nucleotide binding promotes oxidative metabolism to fuel hepatocellular carcinoma cell proliferation
  Kelly O. Otakhor, Mohd Ali Abbas Zaidi, Rebecca E. Oberley-Deegan, Moorthy P. Ponnusamy, Kurt W. Fisher, Micah B. Schott
  Journal of Biological Chemistry.2026; 302(4): 111321.     CrossRef
• Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis
  Gang Zhou, Xihan Gu, Xinyao Zhou, Shuai Chen, Hanyang Liu, Jing Wang
  BMJ Open Gastroenterology.2026; 13(1): e002123.     CrossRef
• Epigenetic regulation in MASLD – insight for therapeutic target discovery
  Jan H. Britsemmer, Nuria Lopez Alcantara, Henriette Kirchner
  Epigenomics.2026; 18(3): 311.     CrossRef
• Astaxanthin alleviates altered hepatic lipid metabolism and oxidative stress in animals fed a high-sucrose diet
  Matias Rodrigo Vargas, María del Rosario Ferreira, Paola Inés Ingaramo, Pablo Collins, María Eugenia D’Alessandro
  Frontiers in Nutrition.2026;[Epub]     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa
  Mohamed El-Kassas, C. Wendy Spearman, Manal El-Sayed, Zobair M. Younossi
  Clinics in Liver Disease.2026; 30(2): 513.     CrossRef
• Patients’ Experience of Stigma as the Hidden Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Descriptive Qualitative Study with Thematic Analysis
  Johanne Lisa Jensen-LeBlanc, Pernille Andreassen, Mette Munk Lauridsen, Lea Ladegaard Grønkjær
  Healthcare.2026; 14(5): 579.     CrossRef
• Targeting magnesium homeostasis: a novel therapeutic strategy for liver diseases
  Lili Ji, Hanhan Yu, Ruwen Wang, Hongmei Yan, Xiaofeng Yin, Shanshan Guo, Ru Wang
  Frontiers in Nutrition.2026;[Epub]     CrossRef
• The Role of Butyrate in People with Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Metabolic Comorbidities: A Systematic Review
  Alicia González-González, Virginia Soria-Utrilla, María Isabel Fontalba-Romero, María Ángeles Núñez-Sánchez, Antonio Adarve-Castro, María Isabel Queipo-Ortuño, Bruno Ramos-Molina, José Ignacio Martínez-Montoro, José Carlos Fernández-García
  Current Obesity Reports.2026;[Epub]     CrossRef
• Creatinine-to-body weight ratio as an independent predictor of hepatic steatosis severity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
  Xiaoning Sun, Xiaozhong Wang, Ayesha Younas, Shuanghu Wang, Muhammad Sohail, Jiaojian Lv, Zuxiu Huang, Yunxiao Liu
  BMC Gastroenterology.2026;[Epub]     CrossRef
• Metabolic liver imaging: What you need to know
  Luigi Asmundo, Amirkasra Mojtahed, Samay Prakash, Theodore T. Pierce, Jingwei Wei, Angelo Vanzulli
  Digestive and Liver Disease.2026; 58(4): 433.     CrossRef
• Gut microbiota supportive dietary pattern associated with reduced MASLD risk mediated by metabolomic profiles: a prospective cohort study
  Dong-Run Li, Ke-Ru Li, Ying Wang, Jia-Qi Zheng, Wen-Rui Zheng, Bang-Quan Liu, Jia-Cheng Liu, Rui-Han Bao, Ting-Ting Gong, Qiu-Ju Sheng, Shan-Yan Gao, Qi-Jun Wu
  Nutrition Journal.2026;[Epub]     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America
  Claudia P. Oliveira, Mario Guimarães Pessoa, Luis Antonio Diaz, Juan Pablo Arab, Adrian Gadano, Marco Arrese
  Clinics in Liver Disease.2026; 30(2): 529.     CrossRef
• Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study
  Chao Yan, Xinxin Shen, Shaojie Han, Jinzheng He, Tongxu Wang, Xiaobing Gong, Jindong Ding Petersen
  Journal of Translational Medicine.2026;[Epub]     CrossRef
• Retatrutide in type 2 diabetes mellitus and obesity: an overview
  Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic, Nikolaos Papanas
  Expert Review of Clinical Pharmacology.2026; 19(4): 313.     CrossRef
• Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
  Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha
  Liver International.2026;[Epub]     CrossRef
• Optimal screening criteria for metabolic dysfunction-associated steatotic liver disease with fibrosis
  Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
  Annals of Hepatology.2026; 31(2): 102199.     CrossRef
• The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases
  Yirui Hu, Ye Yang, Shuyan Wang, Huikuan Chu
  npj Biofilms and Microbiomes.2026;[Epub]     CrossRef
• Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD
  Alex E. Henney, Jo Wilson, David R. Riley, Uazman Alam, Daniel J. Cuthbertson
  Liver International.2026;[Epub]     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer: A Nationwide Cohort Study
  Min Jin Jeong, Yong Seok Lee, Youn Jin Choi, Kyung Do Han
  Cancers.2026; 18(6): 894.     CrossRef
• Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
  Leonidas Diamantopoulos, Markos Kalligeros, Scott D. Isaacs, Didac Mauricio
  Clinics in Liver Disease.2026; 30(2): 271.     CrossRef
• Hospitalization Trends Due to Chronic Liver Diseases: Vicious Circle of Co-Morbidities and Hospitalization Length
  Ivana Pantic, Nikola Grubor, Sofija Lugonja, Nina Rajovic, Svetlana Miltenovic, Marija Brankovic, Tijana Gmizic, Tamara Milovanovic
  Clinics and Practice.2026; 16(3): 57.     CrossRef
• Integrated multi-omics analysis identifies and validates endoplasmic reticulum stress and mitophagy-related biomarkers in MASLD
  Quanrun Chen, Limin Liu, Jinqiu Feng, Chong Zhang, Zongming Zhang
  Scientific Reports.2026;[Epub]     CrossRef
• Non-invasive risk stratification of metabolic dysfunction-associated steatotic liver disease and liver fibrosis in adults with type 1 diabetes
  Manuel Ramón García-Sáenz, Marilu Cervantes-Maldonado, Luis Angel López-Cruz, Eduardo Salif Luna-Avila, Paulo César Gete Palacios, Cristina Martínez-Berdeja, Omar Jaime-Leal, Aldo Ferreira-Hermosillo
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• MEANDERLINE BASED MICROSTRIP ANTENNA DESIGN FOR LIVER TUMOR DETECTION
  Volkan Akdoğan, Fatih Özkan Alkurt
  Kahramanmaraş Sütçü İmam Üniversitesi Mühendislik Bilimleri Dergisi.2026; 29(1): 401.     CrossRef
• Metabolic-associated steatotic liver disease in children and adolescents: a scoping review and narrative synthesis of epidemiology, risk factors, and screening approaches with emerging implications for sub-Saharan Africa
  Bruno Basil, Peace Ngozi Okoro
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions
  Rashmee Patil, Winston Dunn, Mazen Noureddin, Naim Alkhouri
  Drugs.2026; 86(5): 627.     CrossRef
• The Gut‐Liver Axis in Metabolic Dysfunction‐Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics
  Shaoliang Zhu, Mengjie Zou, Qijun Wu, Yan Zou, Tingting Tan, Zhangnan Huang, Zheng Gong, Honglin Luo, Xiaofeng Dong
  The FASEB Journal.2026;[Epub]     CrossRef
• Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes
  Konstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, Emmanouil Sinakos
  Current Diabetes Reports.2026;[Epub]     CrossRef
• Association between weekend catch-up sleep and Metabolic dysfunction-associated steatotic liver disease in US adults
  Jinlong Chen, Wei Wang, Jie He, Xinxin Fang
  Clinical and Experimental Medicine.2026;[Epub]     CrossRef
• Ginsenoside Rg1 alleviates MASH by targeting GLS2 to enhance PINK1/Parkin-mediated mitophagy and improve mitochondrial function
  Zhijian Wang, Yinuo Wang, Peiyun Peng, Huating Luo, Liuling Xiao, Wenxiang Huang
  Biochemical Pharmacology.2026; 249: 117891.     CrossRef
• Heterogeneous associations of regional adipose depots with liver fibrosis in U.S. adults
  Kuan-Yu Lai, Chun-Yi Wang, Hsian-Han Kao, Wen-Yuan Lin, Tsung-Po Chen
  Metabolism Open.2026; 30: 100461.     CrossRef
• MASLD In Children - A Distinct Phenotype?
  Pervej Alom Barbhuiya, Manash Pratim Pathak
  Current Obesity Reports.2026;[Epub]     CrossRef
• DNA hypermethylation of choline kinases drives blockage of choline-phosphatidylcholine biosynthesis: lipidomic biomarkers and epigenetic insights of hepatic steatosis induced by arsenic
  Qiwen Fu, Qi Wang, Dingyi Song, Xingcheng Zhou, Hualin Chen, Shaofeng Wei, Lu Ma
  BMC Medicine.2026;[Epub]     CrossRef
• Comments on “Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection”
  Preeti Lamba
  Journal of the Formosan Medical Association.2026;[Epub]     CrossRef
• Association between triglyceride glucose-body mass index and metabolic dysfunction-associated steatotic liver disease in South Korean pregnant women
  Yuqin Shen, Dongqian Yang, Li Zhang, Rong Shuai
  Scientific Reports.2026;[Epub]     CrossRef
• Combined effect of MASLD and low muscle strength on the risk of osteoporotic fractures: A UK Biobank cohort study
  Yongin Cho, Jong Hyun Jhee, Jong Ho Jhee, Hye-Sun Park
  European Journal of Endocrinology.2026; 194(3): 357.     CrossRef
• Hepatoprotective Effects of Combined Inulin-Glucomannan Non-Starch Polysaccharide Against Western Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease
  I Gede Putu Adhi Wedharga, Made Cahyani Trisna Ananda, Nadilla Faiza Richadini, Bernadette Dian Novita, Herjunianto Herjunianto, Silvia Sutandhio, Adi Pramono Hendrata, Mulya Dinata, Yu Hirata, Suryo Kuncorojakti, Hendy Wijaya, Dawei Chen, Ester Natalia D
  Journal of Pharmaceutical Innovation.2026;[Epub]     CrossRef
• Broccoli-Derived Exosome-like Nanoparticles Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulating the Gut–Liver Axis
  Feng Zhang, Ruolan Liu, Tongxiao Xu, Wentao Xu, Kunlun Huang, Xiaoyun He
  Nutrients.2026; 18(6): 953.     CrossRef
• Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management
  Mary E. Rinella, Silvia Sookoian
  Nature Reviews Gastroenterology & Hepatology.2026; 23(6): 460.     CrossRef
• Association of Metabolic Dysfunction-Associated Steatotic Liver Disease and Kidney Failure in the CKD Population
  Jin Kyung Kwon, Minsang Kim, Jinsun Lee, Jae-ik Oh, Jung Hun Koh, Min Woo Kang, Jeong Min Cho, Seong Geun Kim, Hyuk Huh, Sehyun Jung, Semin Cho, Soojin Lee, Eunjeong Kang, Yaerim Kim, Dong Ki Kim, Kyungdo Han, Sehoon Park
  Kidney International Reports.2026; 11(5): 106414.     CrossRef
• Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study
  Rishi Chowdhary, Manjeet Kumar Goyal, Ashita Rukmini Vuthaluru, Megh Patel, Tanisha Sehgal, Kirti Arora, Rahul Chowdhary, Varun Mehta, Akash Batta, Omesh Goyal
  Hepatology Research.2026; 56(6): 1026.     CrossRef
• Cytoglobin in Hepatic Stellate Cells Plays Anti-Fibrotic Role in Chronic Liver Injury
  Norifumi Kawada
  Antioxidants.2026; 15(3): 383.     CrossRef
• Capabilities of magnetic resonance imaging in quantitative assessment hepatic steatosis in patients with different body mass index
  Yu. N. Savchenkov, G. E. Trufanov, V. A. Fokin, E. A. Ionova, T. A. Anosova, A. V. Anisonyan, E. S. Sbikina, O. V. Bodrova
  Medical alphabet.2026; (4): 40.     CrossRef
• MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome
  Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Qin-Fen Chen, Michael D. Shapiro, Yuxing Dong, Ki-Chul Sung, Gregory Y. H. Lip, Jeffrey V. Lazarus, Ming-Hua Zheng
  Science China Life Sciences.2026; 69(6): 1950.     CrossRef
• Frailty, cardiovascular health, and the risk of mortality and extrahepatic diseases in patients with metabolic dysfunction-associated steatotic liver disease
  Jie Li, Jiang Li, Xiaoqin Xu, Ningjian Wang, Bin Wang, Yingli Lu
  Maturitas.2026; 208: 108917.     CrossRef
• Myeloid KIF13B suppresses the STT3A/CTSD/THBS1 axis to prevent MASH
  Kaikai Lu, Xianqin Shen, Ziyang Guo, Jingxuan Chen, Lei He, Aiden Xian, Si Mei, Yufei Han, Yinqi Zhao, Jinxuan Chen, Sijing Shi, Guolin Miao, Yitong Xu, Zihao Zhou, Lianxin Zhang, Chao Zhai, Ziwei Wang, Ling Zhang, Minghua Zheng, Lin Yao, Wei Huang, Yuhui
  Hepatology.2026;[Epub]     CrossRef
• Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study
  Yue Li, Zixian Li, Siyu Wu, Ling Cao, Beibei Qian, Junxian Tao, Zhimin Qian, Li Xie, Xiaoli Cai, Xiaofang Sun, Ying Li, Zhenwen Zhang, Caifeng Yan, Dunmin She
  BMC Endocrine Disorders.2026;[Epub]     CrossRef
• Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights
  Marina Idalia Rojo-López, Julia Niño-Narvión, Maria Antentas, Berta Fernández-Camins, Elizabeth Martínez-Rojo, Maria Poca, María Antonia Martínez-Sánchez, Bruno Ramos-Molina, Joana Rossell, Didac Mauricio, Josep Julve
  Nutrients.2026; 18(6): 996.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease
  James M. Paik, Linda Henry, Khalid AlNaamani, Ariana Nader, Maria Stepanova, Mei-Hsuan Lee, Ming-Lung Yu, Zobair M. Younossi
  Clinics in Liver Disease.2026; 30(2): 241.     CrossRef
• Assessing the Relationship Between Steatotic Liver Disease and Barrett’s Esophagus: A Cross-Sectional Analysis of 5507 Screening Participants
  Nikolaus Götz, Andreas Völkerer, Hannah Hofer, Sarah Wernly, Franz Singhartinger, Ewald Wöll, Elmar Aigner, Maria Flamm, Christian Datz, Bernhard Wernly
  Zeitschrift für Gastroenterologie.2026; 64(05): 470.     CrossRef
• Prevotella‐Derived Butyrate Inhibits CD8+ T‐Cell Glycolysis via AKT/mTOR Signalling to Alleviate MASH
  Feixiang Xiong, Fengna Yan, Yuyong Jiang, Xiaomin Ji, Tong Wu, Yang Zhou, Xuejie Zhang, Dandan Chen, Yixin Hou
  Liver International.2026;[Epub]     CrossRef
• CT-assessed abdominal visceral adiposity and MASLD: a sex-stratified cross-sectional analysis
  Linying Xu, Ting Chen, Yitian Xie, Xueyu Xiang, Yupeng Liu, Chongyong Xu, Shuran Wang
  Frontiers in Nutrition.2026;[Epub]     CrossRef
• MetALD at the crossroads of metabolic and alcohol-related liver disease
  Gustavo Ayares, Luis Antonio Díaz, Juan Pablo Arab, Marco Arrese
  Trends in Endocrinology & Metabolism.2026;[Epub]     CrossRef
• Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design and translational endpoint interpretation
  Mengdi Lu, Hong Zhang, Xiaoxue Zhu, Jia Xu, Lin Xiang, Yue Hu, Jixuan Sun, Jiajia Mai, Yanhua Ding
  Frontiers in Pharmacology.2026;[Epub]     CrossRef
• Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease
  Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Hye Ryoun Jang, Geum-Youn Gwak
  The Journal of nutrition, health and aging.2026; 30(5): 100827.     CrossRef
• Multi-omics integration reveals ANXA6-high γδ T cell–endothelial communication as a potential link between periodontitis and MASLD
  Zhongxuan Zhang, Zihan Ma, Ruidong Zhang, Min Ye, Zhongyu Shi, Miao Yu, Lingling Ou
  npj Systems Biology and Applications.2026;[Epub]     CrossRef
• Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study
  Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu
  Frontiers in Medicine.2026;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease and acute leukemias – a literature review and future directions
  Tareq Salah, Maximillian Stahl, Jan Philipp Bewersdorf
  Leukemia & Lymphoma.2026; 67(6): 1221.     CrossRef
• Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults
  Tina Reinson, Josh Bilson, Caroline Childs, Ryan M Buchanan, Giovanni Targher, Christopher D Byrne
  BMJ Medicine.2026; 5(1): e002038.     CrossRef
• XBP1s-Regulated GFPT1 via Facilitating O-GlcNAcylation of FASN S509 Is Involved in Arsenic-Induced MASLD through Promoting Fatty Acid Synthesis in Hepatocytes
  Wenjie Li, Bowen Fan, Han Li, Qiong Du, Jiaheng Lin, Yi Yang, Xiaolin Ding, Haoran Zhang, Haibo Xia, Binafsha Manzoor Syed, Cheng Cheng, Qizhan Liu
  Journal of Agricultural and Food Chemistry.2026; 74(14): 11814.     CrossRef
• Combination Training Improves Leptin Regulation, Reduces Body Fat, and Increases Skeletal Muscle Mass in Obese Females
  Dwi Cahyo Kartiko, Purwo Sri Rejeki, Dono Indarto, Irmantara Subagio, Sasminta Christina Yuli Hartati, Bekir Erhan Orhan, Yuni Nurwati, Adi Pranoto
  Physical Education Theory and Methodology.2026; 26(2): 380.     CrossRef
• Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH)
  Mirjana Grocic, Madison Nguyen, Arun J. Sanyal
  Diabetes, Obesity and Metabolism.2026; 28(S2): 3.     CrossRef
• Association of environmental chemical exposure with metabolic dysfunction-associated steatotic liver disease: a cross-sectional and network toxicology analysis
  Guodong Yang, Wenli He, Xin Qiu, Shuang Shen, Yifei Feng, Yi Peng, Taixin Yang, Zhaochan Wen, Peishu Li, Huili Luo, Xinyuan Wu, Ze Su, Bangde Xiang
  European Journal of Medical Research.2026;[Epub]     CrossRef
• Burden of metabolic dysfunction-associated steatotic liver disease in the Asia-Pacific region from 1990 to 2023
  Xiao-Dong Zhou, Qin-Fen Chen, Giovanni Targher, Christopher D Byrne, Luca Valenti, Mark D Muthiah, Seung Up Kim, Daniel Q Huang, Masato Yoneda, Wenhao Li, Yusuf Yilmaz, Herbert Tilg, Vincent Wai-Sun Wong, Ming-Hua Zheng
  eGastroenterology.2026; 4(1): e100369.     CrossRef
• Unraveling the Mechanisms of Wuling Powder Against MASLD by Integrated Metabolomics–Gut Microbiota–Serum Pharmacochemistry
  Huan Yang, Yan-Mei Tang, Shao-Cong Han, Peng-Quan Wang, Yu-Xuan Tao, Hui-Qiong Yang, Min Zhang, Min Li, Jie Yu, Xing-Xin Yang
  Pharmaceuticals.2026; 19(4): 557.     CrossRef
• Crocin II alleviates metabolic dysfunction-associated steatotic liver disease by enhancing autophagic degradation of ANGPTL8
  Rongtian Zhang, Kongdong Li, Ziting Zhao, Xintong Jiang, Rumeng Zhang, Chang Liu, Wenxiang Zhang, Siyu Chen
  Targetome.2026;[Epub]     CrossRef
• Endocrine disruptors reprogram hepatic metabolic and immune gene networks to promote hepatocellular carcinoma
  Yanggang Hong, Yi Wang, Qingyu Chen, Yirong Wang
  npj Gut and Liver.2026;[Epub]     CrossRef
• Exercise-responsive skeletal muscle genes mechanistically linked to metabolic dysfunction-associated steatotic liver disease
  Jia-Hui Zhang, Kang Chen, Xiao-Min Zhu, Huan Zhou, Jia-Mi Jiang, Yu-Qing Zou, Ke-Rong Liu, Le Zhang, Yun Li
  World Journal of Gastroenterology.2026;[Epub]     CrossRef
• Multimodal assessment of hepatic steatosis heterogeneity: segmental MRI-PDFF and ultrasound attenuation coefficient measurement
  M.M. Zhaivoronok, N.V. Deresh, I. Sporea, O.B. Dynnyk, S.V. Feysa, O.A. Pushkarenko, O.A. Fedusenko, O.V. Shcherbina, N.M. Kobyliak
  INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(2): 103.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease, biomarkers, and cardiovascular risk factors in children with excess weight
  Elisabeth A. Machado, Beatriz L.C. Themistocles, Jorge M.R. Teixeira, Fernanda M.G. Jannuzzi, Geísa Tomaz, Cecilia L. Oliveira, Isabel R. Madeira, Carlos Terra, Maria das Graças C. Souza, Alexandra Monteiro, Eliete Bouskela, Marise E. Marsillac, Paulo F.
  Jornal de Pediatria.2026; 102(3): 101534.     CrossRef
• Ubiquitin-Specific Protease 2 (USP2) as a Modulator of Energy Metabolism: A Review of Studies Using Animal and Cellular Models
  Hiroshi Kitamura, Jun Okabe, Himeka Hayashi, Tomohito Iwasaki
  Biomedicines.2026; 14(4): 783.     CrossRef
• Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm
  Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim
  Diabetes, Obesity and Metabolism.2026; 28(6): 5240.     CrossRef
• Longitudinal performance of vibration controlled transient elastography in pediatric metabolic dysfunction associated steatotic liver disease
  Naima Diop‐West, Nicholas Denson, Ana Catalina Arce‐Clachar, Julie Bonn, Kristin Bramlage, Lisa Leesman, Rashmi D. Sahay, Emrah Gecili, Andrew T. Trout, Stavra Xanthakos, Marialena Mouzaki
  Journal of Pediatric Gastroenterology and Nutrition.2026; 82(6): 1366.     CrossRef
• LPCAT3 deficiency Drives phospholipid remodeling and mitochondrial oxidative dysfunction to accelerate MASH-HCC development
  Gaoxuan Shao, Chenhao Ye, Chenceng Sun, Jiashu Pan, Lu Lu, Lei Wang, Tao Wu, Zemin Lin, Guang Ji, Hanchen Xu
  Journal of Advanced Research.2026;[Epub]     CrossRef
• Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies
  Eleni A. Karavia, Andreas Pittaras, Ourania Andreopoulou, Aikaterini Hatziri, Amalia Makrydimitri, Dimitrios Anagnostopoulos, Patroklos Vareltzis, Kyriakos E. Kypreos
  Pharmaceuticals.2026; 19(4): 605.     CrossRef
• Studying serum immunoglobulin levels in metabolic dysfunction-associated steatotic liver disease
  Hazem Abosheaishaa, Emad Ahmad Awad Hussein, Shereen Abou Bakr Saleh, Mahmoud Nassar, Abdulaziz Elmaradny, Mohammed Abdelwahed, Amr Ali, Khaled Elfert, Ahmed Mohamed ElGhandour
  Egyptian Liver Journal.2026;[Epub]     CrossRef
• Association Between Periodontitis and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Cross‐Sectional Study
  Mizuki Saito, Yoshihiro Shimazaki, Saori Yoshii, Tetsuhito Kojima
  Clinical and Experimental Dental Research.2026;[Epub]     CrossRef
• Endoscopy for Metabolic Diseases
  Maria Valeria Matteo, Jana Kefah Ibrahim Hussein, Giorgio Carlino, Vincenzo Bove, Valerio Pontecorvi, Loredana Gualtieri, Martina De Siena, Mariachiara Di Vincenzo, Lorenzo Zileri Dal Verme, Daniele Salvi, Clarissa Ferrari, Cristiano Spada, Ivo Boskoski
  Journal of Clinical Medicine.2026; 15(8): 2832.     CrossRef
• Weekend warrior physical activity pattern and risk of all-cause and cardiovascular mortality among US adults with metabolic dysfunction-associated steatotic liver disease: A prospective cohort study of NHANES 2007–2018
  Mengbiao Cai, Kai Jin, YuLong Wang, Jian Zhu, Changnan Xu, Yi Yang, Zhenxiang Guo
  Science Progress.2026;[Epub]     CrossRef
• Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes
  Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson
  Diabetes, Obesity and Metabolism.2026; 28(7): 5684.     CrossRef
• Ferroptosis in MASLD: From molecular mechanisms to therapeutic opportunities
  Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Wei Xie, Qin-Fen Chen, Yuxing Dong, Fudi Wang, Daolin Tang, Ming-Hua Zheng
  Med.2026; 7(6): 101099.     CrossRef
• Toxic lipid-induced epigenetic activation of ICAM1 in liver sinusoidal endothelium regulates myeloid-driven fibro-inflammatory response in MASH
  Qianqian Guo, Nantawat Satthawiwat, Akitoshi Sano, Chady Meroueh, Asma Hamdi, Xin Dai, Khaled Warasnhe, Alexander M. Washington, Patrick P. Starlinger, Alex Krivonos, Sheng Cao, Enis Kostallari, Johan W. Jonker, Bart van de Sluis, Feda H. Hamdan, Samar H.
  Hepatology.2026;[Epub]     CrossRef
• Updates on paediatric MASLD: insights from an endocrine lens
  Natalie Segev, Marialena Mouzaki
  Diabetologia.2026;[Epub]     CrossRef
• An Integrated Nanozyme‐Exosome Platform for Multi‐Targeted Therapy of Metabolic‐Associated Steatotic Liver Disease
  Kun Yu, Xinwei Li, Yingying Liu, Haonan Zhang, Guojie Liu, Tuo Ji, Yuzhi Gao, Lin Wang, Yuwei Bian, Guohua Chen, Zhiwen Zhao, Feng Wang, Xiaoming Yu, Jiachen He, Xuzhu Gao
  Advanced Healthcare Materials.2026;[Epub]     CrossRef
• Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis
  Kiavash Semnani, Farbod Semnani, Seyed Sahab Aarabi, Shirin Esmaeili, Ehsaneh Taheri, Armita Mahdavi-Gorabi, Mohsen Rajabnia, Shirin Djalalinia, Saba Goodarzi, Amir Kasaeian, Mohammad Shadab Siddiqui, Mostafa Qorbani
  BMJ Open.2026; 16(4): e111933.     CrossRef
• Cholinesterase and the association between hepatic steatosis and liver fibrosis in patients with prior hepatitis E
  Ziteng Wang, Zhe Yu, Wen An, Herui Wei, Jing Luo, Mengqi Li, Lingling He, Jiali Ma, Fan Xiao, Lijuan Sun, Qi Gao, Hui Zhong, Hongshan Wei
  European Journal of Medical Research.2026;[Epub]     CrossRef
• GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes
  Jonggi Choi, Gabby Mitchell, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung
  Hepatology Communications.2026;[Epub]     CrossRef
• Analysis of B-Scan Ultrasonography Using Neural Networks to Predict Risk of Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  Josefine Stansch, Kien Vu Trung, Valentin Blank, Jakob Nikolas Kather, Moritz Herzog, Tobias Seibel, Paul-Henry Koop, Robert Haase, Thomas Berg, Johannes Wiegand, Thomas Karlas
  Ultrasound in Medicine & Biology.2026; 52(7): 1346.     CrossRef
• Sleeve Gastrectomy Alters Exosomal miR-497-5p Cargo to Ameliorate Metabolic Dysfunction–Associated Steatotic Liver by Targeting GABARAPL1
  Zenghui Li, Chenxu Tian, Mengqin Wang, Zhehong Li, Liang Wang, Zheng Wang, Chengyuan Yu, Dezhong Wang, Dongbo Lian, Nengwei Zhang
  Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
• Hypertension in middle childhood
  Mirjam Močnik, Zala Hrovat, Sonja Golob Jančič, Martina Filipič, Mladen Crnobrnja, Nataša Marčun Varda
  BMC Pediatrics.2026;[Epub]     CrossRef
• Blood-based non-invasive tests show comparable accuracy in MetALD and MASLD for MRE-defined advanced fibrosis
  Akash Roy, Surabhi Jajodia, Shardhya Chakraborty, Shruti Keyal, Awanish Tewari, Nikhil Sonthalia, Sourish Roy, Rajat Khandelwal, Anand Kulkarni, Uday Chand Ghoshal, Rajender Reddy, Mahesh Kumar Goenka
  BMC Gastroenterology.2026;[Epub]     CrossRef
• Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
  Veronika A. Prikhodko, Sergey V. Okovityi
  Biomedicines.2026; 14(4): 909.     CrossRef
• Apple polyphenol extract mitigates high-fat diet induced cognitive impairment in C57BL/6 mice via a sex-dependent mechanism
  Jieyu Ma, Jiaxin Li, Le Wang, Jinlin Ma, Shilin Chen, Wenxue Luan, Xintong Tian, Siyuan Shang, Xinli Li
  Food Bioscience.2026; 80: 108892.     CrossRef
• Current status of research on the risk factors and pathogenesis of metabolic dysfunction-associated steatotic liver disease
  Dan Chen, Lingling Yan, Tong Wu, Junpeng Zhao, Xuebing Xu, Weisong Xu, Hong Zhang, Mingbing Xiao
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• Patatin-like phospholipase domain-containing protein 3 rs2896019 and MASLD Susceptibility and Severity in Adults: A Systematic Review and Meta-Analysis of Case–Control Studies
  Wei-Yue Lim, Rosmawati Mohamed, Yuh-Fen Pung, Hak-Keith Leung, Rong-Xiang Ng, Shamsul Mohd Zain
  Metabolic Syndrome and Related Disorders.2026;[Epub]     CrossRef
• Heterogeneity of hepatic macrophages in MASLD/MASH: Lipid-associated programs, molecular mechanisms, spatial niches, and therapeutic implications
  Kaipeng Hu, Siyuan Liu, Shuyan Sheng, Shaobo Zhang, Binghua Li, Beicheng Sun, Anliang Xia
  iLIVER.2026; 5(2): 100234.     CrossRef
• Predictors of metabolic dysfunction-associated steatotic liver diseases (MASLD) in Vietnamese population
  Anh Gia Pham, An Vu-Khanh Le, Yen Thi-Hai Pham, Lanh Sy Nguyen, Huong Lan Nguyen, Nghia Chinh Quach, Thau Manh Cao, Hanh Thi Nguyen, Xuan Thanh Thai, Anh Tuan Luong, Thuy Thi Pham, Hai Duy Vu, Hai Thi-Thanh Tran, Lan Thi Le, Hai Vu, Giang Binh Tran, Hung
  Scientific Reports.2026;[Epub]     CrossRef
• Lactational Western‐Style Fat Exposure in Mice Programs Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) in Male Offspring
  Amy Y. Zhao, Haijing Sun, Leyi Yan, Oyewale Shiyanbola, Dave Bridges, Brigid Gregg
  Molecular Nutrition & Food Research.2026;[Epub]     CrossRef
• Monocyte reprogramming and trained immunity: Linking metabolism to inflammation in non-alcoholic fatty liver disease
  Stanislav Kotlyarov
  World Journal of Hepatology.2026;[Epub]     CrossRef
• Exercise as a Metabolic Therapy for MASLD: Beyond Weight Loss Toward Sustainable Exercise Strategies
  Hee-Tae Roh, Ju-Yong Bae
  Medicina.2026; 62(4): 784.     CrossRef
• Tissue-specific roles of IGFBP2 in glucose and lipid metabolism in obesity-related metabolic diseases
  Xiaoyu Song, Wentao Zhong, Hao Zheng, Xinyang Ou, Dongjin Zheng, Zhuo Li
  Frontiers in Nutrition.2026;[Epub]     CrossRef
• Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study
  Heejoon Jang, Yeonjin Kim, Yoo Kyoung Lim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Gi-Ae Kim, Woojoo Lee, Stefano Romeo, Won Kim
  Clinical and Molecular Hepatology.2026; 32(2): 737.     CrossRef
• High-fat diet, gut dysbiosis, and oxidative stress: A synergistic triangle in metabolic dysfunction-associated steatotic liver disease pathogenesis
  Zi-Rui Zhang, Ling She, Yi-Rong Cao, Yuan-Wen Chen
  World Journal of Hepatology.2026;[Epub]     CrossRef
• Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease
  Allen Anthony Laraño, Silvia Palmisano, Deborah Bonazza, Discipio Marina, Marica Meroni, Anna Ludovica Fracanzani, Lory S Crocè, Claudio Tiribelli, Paola Dongiovanni, Natalia Rosso, Pablo Giraudi
  Annals of Hepatology.2026; : 102206.     CrossRef
• Alcohol-driven phenotypic transition in MASLD and risk of liver-related events
  Seohui Jang, Jihun Song, Eun Seok Kang, Sangwook Cheon, Taeho Kwak, Yihyun Kim, Seokjin Kong, Jinhyeok Choi, Minjeong Kang, Jaewon Khil, Hye Jun Kim, Jeongin Lee, Hwamin Lee, Seogsong Jeong
  JHEP Reports.2026; 8(7): 101866.     CrossRef
• Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver diseas
  Yueying Yang, Ying Yang, Yan Lu
  Clinical and Molecular Hepatology.2026; 32(2): 957.     CrossRef
• Editorial on “Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease”
  Julia Kozlitina
  Clinical and Molecular Hepatology.2026; 32(2): 931.     CrossRef
• Role of MicroRNAs in Precision Hepatology
  Youngwoo Lee, Eunho Choi, Young-Sun Lee
  Journal of Digestive Cancer Research.2026; 14(1): 102.     CrossRef
• Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation
  Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan
  Clinica Chimica Acta.2026; 589: 121028.     CrossRef
• Bupleuri Radix ameliorates MASLD induced by high-fat diet and circadian disruption in rats: Involvement of the NR1D1–SREBF1/CYP7A1 circadian–metabolic axis
  Shuheng Wang, Shuaidong Bai, Tianhui Zhou, Yukun Wang, Xue Bai, Yiming Wang, Junwen Ma, Xuemei Qin, Xiaoxia Gao
  Journal of Ethnopharmacology.2026; 367: 121770.     CrossRef
• Comment on “High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C”
  Wen-Rui Li
  Journal of the Formosan Medical Association.2026;[Epub]     CrossRef
• Calorie restriction mitigates steatotic liver disease in obese rats after bariatric surgery
  Yu-Ning Lin, Chin-Ying Wu, Yin-Ru Hsieh, Yi-Tung Lin, Weu Wang, Chun-Chao Chang, Shih-Yi Huang, Wei-Yu Kao
  Nutrition Research.2026; 151: 52.     CrossRef
• Fucoxanthin Ameliorates MASLD by Directly Targeting GRP78 to Restore ER Homeostasis and Activate AMPK Signaling
  Lin Zhang, Ruifen Zhang, Yu Wu, Binbin Chen, Chao Wang, Cheng Wang, Zhengshun Wen, Jingui Zhang, Haibin Tong, Liang Hong
  Food Science & Nutrition.2026;[Epub]     CrossRef
• Familial hypobetalipoproteinemia in pediatric patients with fatty liver: an under-recognized cause
  Nurit Loberman Nachum, Eyal Shteyer, Hofit Cohen, Odelia Chorin, Maya Granot, Batia Weiss
  Frontiers in Medicine.2026;[Epub]     CrossRef
• The effect of a two-week low glycaemic index, higher fibre diet versus high glycaemic index diet on body composition, ectopic lipids, inflammatory biomarkers, gastrointestinal hormones and gut microbiota in metabolic dysfunction-associated steatotic liver
  Amina A. Al-Awadi, Jane I. Grove, Stephen Bawden, Amrita Vijay, Ana M. Valdes, Penny Gowland, Moira A. Taylor, Guruprasad P. Aithal
  Clinical Nutrition ESPEN.2026; 73: 103306.     CrossRef
• Di(2-ethylhexyl) phthalate exposure: Association with metabolic associated steatotic liver disease and underlying mechanisms
  Dapeng Yin, Yan Li, Wei Wu, Jiacheng Cheng, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li
  Ecotoxicology and Environmental Safety.2026; 317: 120210.     CrossRef
• Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach
  Beom Kyung Kim
  The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
• Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort
  Nicole Shu Ying Tang, Ethan Kai Jun Tham, Nicholas Syn, Ken Liu, Gang Chen, Beom Kyung Kim, Mark Muthiah, Takumi Kawaguchi, Asahiro Morishita, Sung Won Lee, Karn Wijarnpreecha, Hirokazu Takahashi, Daniel Q. Huang
  Journal of Gastroenterology and Hepatology.2026; 41(6): 1883.     CrossRef
• Integrated bioinformatics analysis and experimental validation of SRF as a potential senescence biomarker in MASLD
  Mengyue Li, Chang Gao, Yuhui Shi, Wenyu Peng, Yuan Yin, Bin Lu, Zhang Fu
  Frontiers in Molecular Biosciences.2026;[Epub]     CrossRef
• The Role of MicroRNAs in the Progression of Metabolic Dysfunction-associated Steatotic Liver Disease
  Jang Hyun Choi
  Journal of Digestive Cancer Research.2026; 14(1): 82.     CrossRef
• GCSH promotes MASH progression by regulating cuproptosis through the glycine–GSH metabolic pathway
  Xuan Fu, Yunmeng Li, Jing Chen, Baolong Yin, Mahbuba Nasrin, Rui Huo, Shuxin Tian
  Free Radical Biology and Medicine.2026; 252: 1.     CrossRef
• A Descriptive Analysis of Mediterranean Diet Meal Plans Using the Dietary Inflammatory Index, Dietary Antioxidant Index, and Dietary Lipid Indices: Implications for Dietary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  Melvin Bernardino, Claudio Tiribelli, Natalia Rosso
  Nutrients.2026; 18(8): 1281.     CrossRef
• From Genomic Instability to Epigenetic Signatures: The Evolving Landscape of Circulating Cell‐free DNA in Metabolic Dysfunction‐Associated Steatotic Liver Disease
  Wei‐Yue Lim, Rosmawati Mohamed, Yuh‐Fen Pung, Shamsul Mohd Zain
  Hepatology Research.2026; 56(6): 914.     CrossRef
• Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review
  Brittany Bromfield, Jeremy Chimene-Weiss, Gregory Gheewalla, Theodore Feldman, Emilie K. Mitten, Piero Portincasa, Gyorgy Baffy
  eClinicalMedicine.2026; 95: 103921.     CrossRef
• Concerns about the health effects of industrially produced seed oils are without scientific foundation: a scoping narrative review of the clinical and observational evidence
  Matthew Nagra, David M. Goldman, Martha A. Belury, Mark Messina
  Critical Reviews in Food Science and Nutrition.2026; : 1.     CrossRef
• Neutrophils in Liver Diseases: Functions and Challenging Therapies
  Rui Ma, Haoran Meng, Xiutong Chen, Haiyuan Shen, Li Zuo, Hua Wang
  Seminars in Liver Disease.2026;[Epub]     CrossRef
• The Degree of Liver Steatosis Is Associated with Abnormally High Serum Levels of Markers of Blood–Brain Barrier Dysfunction and Systemic Inflammation in Patients with Morbid Obesity
  Gabriela Hurtado-Alvarado, Karol Iliana Ávila-Soto, Marlene Monserrat Juárez, Lucía Angélica Méndez-García, Verónica Cevallos-López, Juan Antonio Peralta-Calcaneo, Marcela Esquivel-Velázquez, Antonio González-Chávez, Julio César Zavala-Castillo, Ana Alfar
  Medicina.2026; 62(5): 821.     CrossRef
• Portal Vein Thrombosis in Cirrhotic Candidates for Liver Transplantation and Its Impact on the Transplant Accessibility
  Simona Parisse, Flaminia Ferri, Adriano De Santis, Fabio Melandro, Mario Corona, Quirino Lai, Pierleone Lucatelli, Gianluca Mennini, Massimo Rossi, Stefano Ginanni Corradini
  Journal of Clinical Medicine.2026; 15(9): 3358.     CrossRef
• c-FLIP as a master regulator of immune homeostasis and disease mechanisms
  Eliana Urbini, Annalisa Adamo, Yushu Hu, Luca Giacobazzi, Silvia Dusi, Francesco De Sanctis, Carmine Carbone, Davide Gibellini, Sara Pilotto, Vincenzo Corbo, Vincenzo Bronte, Fulvia Vascotto, Stefano Ugel
  Cell Death & Disease.2026;[Epub]     CrossRef
• Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
  Enrico Torre, Sergio Di Matteo, Chiara Martinotti, Giacomo Bruno, Alessandro Cabrino, Emma Fogliati, Andrea Giusti, Marco Barbieri, Luigi Bottaro, Giorgio Colombo
  ClinicoEconomics and Outcomes Research.2026; Volume 18: 1.     CrossRef
• Clinical differentiation between alcohol-associated and metabolic dysfunction-associated steatotic liver disease: a comparative case report
  Chang-Gue Son
  The Journal of Internal Korean Medicine.2026; 47(1): 70.     CrossRef
• Bacterial Extracellular Vesicles in Aging: Mechanisms and Therapeutic Prospects
  Junfei Tan, Muhammad Zubair, Lin Zhang, Likang Liu, Kangrong Li, Yihua Wang, Yongmin Yan, Wenyan Xu
  International Journal of Nanomedicine.2026; Volume 21: 1.     CrossRef
• Elevated liver fat content is independently associated with insulin resistance in people with type 1 diabetes
  Jonathan Mertens, Maarten Spinhoven, Rie Braspenning, Floris Vanhevel, Eveline Dirinck, Christophe De Block, Sven Francque
  JHEP Reports.2026; 8(8): 101887.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease in cushing’s syndrome: a case controlled FibroScan study
  Tugce Apaydin, Caglayan Keklikkiran, Haluk Tarik Kani, Yusuf Yilmaz, Dilek Gogas Yavuz
  Journal of Endocrinological Investigation.2026;[Epub]     CrossRef
• Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction–Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals
  Tinsay A Woreta, Samer Gawrieh, Laura A Wilson, Yuchen Xin, Eduardo Vilar-Gomez, Kathleen E Corey, Richard K Sterling, Jordan E Lake, Susanna Naggie, Sonya Heath, Holly Crandall, Jennifer C Price, Rohit Loomba, Naga Chalasani, Mark S Sulkowski
  Open Forum Infectious Diseases.2026;[Epub]     CrossRef
• Development and validation of the HABIT score: a practical and robust tool to predict hepatic steatosis using HbA1c, BMI, and triglycerides in patients with unexplained elevated liver enzymes
  Eike Humbert, Verena Wilkens, Semjon Bugaichuk, Karoline Horvatits, Ansgar W. Lohse, Samuel Huber, Sven Pischke, Thorben Fründt
  Annals of Hepatology.2026; 31(2): 102218.     CrossRef
• Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease
  Zobair M. Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, Khalid M. Al-Naamani, Frank Tacke, Emmanouil Tsochatzis, Javier Crespo, Mohamed El-Kassas, Fernando Bril, Marco Arrese, Cyrielle Caussy, C. Wendy Spearman, Amalia Gastaldelli, Mário Guimarães Pe
  Clinical Gastroenterology and Hepatology.2026;[Epub]     CrossRef
• Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH)
  Roberto Vettor, Maria Letizia Petroni, Idit Dotan, Gadi Lalazar, Martin Haluzík, C. Wendy Spearman, Joel A. Dave, Faisal Abaalkhail, Salah Abusnana, Ali Alshehri, Radan Bruha, Mariann Harangi, Ahmad Jazzar, Michał Kukla, Shiva Kumar, Vaia Lambadiari, Geor
  Reviews in Endocrine and Metabolic Disorders.2026; 27(2): 213.     CrossRef
• Advances in Diagnostic and Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease
  Ryan Njeim, Omar Abureesh, Ali Sohail, Ryan Tam, Liliane Deeb
  Livers.2026; 6(3): 35.     CrossRef
• The role of the resveratrol-sirtuin axis in the treatment of metabolic dysfunction-associated diseases
  Jiale Yang, Shuping Chen, Tiantian Zeng, Yuxuan Zhang, Zhaoxin Li, Haifang Li
  Exploration of Endocrine and Metabolic Diseases.2026;[Epub]     CrossRef
• GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes
  Xianhua Mao, Hong Fan, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen
  Hepatology.2026;[Epub]     CrossRef
• Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
  Ralf Weiskirchen, Amedeo Lonardo
  Expert Opinion on Therapeutic Targets.2026; 30(5): 473.     CrossRef
• Weight Loss-Induced Metabolic Remodeling in Metabolic dysfunction-associated steatotic liver disease: A Cohort Study Stratified by Genetic Risk
  J. Troisi, P. Torre, L. Schiavo, B.M. Motta, M. Lombardi, M. Festa, T. Sarcina, M. Masarone, M. Persico
  Clinical Nutrition.2026; 61: 106672.     CrossRef
• Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model
  Jens Bjelke Kristensen, Jacob Nøhr-Meldgaard, Susanne E. Pors, Jenny Norlin, Sanne S. Veidal, Kristian Moss Bendtsen, Kristoffer Niss, Maja W. Andersen, Lea M. Harder, Mathilde Teilmann Dalhoff, Martin Rønn Madsen, Kristoffer Voldum-Clausen, Markus Latta,
  American Journal of Physiology-Gastrointestinal and Liver Physiology.2026; 330(6): G659.     CrossRef
• Effectiveness of therapeutic strategies based on dietary patterns on cardiovascular and hepatic markers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) ‒ A systematic review of clinical trials
  Valeria Antonia Rivera Marín, Camila Sanchez, Andrea Herrera-Santelices, Luisa Amanda Ramírez Araya, Edson Yáñez-Barros, Sebastian Cofré
  Nutrición Hospitalaria.2026;[Epub]     CrossRef
• Extracellular Vesicle from Chlorella vulgaris Alleviates Hepatic Fibrosis in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulation of Inflammatory Signaling
  Hinata Harada, Yusuke Ohsaki, Afifah Zahra Agista, Hsin-Jung Ho, Takuo Hirose, Kotaro Yamada, Mutsumi Furukawa, Tomonori Nochi, Wan-Chun Chiu, Ya-Ling Chen, Chiu-Li Yeh, Suh-Ching Yang, Takefumi Mori, Hitoshi Shirakawa
  International Journal of Molecular Sciences.2026; 27(9): 3735.     CrossRef
• Nitric oxide pathway: Emerging therapeutic strategies for MASLD
  Yanling Zhang, Ying Zhang, Hongjin Chen, Fangfang Qi
  Pathology - Research and Practice.2026; 284: 156516.     CrossRef
• Distinct Roles of Myeloid‐ and Hepatocyte‐PLA2G6 Deletion in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease
  Gang Li, Simone Staffer, Sabine Tuma‐Kellner, Uta Merle, Walee Chamulitrat
  Liver International.2026;[Epub]     CrossRef
• MASLD Management in Spain: A Nationwide Survey of Gastroenterologists Highlighting Gaps in Risk Assessment and Primary Care Coordination
  Carolina Jiménez-González, Paula Argos Vélez, Lorena Cayón, Ana Belén García-Garrido, Noelia Fontanillas Garmilla, Antonio Cuadrado, Paula Iruzubieta, Javier Crespo
  Journal of Clinical Medicine.2026; 15(9): 3259.     CrossRef
• Predicting MASLD in People With HIV Using Anthropometric Measures: A Multicenter Cross-Sectional Study
  Jihad Slim, Murad Qirem, Paul Bellafiore, Bereket Tewoldemedhin, Tala B Shahin, Kevin Leyden, Ronald Poblete, Sandhya Nagarakanti, Hugo Vargas
  Open Forum Infectious Diseases.2026;[Epub]     CrossRef
• Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia
  Soo Lim, Hui Zhou, Wataru Ogawa
  Journal of Obesity & Metabolic Syndrome.2026; 35(2): 130.     CrossRef
• The gut-liver/bile axis: Gut microbiota and bacterial extracellular vesicles remodeling hepatobiliary pathogenesis
  Siyang Hu, Chunhui He, Kunqi Sun, Hongye Zhou, Xueyan Liu, Hao Wang, Sen Li, Haifeng Yu, Ke Xu, Wei Li
  iScience.2026; 29(5): 115623.     CrossRef
• Effects of Animal-Based Foods on Metabolic Outcomes in Adults with MASLD and Comorbidities: A Systematic Review of Randomized Controlled Trials (2020–2026)
  Joanna Michalina Jurek, Katarzyna Zablocka-Slowinska, Joanna Pieczynska, Anna Lipert, Helena Clavero-Mestres, Teresa Auguet
  Nutrients.2026; 18(10): 1508.     CrossRef
• Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications
  Yinan Zhao, Ziyan Li, Guoying Yu
  Frontiers in Nutrition.2026;[Epub]     CrossRef
• Impact of modern glucose-lowering therapies on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes
  A.M. Urbanovych, N.Ya. Sidelnyk, O.Z. Lishchuk
  INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(3): 340.     CrossRef
• The Economic Burden of Metabolic Dysfunction‐Associated Steatohepatitis (MASH) With Cirrhosis: A Systematic Review
  Jeffrey V. Lazarus, Caroline Freeman, Hannes Hagström, Mazen Noureddin, Riku Ota, Mary E. Rinella, Giada Sebastiani, Fotis Tefos, Zobair M. Younossi
  Liver International Communications.2026;[Epub]     CrossRef
• Evolving B-mode ultrasound-based techniques for assessing metabolic dysfunction-associated steatotic liver disease: Now and beyond
  Walaa Abdelhamed, Mohamed Elbadry, Mohamed El-Kassas
  Liver Research.2026; 10(2): 109.     CrossRef
• Comparative effectiveness of tirzepatide versus thiazolidinedione in adults with MASLD: a propensity score-matched cohort study
  Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai
  Frontiers in Pharmacology.2026;[Epub]     CrossRef
• Association between metabolic dysfunction-associated steatotic liver disease and overactive bladder: A cross-sectional study
  Shengqi Zheng, Xu Cui, Longyao Xu, Hong Chen, Liang Zheng, Chaoming Zhou
  Continence.2026; 18: 102466.     CrossRef
• Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma
  Vanilla X. Zhang, Tiffany C.-Y. Yu, Yu M. Tsui, Irene O.-L. Ng
  Trends in Molecular Medicine.2026;[Epub]     CrossRef
• Trends of metabolic dysfunction-associated steatotic liver disease in Mexico, 1990–2023: insights from the Global Burden of Disease Study
  Israel Rico-Alba, Alberto Retana-Guzmán, Marcela Agudelo-Botero, Claudio Alberto Dávila-Cervantes
  Annals of Hepatology.2026; : 102224.     CrossRef
• Cross‐Vendor Validation of Proton Density Fat Fraction and T1 Mapping Using a Combined Proton Density Fat Fraction—T1 Phantom
  Jitka Starekova, Sebastian Weingärtner, David R. Rutkowski, Garrett C. Fullerton, Won C. Bae, Hung P. Do, Ananth J. Madhuranthakam, Vadim Malis, Sheng Qing Lin, Suraj D. Serai, Takeshi Yokoo, Scott B. Reeder, Jean H. Brittain, Diego Hernando
  Journal of Magnetic Resonance Imaging.2026;[Epub]     CrossRef
• ПСИХОЛОГІЧНИЙ СТАН ПАЦІЄНТІВ ЗІ СТЕАТОТИЧНОЮ ХВОРОБОЮ ПЕЧІНКИ, АСОЦІЙОВАНОЮ З МЕТАБОЛІЧНОЮ ДИСФУНКЦІЄЮ, ЗА УМОВ ПОЄДНАННЯ З ГІПЕРУРИКЕМІЄЮ: ПІЛОТНЕ ОДНОЦЕНТРОВЕ КРОС-СЕКЦІЙНЕ ДОСЛІДЖЕННЯ
  Ігор Свінціцький , Валерія Каташинська
  Actual Problems of Nephrology.2026; (36-37): 26.     CrossRef
• Natural Product Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Targeted Mitochondrial Quality Control
  Jing Liu, Fuxing Li, Qianru Zeng, Wenxiao Hu, Le Yang, Shengping Luo, Fang Lv, Dingxiang Li, Yihui Deng
  Drug Design, Development and Therapy.2026; Volume 20: 1.     CrossRef
• The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
  Shang-Chin Huang, Tai-Chung Tseng
  Gut and Liver.2026; 20(3): 350.     CrossRef
• KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα
  Min Tang, Yunqin Ma, Jiaqi Wang, Han Cao, Shuangshuang Yao, Xiaohui Wei, Yijiong Tan, Hua Yang, Yi Lin, Bin Hu, Yang Yu, Jiaying Yang, Yufan Wang, Xingdong Zheng, Xiaofang Tang, Fang Liu, Yongde Peng, Nengguang Fan
  Metabolism.2026; 182: 156651.     CrossRef
• Liver Disease Diagnosis: Fuzzy c-means and Scoring Ranking Approach
  Gabriel A. Leite, Beatriz Flamia Azevedo, Sofia Ribeiro Ferreira, Maria F. Pacheco, Florbela P. Fernandes, Ana I. Pereira
  SN Computer Science.2026;[Epub]     CrossRef
• Mitochondrial Dysfunction in MASLD: Evidence in Dietary Models and Potential Therapeutic Interventions
  Elda Cristina Villaseñor-Tapia, Edgar Rubén Mendieta-Condado, David Alejandro Curiel-Pedraza, Edwin Estefan Reza-Zaldívar, Ana Laura Márquez-Aguirre, Venkata Ramireddy Narala
  Biochemistry Research International.2026;[Epub]     CrossRef
• Protocol for volumetric quantification of intrahepatic triglyceride content in adults with obesity
  Alba Camacho-Cardenosa, Antonio Clavero-Jimeno, Alejandro López-Vázquez, Mara Concepción, José L. Martín-Rodríguez, Idoia Labayen, Jonatan R. Ruiz, Rafael Cabeza
  STAR Protocols.2026; 7(2): 104585.     CrossRef
• Gut-liver metabolic and enterohormonal remodeling drives progression from metabolic dysfunction-associated steatotic liver disease to steatohepatitis
  Jaclyn A. Rivas, Alexandria C. Murphy, Praveena Prasad, Mahmoud S. Yahia, Siem S. Goitom, Aaron S. Romero, Crystal Madera Enriquez, Brianna B. Maes, Prithvi R. Akepati, Marcus A. Garcia, Fredine T. Lauer, Rama R. Gullapalli, Kristen M. Gonzales, Jessica M
  Metabolism.2026; 181: 156652.     CrossRef
• Post-Translational Modification Networks in Ferroptosis: Orchestrating Defense, Drug Resistance, and Therapeutic Opportunities in Hepatocellular Carcinoma
  Jie Chen, Lingling Li, Sufang Fang, Haitao Zhou
  Journal of Hepatocellular Carcinoma.2026; Volume 13: 1.     CrossRef
• Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD
  Elda Cristina Villaseñor-Tapia, Adriana Franco-Acevedo, Rebeca Rosas-Campos, Juan Armendariz-Borunda
  Pharmaceutics.2026; 18(5): 584.     CrossRef
• Improving Care Quality for Metabolic Dysfunction-associated Steatotic Liver Disease Through a Structured Yogic Intervention: Protocol for a Randomised Controlled Trial
  Gautam Panwar, Garima Singh, Kanchan Joshi, Sanjay Gupta, Kuldeep Singh, Vikas Upadhyay
  Annals of Neurosciences.2026;[Epub]     CrossRef
• The Evolution of MASLD Management: From Revised Nomenclature to Disease-Modifying Therapies
  Karolina Kornatowska, Szymon Kopciał, Mateusz Wiekiera, Adrianna Wiekiera, Paweł Budzik, Mateusz Tyniec, Kamal Morshed
  Gastroenterology Insights.2026; 17(2): 33.     CrossRef
• Metabolomics-Enhanced Liquid Biopsy Identifies Early Heptocellular Injury in Females with MetALD
  Anika Volkmar, Gregor Mattert, Florian Deisinger, Kornelius Schulze, Asmus Heumann, Werner Dammermann, Selina Strathmeyer, Steffen Heelemann, Thomas Kalinski, Stefan Lüth, Janine Kah
  International Journal of Molecular Sciences.2026; 27(11): 4695.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Profile, Phenotypes, and Risk Stratification. A Narrative Review
  Zalina Yuryevna Sozaeva, Marina Vsevolodovna Atayeva, Elizaveta Olegovna Salatova, Irina Kazbekovna Alikova, Alexandra Evgenievna Dolgaya, Amin Gasaevich Magomedov, Kamilla Ramisovna Hafsi, Nur-Mukhamed Aslanovich Shomakhov, Elena Mukhadinovna Pshukova, Y
  Journal of Biochemical Technology.2026; 17(2): 30.     CrossRef
• X-chromosome gene dosage shapes MASLD beyond sex hormones
  Mohamad Jamalinia, Giovanni Targher, Amedeo Lonardo
  Trends in Endocrinology & Metabolism.2026;[Epub]     CrossRef
• Mediating roles of insulin resistance and inflammatory markers between healthy sleep scores and metabolic dysfunction-associated steatotic liver disease
  Qing-Tao Yu, Yun-Ying Lin, Zi-Hao Gui, Hua-Lin Duan, Jun-Jie Yang, Yuan Meng, Xue-Tao Peng, Lan Liu, Heng Wan, Jie Shen
  World Journal of Gastroenterology.2026;[Epub]     CrossRef
• Acute Effects of Cannabinoid Combination Therapies in a Western Diet-Induced Murine Model of Metabolic Liver Disease
  Jerome Lian, Mohan Patil, Ricky R. Lareu, Marco Falasca
  International Journal of Molecular Sciences.2026; 27(11): 4872.     CrossRef
• Dantrolene attenuates steatohepatitis and liver fibrosis by suppressing Ca2+ dysregulation
  Juri Sakamoto, Takeshi Yamamoto, Minami Sato, Ayano Sasakura, Yoshihide Nakamura, Naoomi Tominaga, Masako Inamitsu, Naoki Yamamoto, Taro Takami, Motoaki Sano
  Biochemical and Biophysical Research Communications.2026; 827: 154042.     CrossRef
• Epigenetic antifibrotic effect of expression of long noncoding RNAs lncR-p21, MEG3, H19 on the development of fibrosis in metabolic dysfunction-associated steatotic liver disease (systematic review and meta-analysis)
  A.E. Abaturov, A.O. Nikulina
  GASTROENTEROLOGY.2026; 60(2): 133.     CrossRef
• Metabolic dysfunction–associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart–liver metabolic axis perspective
  Xuebi Wu, Yongxin Ma, Xueshi Yin, Jianping Liu, Yongheng Zhang
  Frontiers in Pharmacology.2026;[Epub]     CrossRef
• Impact of severe hepatic iron overload on MR and ultrasound time-harmonic elastography
  Steffen P. Häseli, Jakob Schattenfroh, Tom Meyer, Paul Spiesecke, Tobias Puengel, Florian Roßner, Bernhard Gebauer, Raphael Mohr, Münevver Demir, Frank Tacke, Ingolf Sack, Rolf Reiter
  Journal of the Mechanical Behavior of Biomedical Materials.2026; 180: 107480.     CrossRef
• Determination of ultrasound diagnostic thresholds for detecting early hepatic steatosis in children: a comparative evaluation of different ultrasound systems using MRI-PDFF as the reference standard
  O.A. Pushkarenko, M.M. Zhaivoronok, O.B. Dynnyk, O.T. Yemets, N.V. Deresh, V.V. Kaliy
  GASTROENTEROLOGY.2026; 60(2): 90.     CrossRef
• Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis
  Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim
  Clinical and Translational Gastroenterology.2026;[Epub]     CrossRef
• Four new amide alkaloids from the fruits of Piper longum and their anti-adipogenic activities
  Xue-Ting Cui, Ling-Yu Li, Jia Liu, Hui-Hui Wang, Tao Zhang, Zhong-Mei Zou
  Journal of Asian Natural Products Research.2026; : 1.     CrossRef
• Upcycling Agricultural By‐Products: RNA‐Seq‐Based Elucidation of Body Weight‐Independent Hepatoprotective Mechanisms of Cucumis melo var. makuwa Leaf Extract in Diet‐Induced Obese Mice
  Ji Young Hwang, Ji Yun Van, Hyeon Hak Jeong, Yerin Seong, Seokmin Lee, Jaeseong Seo, Bo‐Mi Ryu, Seungjun Lee, Suhyeon Baek, Sanggil Lee, Won‐Kyo Jung, Jae‐Il Kim, Bonggi Lee
  eFood.2026;[Epub]     CrossRef
• Machine learning-based prediction of hepatocellular carcinoma risk in steatotic liver disease: A nationwide cohort study
  Log Young Kim, Ji Soo Lee, Jeong-Ju Yoo, Eun Ju Cho, Sang Gyune Kim, Young Seok Kim, Tyng-Yuan Jang
  PLOS One.2026; 21(5): e0349593.     CrossRef
• Rendimiento del puntaje MAFLD-S para el tamizaje no invasivo de esteatosis hepática metabólica en el primer nivel de atención
  J.A. Torres-Díaz, A. Olivas-Martinez, J.A. Ruiz-Manriquez, A. Kammar-García, L.C. Chávez-García, L.F. Uscanga-Domínguez, S.E. Martínez-Vázquez
  Revista de Gastroenterología de México.2026;[Epub]     CrossRef
• Impact of liver and pancreatic steatosis on behavioral responses in rats under experimental conditions and after cessation of combined exposure to steatogenic factors
  A.M. Halinska, O.A. Maltseva, O.O. Halinskyi
  GASTROENTEROLOGY.2026; 60(2): 82.     CrossRef
• Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease
  Roberta Chianetta, Lydia Giannitrapani, Alessio Giuseppe Lipari, Assunta Brunone, Claudia Cannizzo, Roberto Citarrella, Maurizio Soresi, Antonio Liguori, Nadia Panera, Filomena Morisco, Luca Miele, Anna Licata
  Biomolecules.2026; 16(6): 797.     CrossRef
• EASL position paper on preclinical models of steatotic liver disease
  Suchira Gallage, Rui E. Castro, Jennifer Estall, Ira Tabas, Quentin M. Anstee, Dina G. Tiniakos, Gyongyi Szabo, Jun Yu, Chantal Desdouets, Frank Tacke, Fiona Oakley, Mathias Heikenwalder
  Journal of Hepatology.2026;[Epub]     CrossRef
• Liver Endothelial Heg1 Signal Limits Hepatic Steatosis via Wnt-Mediated Fatty Acid Oxidation in Hepatocytes
  Xiyun Rao, Qianqian Zhao, Jinbiao Chen, Min Zheng, Mingyue Xing, Yu Feng, Jiayuan Chen, Shichao Zhu, Zhiming Han, Geoffrey W. McCaughan, Xiangjian Zheng
  Cellular and Molecular Gastroenterology and Hepatology.2026; 20(9): 101807.     CrossRef
• Risk factors for atherosclerotic plaque formation in MASLD patients: insights from cross-sectional and Mendelian randomization analyses
  Wei-hao Peng, Jing Zhang, Yu-hua Ruan, Yan Li, Ye Liu, Ming-jia Dai, Jing-kun Jin, Xue-bin Yan, Fang Ji
  Nutrition, Metabolism and Cardiovascular Diseases.2026; : 104815.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
  Ruizhe Ren, Xiao Liang, Xiyang Wei
  Molecular Biomedicine.2026;[Epub]     CrossRef
• Structural characterization of the pectic polysaccharide from corn silk and its protective mechanism against MASLD via regulation of the gut-liver axis
  Haichao Wang, Jiajing Yan, Haolin Jia, Xiaoyan Li, Bingxuan Li, Xuefang Zhang, Shujun Wang, Zheng Li, Yuhong Liu, Yifei Bian
  Carbohydrate Polymers.2026; 388: 125510.     CrossRef
• Association of Hepatic Steatosis Burden With Microalbuminuria in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study
  Komal S Jog, Harini Bopaiah, Guru Yogendra Muthyal, Sai Deepika R
  Cureus.2026;[Epub]     CrossRef
• Renal Dysfunction Across Etiologies of Chronic Liver Disease: A Cross-Sectional Study From a Tertiary Care Center
  Asha Saranya Rapeti, Rakesh Pilla, Gayathri Chouthai, Abhinav Maharaj Thota, Mrinal Shashidhar, Chaithanya Shanthi Vanamada
  Cureus.2026;[Epub]     CrossRef
• Steatotic liver disease in Latin America: current views and perspectives
  Francisco Idalsoaga, Luis Antonio Díaz, Francisco Barrera, Adrian Gadano, Claudia P. Oliveira, Juan Pablo Arab, Marco Arrese
  Nature Reviews Gastroenterology & Hepatology.2026;[Epub]     CrossRef
• Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies
  Ioannis Katsaros, Dimitrios Schizas
  Life.2026; 16(6): 915.     CrossRef
• Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease
  Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim
  Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603.     CrossRef
• Post-transplant MASLD: a risk-stratified approach to assessment and personalized management
  He-Yu Huang, Zhong-Qi Fan, Guo-Yue Lv
  Frontiers in Medicine.2026;[Epub]     CrossRef
• The efficacy of carbohydrate-restricted diets on reducing visceral and liver fat in individuals with overweight and obesity: a systematic review and pairwise and network meta-analyses
  Mousa Khalafi, Aref Habibi Maleki, Mahsa Ehsanifar, Maryam Aghaeinejad, Mohammad Hossein Sakhaei, Sara K. Rosenkranz, Michael E. Symonds, Fatemeh Ramezani
  Critical Reviews in Food Science and Nutrition.2026; : 1.     CrossRef
• Synbiotics and antioxidants synergistically attenuate disease progression in metabolic dysfunction-associated steatotic liver disease
  Zhilu Xu, Wenyi Zhu, Qiyun Xia, Wenli Huang, Yuanyuan Chi, Haoyu Qi, Oi Yee Pessy Chan, Jessica YL Ching, Francis KL Chan, Nor Norman Chan, Siew C. Ng
  Biomedicine & Pharmacotherapy.2026; 201: 119656.     CrossRef
• Integrative Multi‐Omics Analysis Elucidates the Progressive Disease Landscape and Reveals Dynamic Protein Biomarkers for MASLD Surveillance
  Kejun Liu, Bozhi Zhang, Yezhen Tang, Zhenyao Tan, Yang Bu, Yongxue Lv
  The FASEB Journal.2026;[Epub]     CrossRef
• A novel serum metabolite classifier for identifying Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) integrating metabolomics and machine learning
  Binghui Li, Yiru Zhang, Ziyang Li, Zhiyang Chen, Zhe Guo, Weimin Wu, Li Tan, Lini Dong, Xiangyu Zhang, Xing Lyu, Min Hu, Qichen Long
  BMC Gastroenterology.2026;[Epub]     CrossRef
• Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
  Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal, Ant
  Nature Medicine.2026;[Epub]     CrossRef
• Bisphenol S induces hepatic steatosis and insulin resistance through AMPK inhibition and endoplasmic reticulum stress
  Vinicius Sepúlveda-Fragoso, Emanuelle Barreto-Reis, Thais de Souza Carvalho-Laureano, Milena Barcza Stockler-Pinto, Eliete Dalla Corte Frantz, Denise Pires de Carvalho, Xavier Palomer, Emma Barroso, Manuel Vázquez-Carrera, Leandro Miranda-Alves, D'Angelo
  Food and Chemical Toxicology.2026; 215: 116222.     CrossRef
• The association between six heavy metal levels and the risk of liver fibrosis in women without gestational diabetes mellitus
  Juan Yu, Li Wang, Shu-lan Zhu, Min Xiao, Hai-xing Huang, Yan-hong Shao, Qi-chen Bao, Miao-miao Ma, Ying-ying Chen
  The American Journal of the Medical Sciences.2026;[Epub]     CrossRef
• Strengthening Dietary Antioxidant Capacity in Primary Care: A Low-Cost Strategy to Prevent Metabolic Syndrome and MASLD in Iran
  M Sepehrinia, A Nikparast, J Mirzay Razzaz, Reza Homayounfar
  Iranian Journal of Nutrition Sciences and Food Technology.2026; 20(5): 83.     CrossRef
• Diversity in metabolic dysfunction-associated steatotic liver disease: a framework for precision medicine
  Donghyun Ko, Jordan Low, Peter Low, Damien Chua, Yock Young Dan, Vincent Chen, Jonathan A. Fallowfield, Timothy J. Kendall, Hirokazu Takahashi, Cheng Han Ng, Nicholas Syn, Mark Muthiah
  npj Gut and Liver.2026;[Epub]     CrossRef
• Shall You Get an Invasive Examination? An AI-Driven Risk Stratification Model for Individuals with Suboptimal Health Status
  Chia-Yu Lai, Jen Yu, Chieh Lee, Guan-Yu Wang, Shania Andea Perdana, Tsung-Hsing Chen, Ta-Sen Yeh
  Service Science.2026;[Epub]     CrossRef
• Incorporating Insulin Resistance Biomarkers into Machine Learning Models Enhances Diagnostic Accuracy for Metabolic Dysfunction–Associated Steatotic Liver Disease
  Jingyuan Nie, Jing Zhou, Yuanjia Hu, Changhong Zhang, Pingping Yu, Xun Lei
  Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
• Exposure to Per- and Polyfluoroalkyl Substances and the Risk of Sarcopenia: The Mediating Role of Serum Albumin
  Mingkun Sun, Chu Chu, Kun Zhao, Zhengmin (Min) Qian, Mario Schootman, Stephen Edward McMillin, Jiaxiang Dong, Wenwen Bao, Muhammad Amjad, Haseeb Tufail Moryani, Yang Zhou, Yan Yang, Peipei Wang
  Toxics.2026; 14(6): 478.     CrossRef
• Non-alcoholic fatty liver disease and Helicobacter pylori infection: problems and solutions. A review
  Elena V. Onuchina
  Consilium Medicum.2026; 28(5): 387.     CrossRef
• Impact of Volatile Organic Compound Mixtures on Cardiovascular Health in Adults With Metabolic Dysfunction–Associated Fatty Liver Disease: A US Population Study
  Qingping Wu, Meiling Jin, Shan Liu, Yue Wu, Tarek Alshaal
  Indoor Air.2026;[Epub]     CrossRef
• A Single-Food Substitution Strategy (SFSS) Improves Fat Mass and Metabolic Parameters in MASLD: A Prospective Pilot Study
  Nicole Cerabino, Caterina Bonfiglio, Leonilde Bonfrate, Rosanna Donvito, Pasqua Letizia Pesole, Dolores Stabile, Endrit Shahini, Gianluigi Giannelli
  Nutrients.2026; 18(12): 1873.     CrossRef
• Limited Agreement of Different Elastography Techniques in Assessing Liver Stiffness in Postmenopausal Women with Early-Stage Metabolic Dysfunction-Associated Steatotic Liver Disease
  Ilias D. Vachliotis, Vasileios Rafailidis, Athanasios D. Anastasilakis, Nikoletta Pyrrou, Stergios A. Polyzos
  Livers.2026; 6(3): 53.     CrossRef
• Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease
  Kuo Fang, Ji Miao, Guobin Song
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• Edible extracellular vesicle-like particles from Exocarpium Citri Grandis: A natural nanoplatform for oral treatment of metabolic dysfunction-associated steatotic liver disease
  Jingxiu Zhao, Tao Huang, Chengshi Fu, Yingjie Xiong, Anran Gao, Kui Wang, Yujia Song, Zanxiang Luo, Xiangyun Teng, Wei Zhao, Jianhua Xu
  International Journal of Biological Macromolecules.2026; 372: 152952.     CrossRef
• Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction–associated steatotic liver disease
  Rishi Chowdhary, Manjeet Kumar Goyal, Megh Patel, Rahul Chowdhary, Kirti Arora, Varun Mehta, Akash Batta, Omesh Goyal, Ashita Rukmini Vuthaluru
  Frontiers in Epidemiology.2026;[Epub]     CrossRef
• Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review
  Karol P. Sagan, Zuzanna Lipiec-Rzepecka, Martyna Patalong-Wójcik, Michał P. Wasilewicz, Elżbieta Andrysiak-Mamos, Anhelli Syrenicz
  Journal of Endocrinological Investigation.2026;[Epub]     CrossRef
• Cardiovascular Risk Factors in Greece: Looking Beyond the Classics. A narrative review.
  George Michas, Grigorios Trikas, Athanasios Trikas
  Hellenic Journal of Cardiology.2026;[Epub]     CrossRef
• Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus
  Ying Zhao, Zhaoyue Li, Tian Yu, Yan Yang, Tingting Du
  BMJ Open Diabetes Research & Care.2026; 14(3): e005841.     CrossRef
• Prevalence and Predictors of MASLD and Fibrosis in an Urban Outpatient Setting: A Cross-Sectional Study
  Nicolás Ortiz-López, Daniela Simian, Máximo Cattaneo, Katherine Rojas, Daniel Durán, Martina Contreras, Diego Lizama, María Fernanda Eyssautier, Camila Meza, Catalina Molina, Gerardo Jara, Jaime Poniachik
  Journal of Clinical Medicine.2026; 15(12): 4533.     CrossRef
• Mortality trends in diabetes with proxy-defined steatotic liver disease in the United States, 1999–2023
  Hongzhou Liu, Ru Wang, Liqin Cui, Linlin Wang, Jia Liu, Yangfan Du, Song Dong, Kaide Xia
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• Nanoformulations for obesity-driven MASLD and MASH: Cell-specific hepatic drug delivery, comorbidity outcomes, and translational perspectives
  Polu Picheswara Rao
  Obesity Medicine.2026; 62: 100720.     CrossRef
• Fatty acid‑activated proton transporter SR4 prevents hepatic steatosis and metabolic alterations in diabetic mice by improving mitochondria function, energy balance and oxidative stress
  James Figarola, Jyotsana Singhal, Sharad Singhal
  Experimental and Therapeutic Medicine.2026; 32(1): 1.     CrossRef
• Non-Invasive Tests in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Diagnosis to Treatment Monitoring
  Han Ah Lee, Young Youn Cho, Hyung Joon Kim
  Clinical Ultrasound.2026; 11(1): 1.     CrossRef
• Selenoprotein P deficiency in MASLD: association with insulin resistance and liver fibrosis: a prospective case-control study
  Mona A Hegazy, Samar Saad Mohamed, Eman H Saad, Ahmed Abdelghani, Dalia Abd el Fattah, Mohamed Ahmed Elsayed Mekki, Mona Fathy, Nora Hassan, Omar Ashoush
  BMC Gastroenterology.2026;[Epub]     CrossRef
• MASLD and sarcopenia research (2012–2025): a multi-database bibliometric analysis
  Keyan Gao, Liwen Xun, Shalei Hao, Min An, Lingfeng Zuo, Jiayu Wang, Ying Wang, Junhua He
  Frontiers in Nutrition.2026;[Epub]     CrossRef
• Integrating UHPLC-Q-TOF/MS and multi-omics to elucidate the regulatory mechanisms of Xiong's Shiwei Wendan decoction in MASLD
  Miao Jiang, Qiu Wu, Rong Yu, Zehua Zhang, Ge Wen, Yuan Zhong, Zhoujin Tan, Zhijian Li, Xuejiao Xie
  Journal of Chromatography B.2026; 1281: 125181.     CrossRef
• Korean red ginseng saponins ameliorate metabolic dysfunction-associated steatohepatitis in mice by inhibiting caspase-11 and NLRP3 inflammasomes
  Eojin Kim, Hee Ryeong Lim, Deok-Hyeong Choi, Young-Su Yi
  Journal of Ginseng Research.2026; : 101075.     CrossRef
• Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation System
  Naim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, Eric Lawitz, Edward Mena, Nadege T. Gunn, Khurram Jamil, Seth Zuckerman, Stephen A. Harrison, Naga Chalasani
  Gastro Hep Advances.2026; 5(8): 101004.     CrossRef
• Integrating the Fatty Liver Index into Primary Care: A Low-Cost Strategy for Early Identification of Chronic Kidney Disease Risk in Iran
  S Bazmi, M Farjam, J Mirzay Razzaz, matin Sepehrinia, R Homayounfar
  Iranian Journal of Nutrition Sciences and Food Technology.2026; 20(5): 117.     CrossRef
• Obesity Management in Primary Care: Clinical Approaches and Policy Implications in the Era of Incretin-Based Therapies
  Chung-woo Lee
  Korean Journal of Family Practice.2026; 16(2): 81.     CrossRef
• A celastrol derivative–based multifunctional nanozyme for oxidative stress scavenging and lipid metabolism regulation in metabolic dysfunction-associated steatotic liver disease
  Haoran Yang, Xue Cui, Kun Yu, Zhiwen Zhao, Longlong Jin, Qing Wang, Huiying Yang, Xinwei Li, Xuzhu Gao, Xianfu Wu
  Biomaterials Advances.2026; 188: 215027.     CrossRef
• Hepatoprotective effects of the branched-chain fatty acids 12-methylmyristic and 13-methylmyristic against palmitate-induced lipotoxicity
  Sara Rico-Chazarra, Carmen García-Melgares, Inmaculada Ros-Madrid, María A. Martínez-Sánchez, Lidia Sánchez-Alcoholado, Alba Oliva-Bolarín, Virginia E. Fernández-Ruiz, Mercedes Ferrer-Gómez, Antonio J. Ruiz-Alcaraz, Carlos M. Martínez, Adriana Mika, María
  Biomedicine & Pharmacotherapy.2026; 201: 119687.     CrossRef
• Reshaping the Future of MASLD - From Pathophysiological Mechanisms to New Therapeutic Horizons
  Dimitrios Patoulias, Manfredi Rizzo
  Current Pharmaceutical Design.2026; 32(20): 1537.     CrossRef
• Steatotic Shadows: The Dark Link Between Metabolic Dysfunction-associated Steatotic Liver Disease and Cancer Risk
  Shakta Mani Satyam, Mohamed El-Tanani, Syed Arman Rabbani, Alaa A. Aljabali, Yahia El-Tanani, Dimitrios Patoulias, Manfredi Rizzo
  Current Pharmaceutical Design.2026; 32(20): 1539.     CrossRef
• Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort
  Hyo Jung Cho, Seong Hee Kang, Hye Yeon Chon, SungA Bae, Eunju Kim, Seong Kyun Na, Su Jin Kim, Dooyeon Kim, Hye Ri Ahn, Huigyeong Kim, Jae Youn Cheong, Soon Koo Baik, Young Kul Jung, Soon Sun Kim, Hyung Joon Yim
  Journal of Korean Medical Science.2026;[Epub]     CrossRef
• LY6D promotes hepatic steatosis via the GRB2–AMPK–SREBP1 signaling axis
  Qiurong Zhao, Linxin Chen, Sha Xie, Juanjuan Meng, Wei Cui, Yao Wu, Ting Zeng, Huaming Mou, Xiaohe Luo
  International Journal of Obesity.2026;[Epub]     CrossRef
• The Hepato-Exposome Axis: How Endocrine Disruptors Hijack Liver Receptors to Drive MASLD
  M. Martín-Grau, J.H. Kamstra, T. Hyötyläinen, M. Orešič, Y. Song, N. Veličković, A. Djordjevic, D. Vojnović Milutinović, R.F. Jackson, R. van Vorstenbosch, J. Massart, A. Vidal-Puig, S. Carobbio
  Journal of Hepatology.2026;[Epub]     CrossRef
• Association of metabolic dysfunction-associated steatotic liver disease trajectories with incident liver cancer: a UK Biobank cohort study
  Ryuk Jun Kwon, Yohwan Lim
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• Therapeutic effects and mechanisms of Artemisia species on metabolic diseases: A systematic review
  Naiyu Wang, Minmin Li, Mingjing Lu, Zheng Wang, Hualin Wang, Meiyue Yao, Hailing Ding, Muhammad Shahbaz, Muhammad Ijaz
  Medicine.2026; 105(25): e49379.     CrossRef
• Dysregulated Lipid Metabolism in Hepatocellular Carcinoma: Mechanisms and Therapeutic Strategies
  Yi Yi, Xi Liu, Xi Zhang, Yongsheng Li, Huakan Zhao
  MedComm – Oncology.2026;[Epub]     CrossRef
• Fibroblast- and Macrophage-Derived Thrombospondin-1 Orchestrates the Fibroinflammatory Niche in Metabolic Dysfunction-Associated Steatohepatitis-Induced Fibrosis
  Sung Woo Cho, Jung Hoon Cha, Deok Wha Seo, Mi Hyun Kwon, Kwon Yong Tak, Hee Sun Cho, Keungmo Yang, Seo Young Jung, SuHyun Hwangbo, Jae Yong Ryu, Si Hyun Bae, Pil Soo Sung
  Diabetes & Metabolism Journal.2026;[Epub]     CrossRef
• Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease
  Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer
  Clinical Pharmacology & Therapeutics.2026;[Epub]     CrossRef
• Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study
  Hyuk Kim, Jeong-Ju Yoo, Young Chang, Jae Young Jang, Tom Ryu, Soung Won Jeong, Sang Gyune Kim, Young Seok Kim, Suyeon Park
  Frontiers in Medicine.2026;[Epub]     CrossRef
• Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review
  Dina Mahoon, Fares Kellany, Imad Khan, Somieya Khan, Alexandra E. Butler
  International Journal of Molecular Sciences.2026; 27(12): 5618.     CrossRef
• Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD
  Eva Katharina Messer, Janett Fischer, Toni Herta, Albrecht Boehlig, Madlen Matz-Soja, Adrienn Tuennemann-Tarr, Susanne Gaul, Ulrich Laufs, Thomas Berg, Pavel Strnad
  PLOS One.2026; 21(6): e0349666.     CrossRef
• Aging and Western Diet Synergistically Impair Hepatic Thyroid Hormone Signaling to Promote Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) in Mice
  Xinru Zhang, Madhulika Tripathi, Chun Ting Goh, Chee Seng Chan, Anita Boelen, Paul M. Yen, Brijesh Kumar Singh, Eveline Bruinstroop
  Aging Cell.2026;[Epub]     CrossRef
• Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States
  Ali A. Abdeen, Turgay Ayer, Aanan Biswas, Chase J. Wehrle, Sobia N. Laique, Ali Aminian
  Diabetes, Obesity and Metabolism.2026;[Epub]     CrossRef
• Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010–2023
  Jialin Wu, Bonan Chen, Fuda Xie, Jiahui Hu, Mingyu Liang, Yang Lyu, Peiyao Yu, Tiejun Feng, Muyang Huang, Canbin Fang, Ka Fai To, Terry Cheuk-Fung Yip, Xingxin Wang, Wei Kang
  Hepatology International.2026;[Epub]     CrossRef
• Letter to the Editor: Steatotic liver disease in chronic hepatitis C - a marker of systemic risk, not direct-acting antiviral treatment failure
  Abdo Imad El Tawil, Claudia Alexandra Pontes Ivantes
  World Journal of Hepatology.2026;[Epub]     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease in Inflammatory Bowel Disease: A Cross-Sectional Study of Prevalence and Associated Factors
  Hüseyin Aykut, Nermin Mutlu Bilgiç, Duygu Demirtaş, Süleyman Sayar, Kamil Özdil
  Metabolites.2026; 16(7): 450.     CrossRef
• Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review
  Jeong-Hwan Lee, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
  Journal of the Korean Medical Association.2026; 69(6): 492.     CrossRef
• Decoding the Gut–Fat–Heart Axis: From Molecular Communication Networks to Clinical Translation Strategies
  Zijin Sun, Wei Shao, Haojia Zhang, Kai Wang, Yongchao Liu, Rui Zhou
  International Journal of Molecular Sciences.2026; 27(12): 5596.     CrossRef
• Macrophage–neutrophil crosstalk via the Selplg–Sell–YAP axis drives NETosis and MASH-associated liver fibrosis
  Fulin Nian, Chen Wu, Dejun Wu, Yifan Ma, Yueying Chen, Lin Xu, Yuqin Li, Ling Dong, Wujun Xiong
  Hepatology.2026;[Epub]     CrossRef
• Diagnostic Performance of Ultrasound-Guided Attenuation Parameter (UGAP) for Hepatic Steatosis Assessment: Comparison with MRI-PDFF and Evaluation of Cohort-Derived Thresholds
  Dimitrios Kavvadas, Natalia-Valeria Pentara, Dimitrios Kourdakis, Aris Liakos, Emmanouil Sinakos, Panos Prassopoulos, Vasileios Rafailidis
  Diagnostics.2026; 16(13): 2006.     CrossRef
• Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD), Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD), Metabolic Associated Steatohepatitis (MASH) and Obesity
  Davor Štimac
  Best Practice & Research Clinical Gastroenterology.2026; : 102116.     CrossRef
• Ammonia in the crosshairs: microbial targets for metabolic dysfunction–associated steatohepatitis prevention
  Vanessa A. Leone, Arion Kennedy
  Journal of Clinical Investigation.2026;[Epub]     CrossRef
• Fibrosis and Perinatal Features Correlated with Telomere Shortening in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease
  Maria Rita Braghini, Salvatore Daniele Bianco, Marzia Bianchi, Giulia Andolina, Antonella Mosca, Cristiano De Stefanis, Michela Piccione, Paola Francalanci, Clara Balsano, Luca Miele, Tommaso Mazza, Anna Alisi
  Life.2026; 16(7): 1068.     CrossRef
• The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH
  Caichen Zhong, Nana Boame, Semiu O. Gbadamosi, Maximilian Jara, Rakesh Luthra, Alex Salamun, Yu Hong, Abdalla Aly, Fernando Bril, Mary E. Rinella
  Expert Review of Pharmacoeconomics & Outcomes Research.2026;[Epub]     CrossRef
• Editorial: Advancing immune research in chronic liver diseases through new approach methodologies
  Sara Massironi, Ana C. Maretti-Mira
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Association of Sleep Characteristics With Suspected Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Risk Among Adults Attending a Community Health Center
  Tushar Prabhakar, Gahan S Jois, Satya V Singh, Bronica Saini, Adarsh Mohan
  Cureus.2026;[Epub]     CrossRef
• Vitamin E dosing study (VEDS) in patients with metabolic dysfunction–associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial
  Srinivasan Dasarathy, Emily P. Mitchell, Laura A. Wilson, Brent A. Neuschwander-Tetri, Naga Chalasani, Jeanne M. Clark, Anna Mae Diehl, Bilal Hameed, Rohit Loomba, Liyun Yuan, Kris V. Kowdley, Arun J. Sanyal
  Hepatology.2026;[Epub]     CrossRef
• MASH‐Related Liver Cancer Estimates Need Aetiology‐Specific Validation in the Asia‐Pacific Region
  Haoyang Hu
  Liver International.2026;[Epub]     CrossRef
• Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics
  Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen
  BMJ Open Gastroenterology.2026; 13(1): e002343.     CrossRef
• Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications
  Kenneth Tachi, Adwoa Agyei-Nkansah, Yacoba Atiase, Bright Forkuo, Victoria Akosua Agyen-Frimpong
  BMJ Open Gastroenterology.2026; 13(1): e002294.     CrossRef
• Artificial intelligence predicts sex-specific risk of metabolic dysfunction-associated steatotic liver disease
  Mohamad Jamalinia, Giovanni Targher, Amedeo Lonardo, Seyed Taghi Heydari, Kamran Bagheri Lankarani
  Biology of Sex Differences.2026;[Epub]     CrossRef
• A carotenoid-rich functional tomato sauce (OsteoCol®) reduces liver fat content in adults with metabolic dysfunction-associated steatotic liver disease: a randomized clinical trial
  Rosario Mare, Yvelise Ferro, Samantha Maurotti, Elisa Mazza, Alberto Castagna, Carmelo Pujia, Francesca Rita Noto, Angelo Galluccio, Angela Mirarchi, Giuseppe Andrea Giampà, Marta Moraca, Tiziana Montalcini, Arturo Pujia
  European Journal of Nutrition.2026;[Epub]     CrossRef
• Association of the cholesterol-HDL-glucose index with prevalent metabolic dysfunction-associated steatotic liver disease and its incremental metabolic-hepatic assessment value: a hospital-based cross-sectional study
  Ziqian Song, Hao Sun, Cai Wang, Yuantao Qi, Yuan Liu
  Frontiers in Nutrition.2026;[Epub]     CrossRef
• Apigenin attenuates hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease by targeting the TGF-β signaling pathway
  Lijun Cao, Yongna Zhao
  Cytotechnology.2026;[Epub]     CrossRef
• A TyG–UHR-based machine learning model for screening lean MAFLD: development and external validation
  Yansong Ji, Hui Zhang, Jingjing Xia, Guilian Chen, Hong Li
  BioMedical Engineering OnLine.2026;[Epub]     CrossRef
• Intermittent fasting strategies for metabolic dysfunction-associated steatotic liver disease: A systematic review and frequentist network meta-analysis of randomized controlled trials
  Husam Abu Suilik, Ahmed Farid Gadelmawla, Mohamed Rifai, Moayad Alhawi, Abdellrahman Ashour, Hassan Abdalshafy, Omar Abdullah Bataineh, Hazem Rezq, Anas Bani Hani, Ismail Elkhattib, Mohamed Abuelazm
  Clinical Nutrition ESPEN.2026; 75: 103415.     CrossRef
• Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide
  V. V. Gorban, E. V. Gorban, P. E. Kocherga
  Meditsinskiy sovet = Medical Council.2026; (8): 126.     CrossRef
• Progression of Metabolic Dysfunction–Associated Steatohepatitis in US Adults Using Linked Records and Claims
  Yestle Kim, Romina Fakhraei, John C. O’Donnell, Karissa Johnston, Melissa Bather, Reem Mustafa, Andrew R. Kennedy, Amreen Dinani
  Gastro Hep Advances.2026; 5(9): 101031.     CrossRef
• Interactive Roles of Metabolic Dysfunction‐Associated Steatotic Liver Disease and Nutritional Status in the Prognosis of Patients With Hepatocellular Carcinoma After Surgical Resection
  Chun‐Ting Ho, Chien‐An Liu, Chia‐Jung Ho, Yi‐Chen Lin, Shin‐Yu Tsai, Hao‐Jan Lei, Shu‐Cheng Chou, Yi‐Hsiang Huang, Ming‐Chih Hou, Jaw‐Ching Wu, Chien‐Wei Su
  The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
• Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study
  Yanqiu Huang, Yadan Xu, Chenghao Zhang, Wen Gu, Yue Li, Haojia Zhang, Tian Wang, Tangyi Su, Yangchen Lhamu, Yichen Chen, Liang Zhou, Lipeng Hao, Yang Yang, Hui Wang
  Cardiovascular Diabetology.2026;[Epub]     CrossRef
• Piezo1 as a novel therapeutic target of salvianolic acid B for metabolic dysfunction-associated steatotic liver disease
  Yuxue Zhang, Chang Liu, Weiyi He, Wenhui Li, Wentao Duan, Chaofeng Wu, Hui Jia, Jieying Lan, Zeyu Tong, Qiaohui Du, Haiyan Lin, Zhuowei Gao, Wenxia Zhao, Piao Luo, Lei Gao
  Phytomedicine.2026; : 158546.     CrossRef
• Phellinus igniarius Polysaccharides Ameliorate Nonalcoholic Fatty Liver Disease Through Suppressing SREBP1
  Ying‐Jun Zhang, Kai‐Yue He, Wei‐Tao Yin, Qing‐Chun Zhao, Xiong‐Yan Xiang, Jun‐Qi Li, Zhi‐Feng Zhang, Yong‐Ping Jian, Zhi‐Xiang Xu
  Food Frontiers.2026;[Epub]     CrossRef
• Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studies
  Jialin Wu, Wenting Wei, Terry Cheuk-Fung Yip, Xinyi Deng, Bonan Chen, Yang Lyu, Peiyao Yu, Tiejun Feng, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Wei Kang
  Clinical and Experimental Medicine.2026;[Epub]     CrossRef
• Weight loss and alcohol reduction synergize for hepatic steatosis remission in elderly patients with metabolic alcohol-associated liver disease (MetALD): a retrospective cohort study
  Tianxiang Lin, Xiaoxue Yuan, Yanrong Zhao, Wei Wang, Chen Wu, Song Yang, Yinwei Qiu
  International Journal of Obesity.2026;[Epub]     CrossRef
• Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic‐Dysfunction Associated Steatotic Liver Disease
  Jarell Jie‐Rae Tan, Joo Wei Ethan Quek, Sean Shao Wei Lam, Ming‐Hua Zheng, Christophe Corpechot, Aldo J. Montano‐Loza, Yu Jun Wong
  Liver International.2026;[Epub]     CrossRef
• A Simple Clinical Prediction Model for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Obesity
  Yang Liao, Fei Wang, Ting-Ting Tian, Xiu-Fen Li
  Indian Journal of Pediatrics.2026;[Epub]     CrossRef
• Esteatosis hepática metabólica en el síndrome cardio-reno-metabólico: la «H» silenciada
  Javier Crespo, Paula Iruzubieta, Tomas de Vega, Jose Luis Calleja
  Medicina Clínica.2026; 166(9): 107536.     CrossRef
• Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults
  Guannan Zong, Wangjia Mao, Ming Wen, Xiaoyun Cheng, Guanghui Liu
  Annals of Hepatology.2025; 30(2): 101583.     CrossRef
• Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease
  Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang
  Diabetes & Metabolism.2025; 51(1): 101602.     CrossRef
• High-Intensity Interval Training Reduces Liver Enzyme Levels and Improves MASLD-Related Biomarkers in Overweight/Obese Girls
  Wissal Abassi, Nejmeddine Ouerghi, Mohamed Bessem Hammami, Nidhal Jebabli, Moncef Feki, Anissa Bouassida, Katja Weiss, Beat Knechtle
  Nutrients.2025; 17(1): 164.     CrossRef
• Hepatic Estrogen Receptor Alpha Overexpression Protects Against Hepatic Insulin Resistance and MASLD
  Ester S. Alves, Jessica D. M. Santos, Alessandra G. Cruz, Felipe N. Camargo, Carlos H. Z. Talarico, Anne R. M. Santos, Carlos A. A. Silva, Henrique J. N. Morgan, Sandro L. Matos, Layanne C. C. Araujo, João Paulo Camporez
  Pathophysiology.2025; 32(1): 1.     CrossRef
• Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
  Fan Zhang, Longgen Liu, Wenjian Li
  Nutrition Journal.2025;[Epub]     CrossRef
• The association between working hours and working type with non-alcoholic fatty liver disease: results from the NHANES 1999-2014
  Ruli Wang, Ningxi Wu, Huan Qu, Xiaowei Zheng, Haoyang Zhang, Lihong Zhu, Xiaolei Wang, Xiaodie Yao, Le Zhang
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Genetic risk amplifies lifestyle effects on hepatic steatosis and its progression: Insights from a population-based cohort
  Xin Zhang, Haili Wang, Chengnan Guo, Shuzhen Zhao, Yi Li, Zhenqiu Liu, Tiejun Zhang
  Digestive and Liver Disease.2025;[Epub]     CrossRef
• Tetrahydrocurcumin Alleviates Metabolic Dysfunction-Associated Steatohepatitis in Mice by Regulating Serum Lipids, Bile Acids, and Gut Microbiota
  Shang Peng, Moran Meng, Ping Luo, Jiao Liu, Junjun Wang, Yong Chen
  International Journal of Molecular Sciences.2025; 26(3): 895.     CrossRef
• Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
  Katharina L. Hupa-Breier, Heiko Schenk, Alejandro Campos-Murguia, Freya Wellhöner, Benjamin Heidrich, Janine Dywicki, Björn Hartleben, Clara Böker, Julian Mall, Christoph Terkamp, Ludwig Wilkens, Friedrich Becker, Karl Lenhard Rudolph, Michael Peter Manns
  Molecular Metabolism.2025; 93: 102104.     CrossRef
• Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
  Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
  Cells.2025; 14(3): 221.     CrossRef
• Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
  Yunfei Wu, Guojun Zheng, Fan Zhang, Wenjian Li
  Frontiers in Immunology.2025;[Epub]     CrossRef
• Liver fibrosis progression analyzed with AI predicts renal decline
  Dan-Qin Sun, Jia-Qi Shen, Xiao-Fei Tong, Ya-Yun Ren, Hai-Yang Yuan, Yang-Yang Li, Xin-Lei Wang, Sui-Dan Chen, Pei-Wu Zhu, Xiao-Dong Wang, Christopher D. Byrne, Giovanni Targher, Lai Wei, Vincent W.S. Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming-Hua Zhen
  JHEP Reports.2025; 7(5): 101358.     CrossRef
• Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis
  Adrian Rotaru, Remus Stafie, Ermina Stratina, Sebastian Zenovia, Robert Nastasa, Horia Minea, Laura Huiban, Tudor Cuciureanu, Cristina Muzica, Stefan Chiriac, Irina Girleanu, Ana-Maria Singeap, Catalin Sfarti, Carol Stanciu, Anca Trifan
  Life.2025; 15(2): 288.     CrossRef
• Sex differences in diet-induced MASLD – are female mice naturally protected?
  Jana Meyer, Ana Mendes Teixeira, Sandy Richter, Dean P. Larner, Asifuddin Syed, Nora Klöting, Madlen Matz-Soja, Susanne Gaul, Anja Barnikol-Oettler, Wieland Kiess, Diana Le Duc, Melanie Penke, Antje Garten
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis
  Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nak
  Journal of Gastroenterology.2025; 60(7): 891.     CrossRef
• Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
• A Narrative Review on the Risk Factors and Healthcare Disparities of Type 2 Diabetes
  Elvira Meni Maria Gkrinia, Andrej Belančić
  Diabetology.2025; 6(4): 25.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur
  Stergios A. Polyzos, Christos S. Mantzoros
  Metabolism.2025; 168: 156253.     CrossRef
• Molecular Landscape and Diagnostic Model of MASH: Transcriptomic, Proteomic, Metabolomic, and Lipidomic Perspectives
  Yilong Chen, Shuixiu Bian, Jiamei Le
  Genes.2025; 16(4): 399.     CrossRef
• Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques
  Pirangi Srikanth, Khaja Moinuddin Shaik, Vijay Patibandla, Deepak Kumar, Sukhendu Nandi
  Exploration of Endocrine and Metabolic Diseases.2025;[Epub]     CrossRef
• Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
  Hannah Mohr, Jonathan G. Stine
  Alimentary Pharmacology & Therapeutics.2025; 61(9): 1565.     CrossRef
• The socioeconomic and environmental determinants of metabolic dysfunction-associated steatotic liver disease: understanding inequalities in prevalence and outcomes
  Dominika Lorek, Krzysztof Łupina, Wiktoria Bisaga, Dominik Malicki, Weronika Stępień, Laura Kumor, Jakub Janczura
  Korean Journal of Family Medicine.2025; 46(2): 61.     CrossRef
• Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
  Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho
  Trends in Endocrinology & Metabolism.2025; 36(11): 1000.     CrossRef
• Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting
  Edgar A. Villavicencio, Cindy Serdjebi, Adriana Maldonado, Estefania Ochoa Mora, Adrien Besson, Naim Alkhouri, David O. Garcia
  Clinics and Research in Hepatology and Gastroenterology.2025; 49(5): 102581.     CrossRef
• Potential bidirectional communication between the liver and the central circadian clock in MASLD
  Frédéric Gachon, Elisabetta Bugianesi, Gabriele Castelnuovo, Henrik Oster, Julie S. Pendergast, Sara Montagnese
  npj Metabolic Health and Disease.2025;[Epub]     CrossRef
• Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy
  云飞 曲
  Journal of Clinical Personalized Medicine.2025; 04(02): 826.     CrossRef
• GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
  Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
  Clinical and Molecular Hepatology.2025; 31(2): e189.     CrossRef
• Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
  Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li
  Clinical and Molecular Hepatology.2025; 31(2): e145.     CrossRef
• Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy
  Yun Feng, Bingran Yu, Anxiao Liu, Chongpeng Cai, Changming Zhou, Tong Tong, Lu Wang, Qi Pan
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• The Unequal Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease in 204 Countries and Territories From 1990 to 2021
  Junqiao Feng, Yudan Fan
  Liver International.2025;[Epub]     CrossRef
• Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs
  Nicola Pugliese, Davide Polverini, Stefano Ciardullo
  Liver International.2025;[Epub]     CrossRef
• Multi‐Center, Multi‐Vendor Validation of Simultaneous MRI‐Based Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat Fraction‐R2* Phantom
  Jitka Starekova, David Rutkowski, Won C. Bae, Hung Do, Ananth J. Madhuranthakam, Vadim Malis, Sheng Qing Lin, Suraj Serai, Takeshi Yokoo, Scott B. Reeder, Jean H. Brittain, Diego Hernando
  Journal of Magnetic Resonance Imaging.2025; 62(3): 800.     CrossRef
• Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease
  Murali Krishna Moka, Deepalaxmi Rathakrishnan, D.K. Sriram, Melvin George
  Clinical Nutrition.2025; 49: 52.     CrossRef
• Targeting Metabolism: Innovative Therapies for MASLD Unveiled
  Weixin Wang, Xin Gao, Wentong Niu, Jinping Yin, Kan He
  International Journal of Molecular Sciences.2025; 26(9): 4077.     CrossRef
• Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease?
  Luciana Agoglia, Maria Chiara Chindamo, Cristiane Villela-Nogueira
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease
  Mariana M Ramírez-Mejía, Froylan D Martínez-Sánchez, Jacqueline Córdova-Gallardo, Nahum Méndez-Sánchez
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Association between glucose time-in-range and the severity of metabolic dysfunction-associated steatotic liver disease in Chinese adults with type 2 diabetes mellitus
  Chun-Hua Wang, Xuan-Yao Ji, Nian Ji, Qing-Feng Yan, Hong-Qing Xu, Xue-Qin Wang, Xiang-Fan Chen, Chun-Feng Lu
  BMC Endocrine Disorders.2025;[Epub]     CrossRef
• Gut microbiota in patients with metabolic, dysfunction-associated steatotic liver disease
  Lissette Duarte, Fabien Magne, Martin Gotteland
  Current Opinion in Clinical Nutrition & Metabolic Care.2025; 28(4): 307.     CrossRef
• Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease
  Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou
  BMC Gastroenterology.2025;[Epub]     CrossRef
• Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies
  Claudia Reytor-González, Daniel Simancas-Racines, Martín Campuzano-Donoso, Janeth Castano Jimenez, Náthaly Mercedes Román-Galeano, Gerardo Sarno, Evelyn Frias-Toral
  Food and Agricultural Immunology.2025;[Epub]     CrossRef
• Association between urinary albumin-to-creatinine ratio and all-cause and cardiovascular-cause mortality among MASLD: NHANES 2001–2018
  Zhengjin Wang, Zhangxin Chen, Hanxu Zhuang
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
  Yee Hui Yeo, Yixuan Zhu, Jingli Gao, Shanghao Liu, Wenjing Ni, Fajuan Rui, Xue Bai, Nan Geng, Rui Jin, Elizabeth K. Speliotes, Chao Wu, Junping Shi, Xiaolong Qi, Vincent L. Chen, Philip N. Newsome, Jie Li
  Alimentary Pharmacology & Therapeutics.2025; 62(2): 168.     CrossRef
• Association of gut microbiota dietary index with metabolic dysfunction-associated steatotic liver disease: the mediating roles of inflammation and body mass index
  Yu Pu, Zongbiao Tan, Yanrui Wu, Suqi Zeng, Haodong He, Jixiang Zhang, Weiguo Dong
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Association of sarcopenia and physical activity on the severity of metabolic dysfunction-associated steatotic liver disease among United States adults: NHANES 2017 - 2018
  Xiaodie Wei, Xiaohui Liu, Jinhan Zhao, Yang Zhang, Lixia Qiu, Jing Zhang
  Frontiers in Aging.2025;[Epub]     CrossRef
• Low carbohydrate and low-calorie diets reduce liver fat and lower brain glutamate and myo-inositol levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  Andreana P. Haley, Jack Knight-Scott, Marie Caillaud, Isabelle Gallagher, Jessica Park, Yanrong Li, Tianyu Wang, Hirofumi Tanaka, Jeffrey D. Browning
  Metabolic Brain Disease.2025;[Epub]     CrossRef
• FGF21 reverses MASH through coordinated actions on the CNS and liver
  Jesse P. Rose, Donald A. Morgan, Andrew I. Sullivan, Xiaorong Fu, Melissa Inigo-Vollmer, Shawn C. Burgess, David K. Meyerholz, Kamal Rahmouni, Matthew J. Potthoff
  Cell Metabolism.2025; 37(7): 1515.     CrossRef
• Liver cirrhosis in metabolic dysfunction-associated steatohepatitis
  Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah
  Gastroenterology Report.2025;[Epub]     CrossRef
• From liver to limb: Exploring the association between fatty liver disease and peripheral artery disease—A systematic review
  Vera Ciornolutchii, Abdulrahman Ismaiel, Jennifer Bogdan, Stefan‐Lucian Popa, Teodora Surdea‐Blaga, Dan L. Dumitrascu
  European Journal of Clinical Investigation.2025;[Epub]     CrossRef
• Developing and validating a predictive model for all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease
  Fan Zhang, Longgen Liu, Wenjian Li
  Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
• The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis
  Zhifa Ge, Qingwei Wu, Chengyu Lv, Qifeng He
  Immunology.2025; 176(2): 145.     CrossRef
• Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma
  Young-Min Jee, Jeong-Yoon Lee, Tom Ryu
  Biomedicines.2025; 13(5): 1260.     CrossRef
• Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry
  Yusuf Yilmaz, Caglayan Keklikkiran, Andrei Racila, Maria Stepanova, Zobair M. Younossi
  Clinical and Translational Gastroenterology.2025; 16(6): e00844.     CrossRef
• Impact of Metabolic Dysfunction–associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure
  Bhavik Bansal, Fannie Lajeunesse-Trempe, Neil Keshvani, Carl J. Lavie, Ambarish Pandey
  Canadian Journal of Cardiology.2025; 41(9): 1777.     CrossRef
• Pathogenesis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Steatohepatitis
  舒惟 梁
  Advances in Clinical Medicine.2025; 15(05): 2063.     CrossRef
• Prevalence of MASLD, Met-ALD, and ALD and Associated Fibrosis Among US Adults
  James M. Paik, Kathryn Hobbs, Amolika Gupta, Rand Jamal Alkalbani, Manuel Alexander Reyes, Zobair M. Younossi
  Journal of Clinical Gastroenterology.2025;[Epub]     CrossRef
• Association between weight fluctuation and the risk of metabolic dysfunction-associated steatotic liver disease
  Jin-Ping Wang, Jia-Yang Wang, Pei-Qi Sun, Xue-Wei Wang, Ze-Ting Yuan, Qin Cao, Shu-Ming Pan, Yuan-Ye Jiang
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease
  Jonathan Mertens, Jonas Weyler, Eveline Dirinck, Luisa Vonghia, Wilhelmus J. Kwanten, Luc F. Van Gaal, Benedicte Y. De Winter, Sven Francque, Christophe De Block
  Cardiovascular Diabetology.2025;[Epub]     CrossRef
• The Significance of the Presence of Gilbert's Syndrome in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Retrospective Cohort Study
  Arjuna P De Silva, Krishanni Prabagar, Anuradha S Wickramasinghage, Aruni A Wanniarachchi, Dileepa S Ediriweera, Madunil A Niriella, Hithanadura J De Silva
  Cureus.2025;[Epub]     CrossRef
• GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD)
  Laura Pagès, Aina Martí-Carretero, Diego Rojo, Clara Sabiote, Farnaz Faninam, Sophia C. Parks, María Martínez-Gómez, M Serra Cusidó, Neda Akhlaghi, Sergio Muñoz-Martínez, Alba Jiménez-Masip, Juan M. Pericàs
  Current Hepatology Reports.2025;[Epub]     CrossRef
• Challenges in applying MASLD risk algorithms in pregnancy: A call for adaptation and inclusion
  Nina Rodriguez, Cecilia Katzenstein, Marcia Lange, Jeanette Rios, Tatyana Kushner, Rachel Meislin, Emma Rosenbluth, Carin Carroll, Theresa Worthington, Shaelyn O’Hara, Joanne Stone, Sonam Rosberger, Keith Sigel, Rhoda Sperling, Norah A. Terrault
  Journal of Hepatology.2025; 83(5): e236.     CrossRef
• Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
  Yong He, Yingfen Chen, Shengying Qian, Schalk van Der Merwe, Debanjan Dhar, David A. Brenner, Frank Tacke
  Cellular & Molecular Immunology.2025; 22(10): 1159.     CrossRef
• Association between trans-palmitoleic acid and metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma: NHANES 1999–2018
  Qirui Li, Luqi Zhan, Qian Li, Shuai Zhu, Shuaihui Liu, He Jiang, Jinlin Cheng, Lanjuan Li
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• To sleeve or not to sleeve: Validation of liver transplantation with sleeve gastrectomy
  Linda W. Moore, Elizabeth W. Brombosz, R. Mark Ghobrial
  Journal of Hepatology.2025; 83(3): 625.     CrossRef
• Redefining Diagnosis and Management in Hepatology with Multiparametric Ultrasound
  Yolande Chalmers
  EMJ Hepatology.2025; : 66.     CrossRef
• Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
  Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual
  Current Obesity Reports.2025;[Epub]     CrossRef
• Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
  Daniel Clayton-Chubb, William W. Kemp, Ammar Majeed, Peter W. Lange, Jessica A. Fitzpatrick, Karl Vaz, John S. Lubel, Alexander D. Hodge, Joanne Ryan, John J. McNeil, Alice J. Owen, Robyn L. Woods, Stuart K. Roberts
  Nutrients.2025; 17(13): 2189.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric population
  Wei Li, Lina Jiang, Meiling Li, Chen Lin, Li Zhu, Bokang Zhao, Yisi Liu, Yan Li, Yiyun Jiang, Shuhong Liu, Ping Liang, Junqi Niu, Jingmin Zhao
  Gastroenterology Report.2025;[Epub]     CrossRef
• Extracellular Vesicles as Biomarkers in Chronic Hepatobiliary Diseases: An Overview of Their Interplay
  Eleni Myrto Trifylli, Sotirios P. Fortis, Anastasios G. Kriebardis, Nikolaos Papadopoulos, Evangelos Koustas, Panagiotis Sarantis, Spilios Manolakopoulos, Melanie Deutsch
  International Journal of Molecular Sciences.2025; 26(13): 6333.     CrossRef
• Relationship between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analyses
  Ninglin Xia, Jiwei Wang, Qian Lu, Xue Fan, Zhenzhou Jiang, Qinwei Yu
  Clinical Nutrition ESPEN.2025; 68: 679.     CrossRef
• Time trends and health inequalities of cirrhosis caused by metabolic Dysfunction-associated steatotic liver disease from 1990 to 2021: A global burden of disease study
  Min Wu, Yifeng Li, Dong Liu, Weinong Wen, Yan Min, Qiang Su, Zhenxiang An, Xiaofang Yang
  Journal of Endocrinological Investigation.2025; 48(11): 2599.     CrossRef
• Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
  Philip N. Newsome, Rohit Loomba
  Journal of Clinical Investigation.2025;[Epub]     CrossRef
• High Prevalence of Fatty Liver in Bangladeshi Adolescents and Young Adults with Type 2 Diabetes: Key Predictors and Screening Recommendations
  Kishore Shil, Mashfiqul Hasan, Nusrat Sultana, Sayad Salam, Syeda Mostafa, Muhammad Hasanat
  Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 2019.     CrossRef
• Adipose Tissue Dysfunction and Hepatic Steatosis in New-Onset Diabetes
  Emilia Rusu, Mariana Jinga, Raluca Cursaru, Georgiana Enache, Adrian Costache, Ioana Verde, Andra Nica, Anca Alionescu, Florin Rusu, Gabriela Radulian
  Diabetology.2025; 6(7): 70.     CrossRef
• Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review
  Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi
  Nutrients.2025; 17(13): 2211.     CrossRef
• Altered HDL Phospholipid and Fatty Acid Profile in MASLD: A Possible Explanation for the Increased CVD Risk
  Sofia Kartsoli, Christina E. Kostara, Athanasios Papathanasiou, Vasilis Tsimihodimos, Eleni T. Bairaktari, Dimitrios K. Christodoulou
  International Journal of Molecular Sciences.2025; 26(13): 6148.     CrossRef
• Pan-immune-inflammation value and mortality in the US adult MASLD: a nonlinear NHANES analysis
  Qing Zhou, Jisu Xue, Lu Hao
  BMC Gastroenterology.2025;[Epub]     CrossRef
• Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018
  Yanshan Yi, Li Yang
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease: Mechanisms, metabolic reprogramming, and therapeutic insights
  Wan-Qi Yang, Ling-Ling Xue, Jing-Lin Wang
  World Journal of Gastroenterology.2025;[Epub]     CrossRef
• Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population
  Ayesha Sualeheen, Sze-Yen Tan, Robin M. Daly, Ekavi Georgousopoulou, Gavin Abbott, Stuart K. Roberts, Jacob George, Elena S. George
  Clinics and Research in Hepatology and Gastroenterology.2025; 49(7): 102649.     CrossRef
• Quantitative US in Metabolic Dysfunction–Associated Steatotic Liver Disease
  Manjiri Dighe, Manish Dhyani
  Radiology.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease and gastrointestinal cancer risk in youth: is it time to unveil a hidden link?
  Gianmario Forcina, Vittoria Frattolillo, Maria Grazia Fusco, Emanuele Miraglia Del Giudice, Anna Di Sessa
  Expert Review of Gastroenterology & Hepatology.2025; : 1.     CrossRef
• Metals in the human liver: An underappreciated risk factor of hepatic insulin resistance and associated pathophysiology
  Rahul Kumar, Ashwin Chinala, Dhruv Grandhe, S. Joseph Endicott, Marcus A. Garcia, Matthew J. Campen, Rama R. Gullapalli
  Environmental Pollution.2025; 383: 126844.     CrossRef
• La alimentación es pieza clave en la patogénesis de la enfermedad hepática esteatósica asociada a disfunción metabólica en la población pediátrica
  R. Vázquez-Frias
  Revista de Gastroenterología de México.2025; 90(3): 347.     CrossRef
• Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring
  Gong Feng, Vincent Wai-Sun Wong, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
  Gut.2025; 74(10): 1741.     CrossRef
• Intestinal TM6SF2 and the gut-liver axis in MASLD: new insights
  Markos Kalligeros, Linda L. Henry, Zobair M. Younossi
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice
  Tomoyo Hara, Hiroki Yamagami, Ryoko Uemoto, Akiko Sekine, Yousuke Kaneko, Kohsuke Miyataka, Taiki Hori, Mayuko Ichimura-Shimizu, Masafumi Funamoto, Takeshi Harada, Tomoyuki Yuasa, Shingen Nakamura, Itsuro Endo, Ken-ichi Matsuoka, Yutaka Kawano, Koichi Tsu
  Antioxidants.2025; 14(7): 891.     CrossRef
• The role of Bergamot Polyphenolic Fraction (BPF) in MASLD-Induced HFpEF: Mitigate diastolic dysfunction by targeting chronic low-grade inflammation
  Cristina Carresi, Antonio Cardamone, Vincenzo Musolino, Rocco Mollace, Annamaria Tavernese, Anna Rita Coppoletta, Micaela Gliozzi, Vincenzo Mollace
  Biomedicine & Pharmacotherapy.2025; 190: 118375.     CrossRef
• Nonlinear Association Between BMI and Depression Among Nonalcoholic Fatty Liver Disease: NHANES (2017–2018)
  Hui Peng, Dan Zhou, Yuan Dai, Weifeng Chen, Tauheed Ishrat
  Behavioural Neurology.2025;[Epub]     CrossRef
• Analysis of gastric electrical rhythm in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus
  Xi-Xi Wang, Chun Yan, Su-Juan Wang, Hong Zhu, Chang-Chun Cao, Li Wu, Shuang Wang, Ji Hu, Hong-Hong Zhang
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration
  Evelien Van Dijck, Steven Van Laere, Emilie Logie, Steven Timmermans, Erik Fransen, Joe Ibrahim, Timothy J. Kendall, Jonathan A. Fallowfield, Ligia M. Mateiu, Claude Libert, Guy Van Camp, An Verrijken, Luc Van Gaal, Sven Francque, Wim Van Hul, Wim Vanden
  Clinical Epigenetics.2025;[Epub]     CrossRef
• Physical Activity and Metabolic Disorders—What Does Gut Microbiota Have to Do with It?
  Aneta Sokal-Dembowska, Ewelina Polak-Szczybyło, Kacper Helma, Patrycja Musz, Maciej Setlik, Weronika Fic, Dawid Wachowiak, Sara Jarmakiewicz-Czaja
  Current Issues in Molecular Biology.2025; 47(8): 630.     CrossRef
• Geniposidic acid alleviated metabolic dysfunction-associated steatotic liver disease by exciting SIRT6 signaling
  Yingya Zhou, Meng Feng, Hongyan Hai, Xinmeng Teng, Xinxin Zhou, Yong Gao, Yanhua Zhong, Changhui Liu
  Phytomedicine.2025; 146: 157140.     CrossRef
• Optimal Vegetable Intake for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) Prevention: Insights from a South Italian Cohort
  Maria Noemy Pastore, Caterina Bonfiglio, Rossella Tatoli, Rossella Donghia, Pasqua Letizia Pesole, Gianluigi Giannelli
  Nutrients.2025; 17(15): 2477.     CrossRef
• Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials
  Alessandro Mantovani, Riccardo Morandin, Veronica Fiorio, Maria Giovanna Lando, Norbert Stefan, Herbert Tilg, Christopher D. Byrne, Giovanni Targher
  Liver International.2025;[Epub]     CrossRef
• Discovery of Highly Potent, Selective, and Liver-Targeted THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
  Ju Liang, Yipei Gu, Liuyu Hu, Hui Qu, Nana Li, Chaoyue Xia, Lei Feng, Li Qin, Li Hai, Yaxi Yang, Ying Leng, Bing Zhou
  Journal of Medicinal Chemistry.2025; 68(16): 17457.     CrossRef
• Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends
  Salvatore Pezzino, Stefano Puleo, Tonia Luca, Mariacarla Castorina, Sergio Castorina
  Biomedicines.2025; 13(8): 1854.     CrossRef
• Dietary Strategies in the Prevention of MASLD: A Comprehensive Review of Dietary Patterns Against Fatty Liver
  Barbara Janota, Karolina Janion, Aneta Buzek, Ewa Janczewska
  Metabolites.2025; 15(8): 528.     CrossRef
• Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017–2020
  Ting Xu, Weifang Zhu
  Diabetes Research and Clinical Practice.2025; 227: 112418.     CrossRef
• Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
  Shikha Patel, Sarfaraz K. Niazi
  Pharmaceutics.2025; 17(8): 1036.     CrossRef
• CircDock6 drives metabolic dysfunction–associated steatotic liver disease progression in mice and mouse hepatocytes via mmu-let-7g-5p/insulin-like growth factor 1 receptor regulation
  Hongpeng Lu, Xiaoyun Ding, Peifei Li
  Journal of International Medical Research.2025;[Epub]     CrossRef
• Multi-omics integration reveals the impact of mediterranean diet on hepatic metabolism and gut microbiota in mice with metabolic dysfunction-associated steatotic liver disease
  Zixuan Wang, Ge Chen, Xutong Sun, Jia Xiao, Lingling Kong, Shunshun Jiang, Tingting Xu, Meijiao Wang, Hong Zhao
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Amaranthus graecizans L. Mitigates Hyperlipidemia-Induced Nonalcoholic Fatty Liver Disease in Experimental Rats: Future Pharmaceuticals
  Nadiah S. Alzahrani, Bayan Aljahdali, Aeshah Alhosain, Abeer Abdullah Alasmari, Touseef Amna, Soha Mohamed Yousef
  Pharmaceuticals.2025; 18(8): 1196.     CrossRef
• Non-invasive biomarkers for monitoring portal hypertension in metabolic dysfunction-associated steatotic liver disease (MASLD)
  Shreya C. Pal, Mariana M. Ramírez-Mejía, Andrew P. Keaveny, Nahum Méndez-Sánchez
  Expert Review of Gastroenterology & Hepatology.2025; 19(9): 1021.     CrossRef
• Controlled Red Blood Cell Apheresis as a Pretreatment of Hepatic Peliosis Resection Surgery for Severe Polycythemia Secondary to Hepatic Peliosis in a Child
  Chun‐Xi Wu, Rong Fu, Jie Yan, Bin Zhang, Zhong‐Mei Yi, Qiang Zhang
  Pediatric Blood & Cancer.2025;[Epub]     CrossRef
• SGLT2 inhibitors and the risk of hepatocellular carcinoma in patients with MASLD and Type 2 diabetes
  Ruey-Shyang Soong, Wan-Ming Chen, An-Tzu Jao, Ming-Che Lee, Szu-Yuan Wu, Chih-Lang Lin
  Diabetes & Metabolism.2025; 51(6): 101698.     CrossRef
• MIND diet score and its association with metabolic dysfunction-associated steatotic liver disease and gut microbiota profiles: a cross-sectional study
  Shengbo Yang, Litao Zhang, Mingli Hu, Weina He
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver Biomarkers
  Pietro Torre, Benedetta Maria Motta, Tommaso Sarcina, Mariano Festa, Mario Masarone, Marcello Persico
  International Journal of Molecular Sciences.2025; 26(17): 8426.     CrossRef
• Higher Food Inflammation Index Is Linearly Associated With Higher Risk of MASLD: A Cross‐Sectional Study Based on the NHANES (1999–2020)
  Qingwan Yang, Xin Cai, Zhenghua Xiao
  Food Science & Nutrition.2025;[Epub]     CrossRef
• Metabolic Divergence Between MASLD and Metabolic Syndrome: Distinct Clinical Phenotypes and Risk Stratification Implications
  Mariana M. Ramírez‐Mejía, Sandra M. Barbalho, Guadalupe Ponciano‐Rodríguez, Mohammed Eslam, Jacob George, Ming‐Hua Zheng, Nahum Méndez‐Sánchez
  Liver International.2025;[Epub]     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review
  Marcelo do Rego Maciel Souto Maior, Nathália de Lacerda Interaminense Ribeiro, Hannah Vicentini Vitoriano Silva, Edmundo Pessoa Lopes, Emilia Chagas Costa
  Biomedicines.2025; 13(9): 2162.     CrossRef
• Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model
  Zhuolin Song, Volodymyr P Tryndyak, Rose A Willett, Igor P Pogribny, Ivan Rusyn, Fred A Wright
  Toxicological Sciences.2025; 208(1): 155.     CrossRef
• Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) rs738409 Variant and Non-Alcoholic Fatty Liver Disease Risk in Vietnamese Working-Age Adults: A Case-Control Study with Metabolic Insights
  Ha Nguyen, Duong Hoang Huy Le, Thinh Nguyen, Hung Cao Dinh, Tuan Nguyen
  Clinical and Experimental Gastroenterology.2025; Volume 18: 191.     CrossRef
• Narrative review of metabolic syndrome and its relationships with non-alcoholic fatty liver disease, gonadal dysfunction and obstructive sleep apnea
  Doha Reda
  Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease in patients with prediabetes and type 2 diabetes mellitus
  Armida N. Sasunova, Alexey A. Goncharov, Sergey V. Morozov, Vladimir I. Pilipenko, Vasily A. Isakov
  Terapevticheskii arkhiv.2025; 97(8): 689.     CrossRef
• Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon?
  Amedeo Lonardo, Ralf Weiskirchen
  Exploration of Drug Science.2025;[Epub]     CrossRef
• Fecal Zonulin as a Non-Invasive Marker of Intestinal Permeability: Findings from a Prospective Cohort Study
  Naomi-Adina Ciurea, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Simona Bataga
  Medicina.2025; 61(9): 1527.     CrossRef
• Steatotic liver disease and cancer: from pathogenesis to therapeutic targets
  Zhihong Yang, Zhenjie Liu, Wanqing Liu, Xiaocheng Charlie Dong
  eGastroenterology.2025; 3(3): e100218.     CrossRef
• Increasing Acute Coronary Syndrome Mortality in Cirrhosis After a Period of Decline: A National Analysis of Temporal and Demographic Disparities
  Abdalhakim Shubietah, Ameer Awashra, Fathi Milhem, Mohammed AbuBaha, Maisam Tobeh, Abubakar Nazir, Mohamed S. Elgendy, Mohammad Bdair, Jehad Zeidalkilani, Hosam I. Taha, Anwar Zahran, Ahmed Emara, Suleiman Khreshi, Islam Rajab
  Catheterization and Cardiovascular Interventions.2025; 106(6): 3136.     CrossRef
• Prenatal Choline Attenuates the Elevated Adiposity and Glucose Intolerance Caused by Prenatal Alcohol Exposure
  Susan M. Smith, Carolyn A. Munson, George R. Flentke, Sandra M. Mooney
  Cells.2025; 14(18): 1429.     CrossRef
• THE CHANGING LANDSCAPE OF TRANSPLANT ONCOLOGY: OPPORTUNITIES AND CHALLENGES
  Emanuele Federico Kauffmann, Michael Ginesini, Allegra Ripolli, Paolo De Simone
  European Journal of Transplantation.2025; 3(1): 3.     CrossRef
• Clinical and Genetic Predictors of Non‐Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals
  Karina Sato‐Espinoza, Robert A. Vierkant, Perapa Chotiprasidhi, Filippo Pinto e Vairo, Shulan Tian, Jun Ma, Daniel O'Brien, Konstantinos N. Lazaridis, Carola Dlugosch, Carolin Scheider, Alina M. Allen, Kirk J. Wangensteen
  Liver International.2025;[Epub]     CrossRef
• MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression
  Clelia Asero, Maria Stella Franzè, Irene Cacciola, Sebastiano Gangemi
  International Journal of Molecular Sciences.2025; 26(17): 8633.     CrossRef
• Diet is a key factor in the pathogenesis of metabolic dysfunction-associated steatotic liver disease in the pediatric population
  R. Vázquez-Frias
  Revista de Gastroenterología de México (English Edition).2025; 90(3): 347.     CrossRef
• Exploring the Role of Extra Virgin Olive Oil (EVOO) in MASLD: Evidence from Human Consumption
  Melvin Bernardino, Claudio Tiribelli, Natalia Rosso
  Nutrients.2025; 17(18): 2932.     CrossRef
• Refining the Classification of Steatotic Liver Disease: Beyond Self-Reported Alcohol Intake
  Won-Mook Choi
  Gut and Liver.2025; 19(5): 639.     CrossRef
• Immunonutrition: Another Player on the MASLD Field
  Iván López-Méndez, Misael Uribe, Eva Juárez-Hernández
  International Journal of Molecular Sciences.2025; 26(18): 8928.     CrossRef
• Extracellular RNAs in Liquid Biopsy: Applications in MASLD and MASH Diagnosis and Monitoring
  Dimitrios Raptis, Shiny Teja Kolli, Sonal Agarwal, Praveen Kumar Komminni, Prashamsha Bhattarai, Prinka Hablani, Rahul Kumar, Petras Das, Martin McIntosh, Michail Kladas, Priyanka Gokulnath, Michail Spanos
  Diagnostics.2025; 15(18): 2346.     CrossRef
• Diagnostic Performance of Fibrosis‐4 Index, Nonalcoholic Fatty Liver Disease Fibrosis Score, AST‐To‐Platelet Ratio Index, and BARD Score Among Young and Older Adults for the Diagnosis of Advanced MASLD Fibrosis: A Retrospective Cohort Study
  Frank Lin, Ayah Obeid, Mehak Sharma, Parampreet Kaur, Kimberly Chaput, Hammad Liaquat
  JGH Open.2025;[Epub]     CrossRef
• The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model
  Oscar René Zambrano-Vásquez, Fernando Cortes-Camacho, Juan Carlos Cabrera-Angeles, Ana Lilia Hernández-Alba, Fernando Enrique García-Arroyo, Jorge Ismael Castañeda-Sánchez, Elena Aréchaga-Ocampo, Omar Emiliano Aparicio-Trejo, Leonardo Del Valle-Mondragón,
  International Journal of Molecular Sciences.2025; 26(18): 9010.     CrossRef
• Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
  Metha Yaikwawong, Khanittha Kamdee, Somlak Chuengsamarn
  International Journal of Molecular Sciences.2025; 26(19): 9286.     CrossRef
• A Systematic Review and Meta-Analysis of Cannabis Use Frequency and Metabolic Dysfunction-Associated Steatotic Liver Disease: Scapegoat or Healer?
  Néstor Israel Quinapanta Castro, Abdel Bermúdez-del Sol
  Cureus.2025;[Epub]     CrossRef
• Cumulative Effect of Metabolic Factors on Hepatic Steatosis
  Anna Egresi, Brigitta Kozma, Márton Karácsony, Aladár Rónaszéki, Klára Werling, Barbara Csongrády, Pál Kaposi Novák, Anikó Folhoffer, Attila Szijártó, Krisztina Hagymási
  Diagnostics.2025; 15(18): 2406.     CrossRef
• A non-apoptotic caspase-8–meteorin pathway in hepatocytes promotes MASH fibrosis
  Xiaobo Wang, Mary P. Moore, Hongxue Shi, Yang Xiao, Jiayu Zhang, Lanuza A. P. Faccioli, Zhiping Hu, Shareef Khalid, Danish Saleheen, Dwayne G. Stupack, Tatiana Kisseleva, Alejandro Soto Gutierrez, Mitchell A. Lazar, Ira Tabas
  Nature Metabolism.2025; 7(10): 2067.     CrossRef
• The impact of aging on liver health and the development of liver diseases
  Sha Neisha Williams, Wen-Xing Ding
  Hepatology Communications.2025;[Epub]     CrossRef
• Timosaponin AIII from Anemarrhena asphodeloides binds and inhibits S100A8-mediated neutrophil infiltration and NET formation ameliorates MASH
  Yunfan Bai, Jingxin Ju, Ruishi Xie, Jing Li, Xinyi Zhao, Xiaoxue Fang, Ming Zhu, Xintian Lan, Haoming Luo
  International Immunopharmacology.2025; 166: 115539.     CrossRef
• Clinacanthus nutans leaf extract prevents metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) progression in western diet-fed C57BL/6 mice
  Nurina Hasanatuludhhiyah, Arifa Mustika, Viskasari Pintoko Kalanjati, Muhammad Miftahussurur, Hirokazu Wakuda, Naoto Uemura
  Pharmacia.2025; 72: 1.     CrossRef
• The role of hypothalamus in the pathophysiological process of MASLD and advances in drug discovery
  Shizhang Wei, Yuan Dong, Yanping Wang, Guohui Li, Yanling Zhao, Ruimao Zheng
  Pharmacological Research.2025; 221: 107972.     CrossRef
• BMI mediates the association of CALLY index with liver steatosis and fibrosis
  Si-Hua Wen, Tao Tang, Zheng-Rong Ye
  Scientific Reports.2025;[Epub]     CrossRef
• Era of metabolic dysfunction-associated steatotic liver disease and impact on the liver donor pool
  Juanita Pérez-Escobar, Aline Huerta-Álvarez, Graciela Elia Castro-Narro, María Isabel Astudillo-Delgado, Paulina Carpinteyro-Espin
  World Journal of Gastroenterology.2025;[Epub]     CrossRef
• Editorial: Metabolic dysfunction-associated steatotic liver disease (MASLD) - pathogenesis, prevention and treatment
  Stanisław Surma, Łukasz Bułdak
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply
  Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
  Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
• Advances in understanding the mechanism of noncoding RNA (ncRNA)-mediated regulation of macrophage polarization in NAFLD
  Chang Ge, Yi Yuan, Xiaoning Li, Jianmin Zhang, Jitao Ling, Xuehong Zheng, Yuting Wu, Xin Huang, Pingping Yang, Xiao Liu, Deju Zhang, Jianping Liu, Jing Zhang, Peng Yu
  Biochemical Pharmacology.2025; 242: 117372.     CrossRef
• Association of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease
  Erfan Banisefid, Sahand Karkon Zonouzi, Sina Hamzehzadeh, Zeinab Nikniaz, Seyedehyasmin Moghaddamziabari, Leila Alizadeh
  Scientific Reports.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease: epidemiological trends, risk factors, and the role of gut microbiota in disease progression (a literature review)
  А.А. Antoniv, L.V. Kanovska, O.V. Kaushanska, Yu.M. Yarinich
  INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(6): 656.     CrossRef
• Preventing false positive imaging diagnosis of HCC: differentiating HCC from mimickers and practical strategies
  Ijin Joo
  Journal of Liver Cancer.2025; 25(2): 217.     CrossRef
• Real-World Lifestyle Interventions are a Practical Model to Improve Liver Stiffness
  Christopher Kasia, Mary Rinella
  Journal of Clinical and Experimental Hepatology.2025; 15(6): 103201.     CrossRef
• The effects of different exercise intensities on body composition and cardiovascular risk indicators in children with metabolic syndrome: a RCT network meta-analysis
  Yimin Hu, Juan Ouyang, Yi Xia, Yi Sheng
  BMC Sports Science, Medicine and Rehabilitation.2025;[Epub]     CrossRef
• Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies
  Sana Raza, Rukshana Mahamood, Pratik Medhe, Ambuj Shahi, Abhishek Yadav, Archana Tewari, Rohit A. Sinha
  npj Metabolic Health and Disease.2025;[Epub]     CrossRef
• Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
  Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon
  International Journal of Molecular Sciences.2025; 26(19): 9715.     CrossRef
• Spatial Transcriptomics and snRNA‐seq Expose CAF Niches Orchestrating Dual Stromal‐Immune Barriers in Hepatocellular Carcinoma
  Yingxue Li, Changxiang Huan, Haoting Sun, Wei Zhang, Zhen Guo, Chuanyu Li, Jia Yao, Zhiqi Zhang, Shizhe Yu, Qiongzhu Dong, Lunxiu Qin, Jinze Li, Lianqun Zhou
  Advanced Science.2025;[Epub]     CrossRef
• Immunosenescence and metabolic reprogramming in MASLD: an age-dependent immunometabolic vicious cycle and therapeutic opportunities
  Yuxin Xu, Qiuxiang Li, Xuehua Jiao
  Frontiers in Cell and Developmental Biology.2025;[Epub]     CrossRef
• Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
  Ralf Weiskirchen, Amedeo Lonardo
  International Journal of Molecular Sciences.2025; 26(19): 9594.     CrossRef
• Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis
  Meng Li, Jianli Hu, Yip Han Chin, Han Shi Jocelyn Chew, Wenru Wang
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Investigation of the Effect of Isotonic Drinks on Quantitative MRI Markers of the Liver and Spleen
  Natassa N. Pittas, Michael Pavlides, Ferenc E. Mózes
  NMR in Biomedicine.2025;[Epub]     CrossRef
• Physiological roles of phosphoinositides and inositol phosphates: Implications for metabolic dysfunction-associated steatotic liver disease
  Zhili Cheng, Magdalene K Montgomery
  Clinical Science.2025; 139(19): 1095.     CrossRef
• Naringin mitigates liver damage in a tissue-engineered liver of metabolic dysfunction-associated steatotic liver disease model by promoting autophagy via the mTOR-ULK1 pathway
  Jihui Jia, Yizhi Zhang, Jing Lin, Zhongping Duan, Yu Chen, Xiaohui Zhang
  Molecular Biology Reports.2025;[Epub]     CrossRef
• Dietary supplementation with a designer metabolic modulator improves MASLD and associated anxiety in mice
  Agnese Segala, Gaia Favero, Emanuela Bottani, Alice Vetturi, Emirena Garrafa, Edoardo Parrella, Chiara Ruocco, Maurizio Ragni, Rita Rezzani, Enzo Nisoli, Alessandra Valerio
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• From Steatosis to Immunosenescence: The Impact of Metabolic Dysfunction on Immune Aging in HIV and Non-HIV Populations
  Carlo Acierno, Maria Frontuto, Giulio Francesco De Stefano, Ana Erezanu, Andrea Limone, Simona Morella, Francesco Picaro, Donatella Palazzo, Michele Gilio
  Biomedicines.2025; 13(10): 2513.     CrossRef
• Constructing biomimetic microenvironments for liver regeneration
  Yawen Zhu, Wanqi Yang, Zhongxia Wang, Dayu Chen, Jinglin Wang, Haozhen Ren
  Journal of Nanobiotechnology.2025;[Epub]     CrossRef
• Linear association between the composite dietary antioxidant index and the prevalence of sarcopenia in metabolic dysfunction-associated steatotic liver disease
  Jue Zhang, Huan Shi
  Lipids in Health and Disease.2025;[Epub]     CrossRef
• Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study
  Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• 2025 Clinical Practice Guidelines for Diabetes: Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
  Jaehyun Bae
  The Journal of Korean Diabetes.2025; 26(3): 172.     CrossRef
• Pharmacotherapy of the metabolically associated fatty liver disease
  E.E. Mulyukova, E.L. Novikova, I.A. Skirdov, K.S. Usmanova, N.V. Yusifzade
  Russian Journal of Preventive Medicine.2025; 28(10): 103.     CrossRef
• Proton Density Fat Fraction and Its Role in Prediction of Metabolic Dysfunction
  Scott B. Reeder, Jitka Starekova
  Radiology.2025;[Epub]     CrossRef
• Coffee and Tea Intake Is Inversely Associated With Hepatic Fat Deposition, Iron Deposition, and Fibroinflammation in the General Population
  Zhuoshuai Liang, Xiaoyue Sun, Huizhen Jin, Wenhui Gao, Xinmeng Hu, Yi Cheng, Jikang Shi, Yawen Liu
  Molecular Nutrition & Food Research.2025;[Epub]     CrossRef
• Hydroxytyrosol Improves Metabolic Dysfunction-Associated Fatty Liver Disease Dependent on the Modulation of Gut Microbiota
  Yuji Xiao, Xue Zhang, Bing Shao, Ziyi Wu, Xiao Li, Dongxin Yi, Tao Li, Tao Yang, Jiaxin Zhu, Tiecheng Huang, Yixue Deng, Tianming Qiu, Guang Yang, Xiance Sun, Ningning Wang
  Journal of Agricultural and Food Chemistry.2025; 73(43): 27450.     CrossRef
• Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis
  Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova
  GASTROENTEROLOGY.2025; 59(3): 206.     CrossRef
• CT-Based Radiomic Models in Biopsy-Proven Liver Fibrosis Staging: Direct Comparison of Segmentation Types and Organ Inclusion
  Andreea Mihaela Morariu-Barb, Tudor Drugan, Mihai Adrian Socaciu, Horia Stefanescu, Andrei Demirel Morariu, Monica Lupsor-Platon
  Diagnostics.2025; 15(21): 2671.     CrossRef
• Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years
  Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna
  Journal of Clinical Medicine.2025; 14(21): 7604.     CrossRef
• Metabolic dysfunction–associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy
  Teresa Cardoso Delgado, Celia Martín-Cuevas, Ana C. Sánchez Hidalgo, Antonio Gil Gómez, Claudia M. Rejano Gordillo, Jon Landa, Rocío Gallego Durán, Naroa Goikoetxea-Usandizaga, Irene González-Recio, Clàudia Gil-Pitarch, L. Estefanía Zapata-Pavas, Jon Ande
  Science Advances.2025;[Epub]     CrossRef
• Association of Diet Quality, Dietary Acid Load, and Dietary Antioxidant Index With Cardiometabolic and NAFLD Risk Factors Among Patients With Metabolic Syndrome: A Cross‐Sectional Study
  Bijan Ghobadian, Seyedeh Atiye Shahrokhi, Saman Rezaei Talabon, Vahid Notash, Fatemeh Maleki Sedgi, Mehran Rahimlou
  Food Science & Nutrition.2025;[Epub]     CrossRef
• Quantitative Approaches to Accelerate MASH Drug Discovery and Development
  Yasmeen Abouelhassan, Shailendra Tallapaka, Ramin Mehrani, Scott Q. Siler, Li Qin, Zeyuan Wang, Maria E. Trujillo
  Clinical Pharmacology & Therapeutics.2025; 118(6): 1378.     CrossRef
• Mitochondrial transplantation and platelet rich plasma for the treatment of non-alcoholic fatty liver disease
  Manuel Alejandro Vargas-Vargas, Marcela González-Montoya, Olin Torres-Isidro, Omar Ortiz-Avila, Elizabeth Calderón-Cortés, Christian Cortés-Rojo
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease
  Leonidas H. Duntas, Stergios A. Polyzos, Ulrike Gottwald-Hostalek, Bogumila Urgatz, Paul M. Yen
  Endocrine.2025; 90(3): 1043.     CrossRef
• Genetic polymorphisms associated with metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk susceptibility in the Chinese Han population
  Mingjia Dai, Yan Li, Jing Zhang, Yuhua Ruan, Ye Liu, Jungui Hao, Fang Ji, Xuebing Yan
  Human Genomics.2025;[Epub]     CrossRef
• Lipid-lowering mechanism of Swietenia macrophylla king leaves through SREBP-1c/FASN axis and RNA sequencing validation
  Yingwei Liu, Yunpeng Sun, Ting Zhou, Xiao Huang, Guokai Wang, Lijuan Sun
  Food Bioscience.2025; 74: 107860.     CrossRef
• Reconsidering Cardiovascular Risk Assessment in Patients With MASLD
  Ming Hou
  Liver International.2025;[Epub]     CrossRef
• From steatosis to cirrhosis: the role of obesity in the progression of liver disease
  Klaudia Nowak, Maria Paluch, Maja Cudzik, Klaudia Syska, Wiktoria Gawlikowska, Jakub Janczura
  Journal of Diabetes & Metabolic Disorders.2025;[Epub]     CrossRef
• Triglyceride-cholesterol-body weight index associated with the risk of metabolic dysfunction-associated steatotic liver disease: a population-based cross-sectional study
  Li Fan, Yongkang Su, Yue Chen, Ling Xu, Hairong Huang, Chunsheng Lu, Jia Peng, Yingbin Sun, Min Jia
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism
  Rosellina M. Mancina, Luca Valenti, Stefano Romeo
  Nature Metabolism.2025; 7(11): 2199.     CrossRef
• The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
  Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano
  Exploration of Medicine.2025;[Epub]     CrossRef
• The effects of salvia hispanica (chia seeds) on insulin sensitivity, hematological inflammatory indices and liver function in obese patients with non-alcoholic fatty liver disease (NAFLD)
  Sara Arefhosseini, Maryam Parimi, Helda Tutunchi, Mehrangiz Ebrahimi-Mameghani
  Nutrition & Metabolism.2025;[Epub]     CrossRef
• Prevalence and Risk Factors of Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus at a Tertiary Center in Saudi Arabia: Cross-Sectional Questionnaire Study
  Abdulrahman M Elnasieh, Mohammed Almesned, Akram N Al Hazmi, Atheer Alturki, Faisal I Alhawaidi, Razan K Alhadlq, Maryam Alramadhan, Nasser Alobilan, Yasser Sheikh Qroosh
  JMIR Diabetes.2025; 10: e77772.     CrossRef
• Differentiating MASL and MASH: Clinical Insights from Comparative Case Reports in MASLD
  Chang-Gue Son
  The Journal of Internal Korean Medicine.2025; 46(4): 954.     CrossRef
• Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin
  Jiao-Xiang Wu, Yue-Lan Wu, Mei-Fang Li, Nian Liu, Ying Liu, Yan-Ping Huang, Yuan Gan, Xiao-Yu Wang, Hai-Sheng Chai, Jin Xu, Qian Xi, Xi-Rong Guo, Hui-Ming Sheng, Ting-Ting Shen, Qin Zhang
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• Implications of the Liver-Gut Axis in Liver Disease: From Mechanisms to Therapeutic Targets
  Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Nahum Méndez-Sánchez
  Archives of Medical Research.2025; 56(8): 103335.     CrossRef
• Herbal Medicine for Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Effectiveness and Research Trends - A Systematic Review and Meta-Analysis
  Min-jo Seo, Su-na Park, Ji-won Lee, So-rim Kim, Jin-hyun Kim, Min-ji Sun, Geon-sik Kong, Yo-sup Choi
  The Journal of Internal Korean Medicine.2025; 46(4): 774.     CrossRef
• Primary Human Tissue Models for Metabolic Dysfunction‐Associated Liver Disease ‐ toward Streamlining Drug Discovery with Patient‐Derived Assays
  Sonia Youhanna, Nayere Taebnia, Yingxin Liang, Ningtao Cheng, Yi Wang, Maurice Michel, Volker M. Lauschke
  Advanced Biology.2025;[Epub]     CrossRef
• The Impact of Liraglutide on Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
  Jae Eun So, Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Hye Won Lee, Seung Up Kim
  Journal of Gastroenterology and Hepatology.2025; 40(12): 2976.     CrossRef
• Remnant cholesterol, low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: a cohort study
  Di Zhou, Mengge Zhou, Shuohua Chen, Chenlu Yang, Yanhong Wang, Yang Zhou, Shutong Wu, Shouling Wu, Li Wang
  Lipids in Health and Disease.2025;[Epub]     CrossRef
• Effects of long working hours on metabolic dysfunction-associated steatotic liver disease, with and without increased alcohol intake, in healthy workers: A 10-year cohort study
  Yesung Lee, Woncheol Lee, Anna Di Sessa
  PLOS One.2025; 20(11): e0336569.     CrossRef
• Association between longitudinal weight change and clinical outcome in individuals with MASLD
  Yu Shi, Ruoqi Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Atsushi Nakajima, Hannes Hagström, Elisabetta Bugianesi, Wah-Kheong Chan, Jérôme Boursier, Boon-Bee George Goh, Arun J. Sanyal, Manuel Romero-Gomez, José Luis Ca
  Hepatology.2025;[Epub]     CrossRef
• Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
  Mazen Noureddin, Stephen A Harrison, Rohit Loomba, Naim Alkhouri, Naga Chalasani, Muhammad Y Sheikh, Shaheen Tomah, Julio A Gutierrez, Silvia Urbina, John J Suschak, Randy Brown, Ozioma Odili, Jay Yang, Stephine Keeton, Guy Neff, Edward Mena, M Scot Rober
  The Lancet.2025; 406(10520): 2644.     CrossRef
• Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Fatigue and Pruritus in Primary Sclerosing Cholangitis: A U.S. Single-Center Study
  Natalia Rojas-Amaris, Ana Marenco-Flores, Carmen Lara-Romero, Romelia Barba, Denisse Rubio-Cruz, Ximena Parraga, Daniela Goyes, John Esli Medina-Morales, Leandro Sierra, Manuel Romero-Gomez, Michelle Lai, Behnam Saberi, Vilas Patwardhan, Alan Bonder
  Journal of Clinical Medicine.2025; 14(22): 8083.     CrossRef
• Personalized management of metabolic dysfunction-associated steatotic liver disease
  Zhen Sun, Kui Ming Chan, Haojie Jin
  iLIVER.2025; 4(4): 100207.     CrossRef
• Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum
  Cong Xie, Yulian Yuan, Yunjing Wang, Cong Qi, Wei Wang, Chuan An, Aifeila Aikepaer, Yaofu Zhang, Ge Zhang, Xingzhong Feng, Huijuan Gao
  Current Obesity Reports.2025;[Epub]     CrossRef
• Immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: The critical role of subgroup analyses
  Tingfeng Huang, Jia-Hao Law, Ningqi Pang, Shichuan Tang
  iLIVER.2025; 4(4): 100208.     CrossRef
• Plasma Extracellular Vesicles Contain Protein Biomarkers for Capturing Stages of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Preliminary Exploratory Study
  Yakun Li, Koen C. van Son, Sandra Serna-Salas, Justina C. Wolters, Nienke P. M. Wassenaar, Stan Driessen, Anne Linde Mak, Anne-Marieke van Dijk, Veera A. T. Houttu, Julia J. Witjes, Diona Zwirs, Michail Doukas, Joanne Verheij, Robin P. F. Dullaart, Hans B
  Biomolecules.2025; 15(11): 1596.     CrossRef
• Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances
  Dalia M. Miller, Kiana F. McCauley, Kimberly J. Dunham‐Snary
  Endocrinology, Diabetes & Metabolism.2025;[Epub]     CrossRef
• Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions
  Said A. Al-Busafi, Mohammed Eslam
  Transplantology.2025; 6(4): 35.     CrossRef
• The albumin-to-creatinine ratio predicts and explores potential mediation of mortality in metabolic dysfunction-associated steatotic liver disease in U.S. adults: evidence from NHANES 1999–2018
  Huanjie Zhou, Hao Huang, Huiliu Zhao, Naiqi Pang, Meifang Huang, Chao Ou, Ming Lao
  BMC Gastroenterology.2025;[Epub]     CrossRef
• Signatures of proteomics and glycoproteomics revealed liraglutide ameliorates MASLD by regulating specific metabolic homeostasis in mice
  Yuxuan Chen, Chendong Liu, Qian Yang, Jingtao Yang, He Zhang, Yong Zhang, Yanruyu Feng, Jiaqi Liu, Lian Li, Dapeng Li
  Journal of Pharmaceutical Analysis.2025; 15(11): 101273.     CrossRef
• К эпидемиологии жировой болезни печени, связанной с метаболической дисфункцией (систематический обзор литературы)
  Вера Людвиговна Грицинская, Валерия Павловна Новикова
  Children's medicine of the North-West.2025; 13(3): 108.     CrossRef
• The shifting burden of gastrointestinal and liver diseases in Southeast Asia and effective control strategies
  
  Asian Biomedicine.2025; 19(5): 218.     CrossRef
• An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease
  Gvzalnur Kurban, Xiangjun Chen, Xingyi Jin, Hui Xia, Shaokang Wang, Guiju Sun
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Linking bisphenol a exposure to MASLD: insights from network toxicology and machine learning based on NHANES 2005–2012 data
  Jiaquan Yuan, Haoyang Xu, Junhong Gan, Haiyan Zhao
  Toxicology Research.2025;[Epub]     CrossRef
• Curcumin and Tetrahydrocurcumin as Multi-Organ Modulators of the Adipose Tissue–Gut–Liver Axis: Mechanistic Insights, Therapeutic Potential, and Translational Challenges
  Marina Konaktchieva, Radoslav Stojchevski, Nikola Hadzi-Petrushev, Hristo Gagov, Rositza Konakchieva, Vadim Mitrokhin, Gjoko Kungulovski, Mitko Mladenov, Dimiter Avtanski
  Pharmaceuticals.2025; 18(12): 1791.     CrossRef
• Ten-Year Atherosclerotic Cardiovascular Disease Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Separate Analyses from Romanian and Italian Cohorts Integrating Metabolic, Hepatic, and Gut–Liver Axis Markers
  Naomi-Adina Ciurea, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Ilaria Farella, Simona Bataga, Agostino Di Ciaula, Piero Portincasa
  Journal of Clinical Medicine.2025; 14(23): 8361.     CrossRef
• Ultra-processed food consumption and the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD): a five-year prospective cohort study in Iranian adults
  Omid Emami, Ali Nikparast, Matin Sepehrinia, Saeid Hadi, Jalaledin Mirzay Razzaz, Reza Homayounfar
  Journal of Health, Population and Nutrition.2025;[Epub]     CrossRef
• MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury
  Sarmis Marian Săndulescu, Denisa Ștefania Ghiga, Diana Rodica Tudorașcu, Daniela Larisa Săndulescu, Adrian Mită, Marinela Cristiana Urhuț, Citto-Iulian Taisescu
  Life.2025; 15(12): 1805.     CrossRef
• NAD + in fatty liver disease: mechanistic insights and associated targets
  Yaxin Guo, Yuting Wang, Shiran Wu, Yong Wang, Xinde Liu
  Cell Biology and Toxicology.2025;[Epub]     CrossRef
• The impact of high fructose corn syrup on liver injury and glucose metabolism: a systematic review
  Zane Z. Yu, Sneha Varahala, Sean L. C. Lim, Maimuna C. Marenah, Julia Wattacheril
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Association Between Subclinical Hypothyroidism and MASLD: A Systematic Review and Meta‐Analysis
  Gedion Yilma Amdetsion, Chun-Wei Pan, Hiwot Tebeje, Abhin Sapkota, Shreyas Nandyal, Vikram Kotwal, Fortofoiu Mircea-Catalin
  International Journal of Hepatology.2025;[Epub]     CrossRef
• Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis
  Chun-Ye Zhang, Shuai Liu, Yu-Xiang Sui, Ming Yang
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Liver fibrosis index and mortality in metabolic dysfunction–associated steatotic liver disease: a Korean cohort study
  Yesung Lee, Woncheol Lee
  Scientific Reports.2025;[Epub]     CrossRef
• Macrophage-tregs crosstalk: the “hub” of the immune network in MASLD
  Huihui Zhao, Weili Wang, Pengchao Zhu, Zhaohong Shi
  Frontiers in Immunology.2025;[Epub]     CrossRef
• Proteolysis targeting chimera degraders target pseudokinases to treat metabolic dysfunction-associated steatohepatitis and fibrosis: Mechanisms and therapeutic insights
  Yibing Wang, Jiajing Peng
  Pharmacological Research.2025; 222: 108054.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease is associated with androgenetic alopecia in adults with stronger effects in women and unhealthy lifestyles
  Sina Bazmi, Mohammad Saeed Soleimani-Meigoli, Mohammadreza Fardaei, Zahra Mohammadi, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Mojtaba Farjam
  Scientific Reports.2025;[Epub]     CrossRef
• Nutritional and Fasting Strategies for the Management of MASLD/MASH: An Integrative Review
  Diya Tawk, Ghalia Ghader, Yasmina Khatib, Philippe Attieh, Tya Youssef, Mahmoud Othman, Frederic Harb, Sami Azar, Hilda E. Ghadieh
  JGH Open.2025;[Epub]     CrossRef
• Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis
  Mei-jun Wang, Yu-nuo Jiang, Pei-pei Li, Yuan-jie Wu
  Systematic Reviews.2025;[Epub]     CrossRef
• A network meta-analysis of the clinical efficacy of different dietary patterns in the treatment of adult metabolic dysfunction-associated steatotic liver diseases
  Diwen Yu, Peipei Yu, Wanting Huang, Pengwei Zhang, Li Li
  Clinical Nutrition Open Science.2025; 64: 357.     CrossRef
• Synergistic Impact of Sarcopenia and T2DM on Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD)
  Qi Zhou, Peiyan Liu, Lixiang Li, Tengfei Yin, Hao Bai, Yanqing Li
  The FASEB Journal.2025;[Epub]     CrossRef
• Early-Life Nutritional Determinants of Pediatric MASLD
  Johanna K. DiStefano
  Nutrients.2025; 17(24): 3871.     CrossRef
• From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease
  Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa
  Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1329.     CrossRef
• The association of multiple metabolic disorders with the severity of fasting blood glucose and hepatic steatosis in a Chinese population with MAFLD: a cross-sectional study of over 3000 participants
  Xue Qu, Shanshan Jin, Yuqing Shi, Weisong Zhang, Delong Cong, Yangyang Liu
  Scientific Reports.2025;[Epub]     CrossRef
• Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide
  Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz
  Current Medical Research and Opinion.2025; 41(11): 2089.     CrossRef
• Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD–EPI 2021 definitions: a population-based study with region-specific cutoffs
  Sina Bazmi, Mohammadreza Fardaei, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Reza Malekzadeh, Nasrollah Ghahramani, Mojtaba Farjam
  European Journal of Medical Research.2025;[Epub]     CrossRef
• The Impact of the Mediterranean Diet, Physical Activity, and Nutrition Education on Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Review
  Melvin Bernardino, Claudio Tiribelli, Natalia Rosso
  Nutrients.2025; 18(1): 28.     CrossRef
• Machine learning-based model for predicting metabolic dysfunction-associated steatotic liver disease using non-invasive parameters in young adults
  Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Young Hoon Youn, Su Jung Baik, Hye Sun Lee, Hyun Wook Chae
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Soft drink consumption and liver fibrosis in type 2 diabetes
  Arianna Ferro, Martina Bollati, Gian Paolo Caviglia, Angelo Armandi, Stefania Bellini, Selene Limoncelli, Giulio Mengozzi, Federica Barutta, Fabio Broglio, Guglielmo Beccuti, Elisabetta Bugianesi, Marilena Durazzo, Gabriella Gruden
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Artificial intelligence applications for managing metabolic dysfunction-associated steatotic liver disease: Current status and future prospects
  Jian-Jun Lou, Jing Zeng
  World Journal of Gastroenterology.2025;[Epub]     CrossRef
• Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus
  Virginia Markoutsaki, Georgios Dimakopoulos, Emmanouil Sinakos, Kalliopi Kotsa, Theocharis Koufakis
  Hormones.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease and risk of heart failure: a nationwide cohort study
  Chan Kyeol Kim, Sangyong Jo, Kyupin Ha, Bongjo Kim, Hyeon Ji Kim, Sang Yi Moon, Byoung-Gwon Kim, Kyungil Park, Jong Sung Park, Young Rak Cho, Tae-Ho Park, Kyunghee Lim, Minkook Son
  Heart.2025; : heartjnl-2025-327102.     CrossRef
• Association between vitamin D and metabolic-associated steatotic liver disease in type 2 diabetes mellitus patients: a systematic review and meta-analysis
  Bruno Basil, Winifred Adiri, Ejike Lawrence Ugwu, Ngozi Ijeoma Okoro
  Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
• Association between atherosclerosis-related indicators and fatty liver: a population-based observational study
  Xiaoping Liu, Ping Yuan, Ying Huang
  European Journal of Medical Research.2025;[Epub]     CrossRef
• Associations Between Systemic Inflammatory Markers, Metabolic Dysfunction, and Liver Fibrosis Scores in Patients with MASLD
  Ragaey Ahmad Eid, Ahmed Moheyeldien Hamed, Sara O. Elgendy, Khalid M. Orayj, Ahmed R. N. Ibrahim, Ahmed M. Abdel Hamied, Engy A. Wahsh, Maha Youssif, Hoda Rabea, Yasmin M. Madney, Dina Attia, Shaymaa Nafady
  Metabolites.2025; 16(1): 25.     CrossRef
• Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients
  Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, Javeed Mohammad, Mamatha Reddy Dundigalla, Pavan Kumar Madala, Sanyasirao KSSVV, Althaf Shaik
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Interplay between intestinal permeability and metabolic dysfunction-associated steatotic liver disease: Could there be a role for extra virgin olive oil consumption?
  Lydia Giannitrapani, Marinella Ferraro, Aurelio Seidita, Anna Licata, Maurizio Soresi
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Does Continuous Positive Airway Pressure Improve Liver Outcomes in MASLD with Obstructive Sleep Apnea? A Systematic Review
  Theja V. Channapragada, Clinton R. Brenner, Keven Guruswamy, Rewanth Katamreddy, Alwyn T. Pandian, Vyshnavi Pendala, Jaydon J. Sam, Jonathan G. Stine, Michael J. Brenner, Vinciya Pandian
  Journal of Clinical Medicine.2025; 15(1): 225.     CrossRef
• Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction
  Chae-Been Kim, Jinwoo Sung, Dohyun Ahn, Eun-Ah Jo, Kyung-Wan Baek, Hae-Ri Heo, Ju-Hwan Oh, Fengrui Zhang, Hyoung-Su Park, Hong-Soo Kim, Jung-Jun Park
  Nutrients.2025; 18(1): 83.     CrossRef
• SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
  Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh
  Endocrinology and Metabolism.2025; 40(6): 851.     CrossRef
• Impact of liraglutide and dapagliflozin on steatosis, fibrosis, aminotransferases, and lipid profile in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: results of a 6-month randomized study
  V.V. Cherniavskyi, A.I. Akimov, V.V. Tishchenko, L.M. Parunian
  GASTROENTEROLOGY.2025; 59(4): 269.     CrossRef
• Circulating histones as potential biomarkers of MASLD-MASH-HCC progression
  Desislava K. Tsoneva, Diana Buzova, Salvatore Daniele Bianco, Maria Rita Braghini, Giulia Andolina, Antonio Liguori, Francesca D’ Ambrosio, Andrea Urbani, Antonio Gasbarrini, Maurizio Pompili, Anna Alisi, Jan Cerveny, Tommaso Mazza, Manlio Vinciguerra, Lu
  Epigenomics.2025; 17(18): 1435.     CrossRef
• Modelos Animais de MASLD/NAFLD: uma revisão narrativa do estado atual e perspectivas futuras
  Gabriel dos Santos, Fabio de Castro Machado, Ana Beatriz Serrato Carmo, Alvaro Ivanski Sabedotti, Laura Moscardi Milléo, Lorenzo Cultz, Mateus Baptista Pizyblski, Leonardo Henrique de Figueiredo Lima, Mário Cláudio Soares Sturzeneker
  Cuadernos de Educación y Desarrollo.2025; 17(12): e10446.     CrossRef
• THE EFFECT OF S-ADENOSYLMETHIONINE ON LIPID PROFILE PARAMETERS IN PATIENTS WITH MULTIPLE MYELOMA AND CONCOMITANT METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE DURING CHEMOTHERAPY
  Y. Stadnik, G. Maslova
  Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії.2025; 25(4): 76.     CrossRef
• Serum Biomarkers for Hepatocellular Carcinoma: A Comparative Review of Traditional and Emerging Markers
  Min Kyung Park
  Journal of Digestive Cancer Research.2025; 13(3): 242.     CrossRef
• Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
  Xiao-Dong Zhou, Qin-Fen Chen, Qiong-Yue Fan, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victo
  Hepatology.2025;[Epub]     CrossRef
• Risk Factors for Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction–Associated Steatotic Liver Disease in Brazzaville
  Farel Elilie Mawa Ongoth, Rudel Godrèche Kondo, Philestine Clausina Mikolélé Ahoui Apendi, Nestor Ghislain Andzouana Mbamognoua, Raïssa Laure Mayanda Ohouana, Aymande Okoumou-Moko, Ornella Marline Yvonne Dinghat, Joël Rudy Ekoundzola, Sévérin Nkoua Eloi,
  Open Journal of Endocrine and Metabolic Diseases.2025; 15(08): 142.     CrossRef
• Kidney function mediates the association of per- and poly-fluoroalkyl substances (PFAS) and heavy metals with hepatic fibrosis risk
  Zhengqi Wei, Jincheng Liu, Na Wang, Keke Wei
  Environmental Research.2024; 263: 120092.     CrossRef
• Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis
  Fahad Lakhdhir, Agha Syed Muhammad, Ahmed Nasir Qureshi, Imran A Shaikh, Imran Joher, Jawaria Majeed, Javaria Khan
  Cureus.2024;[Epub]     CrossRef
• Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Clinical and Molecular Hepatology.2024; 30(4): 982.     CrossRef
• Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classification
  Han Ah Lee
  The Korean Journal of Internal Medicine.2024; 39(6): 869.     CrossRef
• AI in Hepatology: Revolutionizing the Diagnosis and Management of Liver Disease
  Sheza Malik, Rishi Das, Thanita Thongtan, Kathryn Thompson, Nader Dbouk
  Journal of Clinical Medicine.2024; 13(24): 7833.     CrossRef

Citations

Citations to this article as recorded by  

• Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period
  Kazuma Mori, Marenao Tanaka, Tatsuya Sato, Yukinori Akiyama, Keisuke Endo, Toshifumi Ogawa, Toru Suzuki, Hiroki Aida, Wataru Kawaharata, Kei Nakata, Itaru Hosaka, Araya Umetsu, Nagisa Hanawa, Masato Furuhashi
  Hepatology Research.2025; 55(1): 34.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases
  Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen
  Annals of Hepatology.2025; 30(1): 101750.     CrossRef
• Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea
  Dong Wook Kim, Minkook Son, Hye Jung Lee, Chi Hyeon Choi, Yeo Wool Kang, Sang Yi Moon, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek, Won Suk An
  Hepatology Research.2025; 55(9): 1239.     CrossRef
• Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region
  Pojsakorn Danpanichkul, Kanokphong Suparan, Banthoon Sukphutanan, Chuthathip Kaeosri, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Markos Kalligeros, Natchaya Polpichai, Yanfang Pang, Karn Wijarnpreecha, Pimsiri Sripongpun, Naichaya Chamroonkul, M
  Scientific Reports.2024;[Epub]     CrossRef
• Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3
  Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki
  Internal Medicine.2024;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Astragaloside IV alleviates metabolic associated fatty liver disease by regulating ferroptosis via the SLC7A11/GPX4 pathway
  Sitong CHEN, Hanying XU, Zipei ZHANG, Xiaonan LI, Xiaolei TANG, Dashi YING
  Chinese Journal of Analytical Chemistry.2026; 54(2): 100625.     CrossRef
• Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum
  Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
  Clinical Gastroenterology and Hepatology.2026; 24(6): 1644.     CrossRef
• Obstructive sleep apnea is associated with greater MASH and significant fibrosis severity in patients with obesity: A prospective clinicopathological study
  Jia Feng, Wenhui Chen, Zunhao Zhang, Fuqing Zhou, Yang Liu, Zhirui Qiu, Yan Liu, Zhiyong Dong, Cunchuan Wang, Hao Wang, Yi Ma
  Diabetes, Obesity and Metabolism.2026; 28(3): 1972.     CrossRef
• Rising burden of MASLD and CKM syndrome in Asia: A decade of trends and future projections
  Tianqi Duo, Yun Wen, Yu Bian, Yizheng Wang, Xiaofang Zhang, Jin Ju, Yanjie Lu, Zhiguo Wang, Jinghao Wang, Baofeng Yang
  Metabolism.2026; 178: 156549.     CrossRef
• Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study
  Yaxuan He, Yu Cao, Zekai Chen, Rong Xiang, Fang Wang
  Scientific Reports.2026;[Epub]     CrossRef
• Comparison of patients with HCC with and without MASLD after surgical resection
  Chia-Jung Ho, Hao-Jan Lei, Chun-Ting Ho, Gar-Yang Chau, Shu-Cheng Chou, Elise Chia-Hui Tan, Pei-Chang Lee, Yi-Hsiang Huang, Ying-Ying Yang, Teh-Ia Huo, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
  JHEP Reports.2026; 8(4): 101768.     CrossRef
• Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection
  Talal K Bhatti, Joseph K Lim
  World Journal of Gastroenterology.2026;[Epub]     CrossRef
• Comparison of the efficacy of transarterial chemoembolization combined with radiofrequency ablation or sintilimab and bevacizumab for unresectable hepatocellular carcinoma
  Tingting Li, Hongyi Zhao, Chengbin Dong, Yang Song, Miaomiao Li
  BMC Gastroenterology.2026;[Epub]     CrossRef
• Integrative Multiomics Analysis Reveals the Ameliorative Effects of Astragalus membranaceus Extract on Metabolic Dysfunction-Associated Steatotic Liver Disease
  Jiayi An, Yi Li, Zunhan Zhang, Yaru Chang, Guanxiu Xiao
  Molecules.2026; 31(7): 1120.     CrossRef
• Noncanonical function of epigenetic reader YTHDF1 inhibits MASLD progression by maintaining peroxisomes and mitochondrial homeostasis
  Chenyang Mu, Jian Tan, Yuefan Wang, Haozan Yin, Zhihui Dai, Zenghan Wang, Dongyang Ding, Zhichao Zhang, Sijie Wang, Hui Liu, Fu Yang
  Experimental & Molecular Medicine.2026; 58(4): 1172.     CrossRef
• ​​Integrating machine learning and spatial transcriptomics uncovers shared immunomodulatory deubiquitinases in MAFLD and HCC
  Yu-xi Han, Hongze Li, Wendi Xia, Junyi Ma, Jiaqi Zhang, Yiling Li
  Human Genetics.2026;[Epub]     CrossRef
• Role of the NF-κB signaling pathway in vascular endothelial cell injury associated with metabolic dysfunction-associated steatotic liver disease under hypoxia
  Jingxuan Zhang, Chenguang Zhang, Chao Yang, Yongjun Miao, Xiaomeng Wei, Zijian Zhang, Zihan Shen, Guodan Bao
  Biochemical and Biophysical Research Communications.2026; 817: 153710.     CrossRef
• Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach
  Beom Kyung Kim
  The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
• Association Between Uric‐Acid‐to‐HDL Ratio and Hepatic Steatosis Diagnosed by Liver Ultrasound Transient Elastography
  Lili Chu, Meng Wu, Bo Zhang, Jinger Lu, Ying Chen, Zhiwen Luo
  International Journal of Clinical Practice.2026;[Epub]     CrossRef
• Risk factors for non-alcoholic fatty liver disease in pregnant women as a basis for in-depth examination and prevention of obstetric complications
  Elena V. Mozgovaya, Marina A. Kryshnia
  Journal of obstetrics and women's diseases.2026; 75(2): 42.     CrossRef
• Reply to “Enhancing Capsule on Liver CT: Implications for Steatotic Liver Disease”
  Se Jin Choi, Dong Hwan Kim, Jae Ho Byun
  American Journal of Roentgenology.2026;[Epub]     CrossRef
• Valerenic acid attenuates chronic stress-exacerbated metabolic dysfunction-associated steatotic liver disease via the estrogen receptor α-GDF15 axis
  Xingli Wu, Yuzi Jiang, Junmin Wang, Simin Gu, Yanping Wang, Ning Li, Chunmei Qian, Hongming Nie, Yiyuan Zheng, Yong Li
  European Journal of Pharmacology.2026; 1030: 179106.     CrossRef
• Traditional Chinese Medicines for Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Mixed‐Method Systematic Review
  Zhipeng Wei, Liping Guo, Guohua Zhang, Yicheng Qian, Zhou Lan, Kehu Yang
  Journal of Evidence-Based Medicine.2026;[Epub]     CrossRef
• Association of the Number of Concurrent Metabolic Syndrome Risk Factors with Textbook Outcomes Following Liver Resection for Patients with Hepatocellular Carcinoma: A Multicenter Study
  Zhan-Cheng Qiu, Jun-Long Dai, Yu Zhang, Fei Xie, Yu Yu, Shu-Sheng Leng, Tian-Fu Wen, Chuan Li
  Annals of Surgical Oncology.2025; 32(1): 399.     CrossRef
• Deciphering the roles of neddylation modification in hepatocellular carcinoma: Molecular mechanisms and targeted therapeutics
  Wenxin Wu, Xuanyi Wang, Ruijie Ma, Shuhong Huang, Hongguang Li, Xinxing Lyu
  Genes & Diseases.2025; 12(4): 101483.     CrossRef
• Alterations of Krüppel-like Factor Signaling and Potential Targeted Therapy for Hepatocellular Carcinoma
  Rongfei Fang, Chunxiu Sha, Qun Xie, Dengfu Yao, Min Yao
  Anti-Cancer Agents in Medicinal Chemistry.2025; 25(2): 75.     CrossRef
• Associations of MAFLD subtypes and air pollutants with multi-system morbidity and all-cause mortality: A prospective cohort study
  Jingyi Zhang, Shanshan Ran, Shengtao Wei, Fei Tian, Lan Chen, Zijun Yang, Ge Chen, Hualiang Lin
  Ecotoxicology and Environmental Safety.2025; 291: 117893.     CrossRef
• Global burden and international disparities in NASH-associated liver Cancer: mortality trends (1990–2021) and future projections to 2045
  Qilong Nie, Yongwen Jiang, Mingyang Li, Qiuyan Liang, Xiaoai Mo, Tengyu Qiu, Qunfang Jiang, Kaizhou Huang, Youqing Xie, Ying Chen, Xiaojun Ma, Jianhong Li, Kaiping Jiang
  Frontiers in Public Health.2025;[Epub]     CrossRef
• Exploring emerging frontiers in hepatology: iLIVER's continuing journey
  Ming-Da Wang, Xin-Fei Xu, Lei Cai, Tian Yang
  iLIVER.2025; 4(1): 100148.     CrossRef
• A review of image guidance and localization methods for liver puncture robots
  Yongde Zhang, Jiabin Yang, Xuequan Huang, Chuang He
  Journal of Robotic Surgery.2025;[Epub]     CrossRef
• Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
  Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
  Liver International.2025;[Epub]     CrossRef
• Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis
  Sahana Shetty, Renuka Suvarna, Vanessa Ambrose Fistus, Shivam Modi, Joseph M Pappachan
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Characterisation of non-cirrhotic MAFLD-related hepatocellular carcinoma: a retrospective cohort study
  Shadi Zerehpooshnesfchi, Fatema Safri, Ziyan Pan, Romario Nguyen, Lawrence Yuen, Vincent Lam, Christopher Nahm, Tony Pang, Golo Ahlenstiel, Jacob George, Mohammed Eslam, Liang Qiao
  Therapeutic Advances in Chronic Disease.2025;[Epub]     CrossRef
• Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide
  Yuki Oe, Takashi Omori, Eriko Aimono, Shin Furukawa, Hirohiko Kitakawa, Masatoshi Tateno, Kiyoshi Sakai, Kyu Yong Cho
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Trends and visualization analysis of research on MASLD-Related hepatocellular carcinoma: a bibliometric analysis
  Hongkun Yin, Xusheng Zhang, Qi Wang
  Discover Oncology.2025;[Epub]     CrossRef
• Overweight and Helicobacter pylori infection: a correlation in metabolic dysfunction-associated fatty liver disease
  Xu Chen, Jiayue Fu, Kejia Jin, Zixuan Yang, Yidan Qian, Kehan Mei, Yihan Wang, Jialei Min, Yilin Du, Zaisheng Zhu, Shengcun Li
  Frontiers in Cellular and Infection Microbiology.2025;[Epub]     CrossRef
• Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE)
  David E. González-Mendoza, Francisco Fernández-Nogueira, Misael Uribe, Norberto C. Chávez-Tapia, Natalia Nuño-Lámbarri
  Thrombosis Research.2025; 253: 109395.     CrossRef
• Rewriting the MASLD‐associated hepatocellular carcinoma script: Targeting epigenetics and metabolism
  Chiara Aiello, Eric Felli, Teresa Musarra, Lorenzo Nevi, Annamaria Altomare, Jordi Gracia‐Sancho, Andrea Baiocchini, Simone Carotti
  International Journal of Cancer.2025; 157(10): 1991.     CrossRef
• Role of mac-2 binding protein glycosylation isomer in predicting fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
  Thuy Thi Thu Pham, Dat Tan Ho, Chanh Pham, Hoan Phan, Bieu Phu, Toan Nguyen, Dang Nguyen, Hai Thanh Phan, Khue Minh Nguyen
  World Journal of Hepatology.2025;[Epub]     CrossRef
• The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management
  Yuxi Jin, Mohammed Alissa, Ahmed Ezzat Ahmed, Amin A. Al-Doaiss, Naif Asiri, Yasser Assiri, Shahid Ullah Khan, Munir Ullah Khan, Samuel Joseph
  Current Problems in Cardiology.2025; 50(11): 103170.     CrossRef
• Exploring the Link Between Irritable Bowel Syndrome and Chronic Diseases: A Narrative Overview
  Sneha Reddy, Savithri C. Veluri
  Academic Medicine & Surgery.2025;[Epub]     CrossRef
• Fibrosis Severity in MASLD Determines the Predictive Value of Lp-PLA2 for Carotid Atherosclerosis in Type 2 Diabetes: A Cross-Sectional Study
  Junzhao Ye, Rui Song, Xiaorong Gong, Xin Li, Congxiang Shao, Bihui Zhong
  Biomedicines.2025; 13(10): 2431.     CrossRef
• Lipid metabolism in cancer cells: Its role in hepatocellular carcinoma progression and therapeutic resistance
  Tin Lok Wong, Yanshu Kong, Stephanie Ma
  Hepatology Communications.2025;[Epub]     CrossRef
• Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis
  Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova
  GASTROENTEROLOGY.2025; 59(3): 206.     CrossRef
• Protective effect and mechanisms of puerarin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of animal studies
  Xiang-yun Zou, Yu-cheng Yang, Xue-han Liu, Wen-ying Qi, Xiao-bin Zao, Xiao-ke Li, Yong’an Ye
  Pharmacological Research.2025; 222: 108024.     CrossRef
• A comprehensive bibliometric and visual analysis of tumor-associated macrophages in hepatocellular carcinoma
  GuanBo Zhang, Gang Li, JinSong Li, Jie Zhang, Zhi Yang, Lin Yang, ShiJie Jiang, ShiFan Zhu, JiaXing Wang
  Discover Oncology.2025;[Epub]     CrossRef
• Targeting Ferroptosis: New Insights and Therapeutic Advances in MAFLD Complicating T2DM
  Fang Yao, Gaochao Wang, Fan Ning, Yanbo Shi
  Frontiers in Bioscience-Landmark.2025;[Epub]     CrossRef
• Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Wolf in Sheep's Clothing
  Xixi Fang, Chenhao Xu, Jun Lu, Runzhou Zhuang, Xiao Xu, Xuyong Wei
  Cell Biochemistry and Function.2025;[Epub]     CrossRef
• Glucagon‐Like Peptide‐1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta‐Analysis and Clinical Decision Framework
  Andrea Dalbeni, Marco Vicardi, Leonardo Antonio Natola, Filippo Cattazzo, Alessandra Auriemma, Rosa Lombardi, Felice Cinque, Luca Dalle Carbonare, Alessandro Mantovani, David Sacerdoti
  Cancer Medicine.2025;[Epub]     CrossRef
• Mechanistic roles and intervention strategies involving gut microbiota, amino acid metabolism, and the tumor immune microenvironment in MAFLD-HCC progression
  Ziwei Guo, Ziang Yao, Xiaohan Chen, Dongjie Wu, Yaqi Ouyang, Yaocun Shen, Yi Wang, Houyan Zhang, Yanping Lu, Wenliang Lv
  Clinical and Experimental Medicine.2025;[Epub]     CrossRef
• Splanchnic inflammatory syndrome and the not-so-silent risk of cancer
  Richard C Semelka MD, Miguel Ramalho MD
  Gastroenterology & Hepatology: Open access.2024; 15(3): 63.     CrossRef
• Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c
  Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
  Clinical and Molecular Hepatology.2024; 30(4): 705.     CrossRef
• Unraveling the epidemiology of metabolic dysfunction-associated liver cancer: Insights from mixed etiologies, regional variations, and gender disparities
  Gong Feng, Ya-Fei Fan, Ru-Xin Li, Giovanni Targher, Christopher D. Byrne, Ming-Hua Zheng
  iLIVER.2024; 3(3): 100113.     CrossRef
• Impact of occult hepatitis B virus infection and high-fat diet on hepatocellular carcinoma development
  Kun Chen, Chunfeng Qu
  Hepatoma Research.2024;[Epub]     CrossRef
• Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
  Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George
  Hepatology International.2024; 18(6): 1740.     CrossRef
• Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy
  Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li
  Clinical and Molecular Hepatology.2024; 30(4): 965.     CrossRef
• Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis
  Muhammed Shabil, Mahalaqua Nazli Khatib, Suhas Ballal, Pooja Bansal, Balvir S. Tomar, Ayash Ashraf, M. Ravi Kumar, Aashna Sinha, Pramod Rawat, Abhay M. Gaidhane, Sanjit Sah, Afukonyo Shidoiku Daniel, Ambanna Yappalparvi, Ganesh Bushi
  BMC Endocrine Disorders.2024;[Epub]     CrossRef
• APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
  George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Haitao Zhao, Motoyuki Otsuka, Sadahisa Ogasawara, Jacob George, Pierce K. H. Chow, Jianqiang Cai, Shuichiro Shiina, Naoya Kato, Osamu Yokosuka, Kyoko Oura, Thomas Yau, Stephen L. Chan, Min
  Hepatology International.2024; 18(6): 1661.     CrossRef

Citations

Citations to this article as recorded by  

• Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases
  Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen
  Annals of Hepatology.2025; 30(1): 101750.     CrossRef
• Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
  Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
  Clinical and Molecular Hepatology.2025; 31(Suppl): S51.     CrossRef
• Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
  Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
  Cells.2025; 14(6): 428.     CrossRef
• Efficacy of measuring natural killer-activating receptor ligands to predict the pathogenesis of metabolic dysfunction-associated steatotic liver disease
  Jun Arai, Akinori Okumura, Satoshi Kimoto, Kazumasa Sakamoto, Tomoya Kitada, Rena Kitano, Tadahisa Inoue, Sayaka Nishimura, Noriko Inden, Yukiko Muraki, Naoya Kato, Kiyoaki Ito
  Hepatology International.2025; 19(4): 836.     CrossRef
• C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1
  Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li
  Metabolism.2025; 168: 156242.     CrossRef
• Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication
  Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi
  Hepatology Research.2024; 54(8): 729.     CrossRef
• Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease
  Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto
  JGH Open.2024;[Epub]     CrossRef
• Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019
  Pojsakorn Danpanichkul, Kanokphong Suparan, Priyata Dutta, Chuthathip Kaeosri, Banthoon Sukphutanan, Yanfang Pang, Narathorn Kulthamrongsri, Methasit Jaisa-aad, Cheng Han Ng, Margaret Teng, Masahito Nakano, Asahiro Morishita, Naim Alkhouri, Ju Dong Yang,
  Metabolism.2024; 158: 155958.     CrossRef
• Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
  Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
  Clinical and Molecular Hepatology.2024; 30(3): 577.     CrossRef
• Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?
  Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su
  JGH Open.2024;[Epub]     CrossRef
• Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
  Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
  Clinical and Molecular Hepatology.2024; 30(4): 962.     CrossRef

Citations

Citations to this article as recorded by  

• Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
  Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
  Journal of Advanced Research.2026; 80: 893.     CrossRef
• Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis
  Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
  Clinical and Molecular Hepatology.2026; 32(1): 339.     CrossRef
• Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study
  Soichi Komaki, Michikazu Nakai, Yunosuke Matsuura, Kinuko Yamamoto, Hiroki Tanaka, Yuri Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Hiroshi Kawakami, Toshihiro Tsuruda, Koichi Kaikita
  Diabetic Medicine.2026;[Epub]     CrossRef
• Targeted Food-Grade Delivery Systems for Liver Injury Intervention: A Comprehensive Review of Nanocarrier Strategies
  Jixian Zhang, Jieyu Wang, Guoyan Liu, Xin Xu, Chaoting Wen
  Advanced Functional Foods.2026; 2(2): 98.     CrossRef
• Reply to: “Is liver fibrosis more advanced in MetALD than in MASLD?”
  Joo Hyun Oh, Dae Won Jun
  Journal of Hepatology.2025; 82(1): e58.     CrossRef
• Statin use and liver-related prognosis among patients with MASLD
  Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
  JHEP Reports.2025; 7(4): 101313.     CrossRef
• Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults
  Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang
  Gut and Liver.2025; 19(1): 116.     CrossRef
• Optimal BMI cutoff for lean MASLD/MetALD and adverse hepatic outcomes in East-Asian populations
  Byungyoon Yun, Juyeon Oh, Heejoo Park, Beom Kyung Kim, Jin-Ha Yoon
  European Journal of Internal Medicine.2025; 133: 141.     CrossRef
• Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
  Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
  Cells.2025; 14(3): 221.     CrossRef
• Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
  Hanne Åström, Christine Takami Lageborn, Hannes Hagström
  Expert Review of Gastroenterology & Hepatology.2025; 19(3): 273.     CrossRef
• Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
  Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
  European Journal of Gastroenterology & Hepatology.2025; 37(5): 652.     CrossRef
• A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population
  Ji Eun Kim, Yun Kim, Jiwon Bae, Eileen Laurel Yoon, Hyun Sung Kim, Sung Ryol Lee, Tae Hyun Yoon, Dae Won Jun
  Archives of Pharmacal Research.2025; 48(2): 166.     CrossRef
• Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis
  Gina Ryu, Eileen Laurel Yoon, Wankyu Kim, Dae Won Jun
  Diagnostics.2025; 15(3): 342.     CrossRef
• Dietary Patterns Rich in Soybean Products, Vegetables, Fish, Fruits, and Miso Soup Were Inversely Associated with Fatty Liver Index: The Nagahama Study
  Yoko UEBA, Kaori IKEDA, Yasuharu TABARA, Takeo NAKAYAMA, Daisuke TANAKA, Yoshimitsu TAKAHASHI, Shinji KOSUGI, Kazuya SETOH, Takahisa KAWAGUCHI, Fumihiko MATSUDA, Nobuya INAGAKI
  Journal of Nutritional Science and Vitaminology.2025; 71(1): 25.     CrossRef
• Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization
  Jialin Ren, Min Wu
  International Journal of Molecular Sciences.2025; 26(7): 3166.     CrossRef
• Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
  Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
  Liver International.2025;[Epub]     CrossRef
• Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
  Beom Kyung Kim
  Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
• Navigating the Paradox of IL‐22: Friend or Foe in Hepatic Health?
  Jianqi Qin, Weixiong Zhu, Wence Zhou
  Journal of Gastroenterology and Hepatology.2025; 40(6): 1393.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications
  Hyo Young Lee, Eileen L. Yoon
  The Korean Journal of Gastroenterology.2025; 85(2): 126.     CrossRef
• Young Adults With Metabolic Dysfunction–Associated Steatotic Liver Disease Have an Increased Risk of Early-Onset Cancer: A Nationwide Cohort Study Differentiating the Risk of 23 Site-Specific Cancers
  Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Qiang Xia, Meng Sha, Yoosoo Chang, Won Kim
  Clinical Gastroenterology and Hepatology.2025; 23(13): 2540.     CrossRef
• The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco
  Journal of Clinical Medicine.2025; 14(11): 3821.     CrossRef
• Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up
  Mimi Kim, Huiyul Park, Eileen L. Yoon, Ramsey Cheung, Donghee Kim, Hye-Lin Kim, Dae Won Jun
  Scientific Reports.2025;[Epub]     CrossRef
• Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
  Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang
  Gut and Liver.2025; 19(4): 479.     CrossRef
• Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
  Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
  Gut and Liver.2025; 19(5): 758.     CrossRef
• Misclassification of Alcohol Use Disorder in MASLD and MetALD: Prevalence, Clinical Characteristics, and Outcomes
  Jun-Hyuk Lee, Sung-Ho Ahn, Jimin Park, So Young Jeon, Eileen L. Yoon, Hye Sun Lee, Dae Won Jun
  Gut and Liver.2025; 19(5): 735.     CrossRef
• Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
  Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
  Hepatology Communications.2025;[Epub]     CrossRef
• Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD
  Hiroyuki Suzuki, Toshimitsu Tanaka, Shotaro Yamaguchi, Keisuke Miwa, Takumi Kawaguchi
  Journal of Hepatology.2024; 80(4): e150.     CrossRef
• Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population
  Joo Hyun Oh, Dae Won Jun
  Gut and Liver.2024; 18(2): 197.     CrossRef
• Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
  Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
  Clinical and Molecular Hepatology.2024; 30(2): 263.     CrossRef
• Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
  Joo Hyun Oh, Dae Won Jun
  Clinical and Molecular Hepatology.2024; 30(2): 168.     CrossRef
• Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
  Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi
  Clinical and Molecular Hepatology.2024; 30(2): 266.     CrossRef
• Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
  Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Na
  Clinical and Molecular Hepatology.2024; 30(2): 225.     CrossRef
• Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
  Muhammed Mubarak
  World Journal of Gastrointestinal Pathophysiology.2024;[Epub]     CrossRef
• Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics
  Huiyul Park, Mimi Kim, Hye‐Lin Kim, Seon Cho, Eileen L. Yoon, Dae Won Jun
  Hepatology Research.2024; 54(11): 1027.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
  Piero Portincasa, Gyorgy Baffy
  European Journal of Internal Medicine.2024; 124: 35.     CrossRef
• Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability
  Jiwon Yang, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Jonggi Choi
  Journal of Gastroenterology and Hepatology.2024; 39(10): 2112.     CrossRef
• Barriers to care linkage and educational impact on unnecessary MASLD referrals
  Jun-Hyuk Lee, Eileen Laurel Yoon, Ju Hyun Oh, Kyunam Kim, Sang Bong Ahn, Dae Won Jun
  Frontiers in Medicine.2024;[Epub]     CrossRef
• A New Korean Nomenclature for Steatotic Liver Disease
  
  The Korean Journal of Gastroenterology.2024; 84(1): 1.     CrossRef
• A New Korean Nomenclature for Steatotic Liver Disease
  
  The Korean Journal of Medicine.2024; 99(4): 189.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
  Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
  Cancers.2024; 16(18): 3161.     CrossRef
• A New Korean Nomenclature for Steatotic Liver Disease
  
  Gut and Liver.2024; 18(5): 924.     CrossRef
• A new Korean nomenclature for steatotic liver disease
  
  Clinical and Molecular Hepatology.2024; 30(Suppl): S214.     CrossRef
• Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease
  Yun Kyu Lee, Dong Hyeon Lee, Sae Kyung Joo, Heejoon Jang, Young Ho So, Siwon Jang, Dong Ho Lee, Jeong Hwan Park, Mee Soo Chang, Won Kim
  Gut and Liver.2024; 18(6): 1048.     CrossRef
• Establishment and characterization of mouse metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma organoids
  Sumin Kim, Nahyun Jeong, Jeayeon Park, Hyojin Noh, Ja Oh Lee, Su Jong Yu, Ja-Lok Ku
  Scientific Reports.2024;[Epub]     CrossRef
• Metabolic Dysfunction-associated Steatotic Liver Disease–related Hepatocellular Carcinoma: Current Research Insights
  Ho Soo Chun, Minjong Lee, Tae Hun Kim
  Journal of Digestive Cancer Research.2024; 12(3): 184.     CrossRef
• From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
  Li Chen
  World Journal of Hepatology.2023; 15(12): 1253.     CrossRef
• Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
  Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon
  Clinical and Molecular Hepatology.2023; 30(1): 118.     CrossRef
• Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
  Eileen L. Yoon, Dae Won Jun
  Clinical and Molecular Hepatology.2023; 30(1): 126.     CrossRef
• Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
  Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi
  Clinical and Molecular Hepatology.2023; 30(1): 121.     CrossRef

Citations

Citations to this article as recorded by  

• Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis
  Xuanlin Wu, Tao Pan, Zhihao Fang, Titi Hui, Xiaoxiao Yu, Changxu Liu, Zihao Guo, Chang Liu
  Journal of Inflammation Research.2025; Volume 18: 1639.     CrossRef
• Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis
  Gina Ryu, Eileen Laurel Yoon, Wankyu Kim, Dae Won Jun
  Diagnostics.2025; 15(3): 342.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications
  Hyo Young Lee, Eileen L. Yoon
  The Korean Journal of Gastroenterology.2025; 85(2): 126.     CrossRef
• Association of elevated Alpha-1-Acid glycoprotein with MAFLD prevalence in young and middle-aged women: a cross-sectional study based on NHANES 2017–2020
  Yi Xiao, Xian Luo, Yinghao Fu, Haijuan Huang, Qiaoping Gao, Jiansong Liu, Daxin Pang, Xiaolu Liang, Huadi Chen, Hao Xu
  Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
• The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what’s different?
  Priyankar Dey
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Laboratory monitoring in patients with moderate to severe plaque psoriasis
  Jonathan M. Fenkel, John A. Osborne, April W. Armstrong, Bruce Strober, Linda Stein Gold, Michael Cameron, Mark Lebwohl
  Journal of Dermatological Treatment.2025;[Epub]     CrossRef
• Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
  Joo Hyun Oh, Dae Won Jun
  Clinical and Molecular Hepatology.2024; 30(2): 168.     CrossRef
• Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies
  Shaghayegh Khanmohammadi, Amirhossein Habibzadeh, A. B. M. Kamrul‐Hasan, Art Schuermans, Mohammad Shafi Kuchay
  Diabetic Medicine.2024;[Epub]     CrossRef
• Exploring the relationship between air pollution, non-alcoholic fatty liver disease, and liver function indicators: a two-sample Mendelian randomization analysis study
  Qingliang Song, Jinyue Pan, Maoxing Pan, Chuiyang Zheng, Wen Fan, Jianwei Zhen, Dajin Pi, Zheng Liang, Haiyan Shen, Yuanyou Li, Qinhe Yang, Yupei Zhang
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Waiting for the changes after the adoption of steatotic liver disease
  Eileen L. Yoon, Dae Won Jun
  Clinical and Molecular Hepatology.2023; 29(4): 844.     CrossRef
• Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
  Eileen L. Yoon, Dae Won Jun
  Clinical and Molecular Hepatology.2023; 30(1): 126.     CrossRef

Citations

Citations to this article as recorded by  

• Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis
  Won-Mook Choi, Wai-Kay Seto
  Hepatology.2026; 83(5): 1046.     CrossRef
• Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B
  Maria Kalafateli, Roberta Forlano, Eleanor Barnes, Laura Martinez-Gili, Madeleine Lacey, Giordano Sigon, Benjamin H. Mullish, Vincent Mallet, Lucia Parlati, Paul Richardson, Niamh Forde, Gaetano Serviddio, Rosanna Villani, Sabela Lens, Maria Buti, Elena V
  Clinical Gastroenterology and Hepatology.2026; 24(3): 701.     CrossRef
• Triglyceride-based lipotoxicity in the pathophysiology of chronic diseases
  Junjun Liu, Xiude Fan, Yongfeng Song, Jiajun Zhao
  Trends in Endocrinology & Metabolism.2026; 37(4): 371.     CrossRef
• CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma
  Subhrojyoti Mukherjee, Manish Kumar
  Expert Review of Anticancer Therapy.2026; 26(5): 599.     CrossRef
• Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
  Shang-Chin Huang, Jia-Horng Kao
  Clinical and Molecular Hepatology.2026; 32(1): 423.     CrossRef
• The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B
  Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Association between fatty liver and risk of liver failure in patients with acute hepatitis B: a retrospective cohort study
  Xiao-hao Wang, Yu-nan Chang, Lu Zhang, Yan-li Yang, Lu-wen Liang, Yi Zeng, Zhi Zhou, Shan Zhong, Hu Li
  Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
• Viral hepatitis and liver disease in the Mongolian community in London ('MoLo'): A mixed methods study protocol to investigate the epidemiology and burden of disease to inform clinical and public health interventions
  Emily Martyn, Nara Dashdorj, Jessica Carter, Indrajit Ghosh, Enkh-Oyun Amarbayasgalan, Khadija Said Mohammed, Elizabeth Waddilove, Marion Delphin, Kathryn Jack, Camila Picchio, Joy Ko, Michelle Berkeley, Rubin Rose-Key, Eleni Nastouli, Sema Mandal, Monica
  Wellcome Open Research.2026; 11: 72.     CrossRef
• Clinical and histopathological features of chronic hepatitis B with normal alanine aminotransferase levels with or without concomitant non-alcoholic fatty liver disease
  Wencong Li, Shiheng Liu, Weiguang Ren, Xiaoxiao Zhang, Lingdi Liu, Fang Han, Ying Zhang, Yuemin Nan, Suxian Zhao
  Frontiers in Medicine.2026;[Epub]     CrossRef
• Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study
  Soichi Komaki, Michikazu Nakai, Yunosuke Matsuura, Kinuko Yamamoto, Hiroki Tanaka, Yuri Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Hiroshi Kawakami, Toshihiro Tsuruda, Koichi Kaikita
  Diabetic Medicine.2026;[Epub]     CrossRef
• Hepatitis B virus exposure and metabolic dysfunction-associated steatotic liver disease in U.S. adults: A nationally representative analysis from NHANES 2017-2020
  Youping Lin, Yanjuan Song, Qiuming Lin, Minran Li
  The American Journal of the Medical Sciences.2026; 372(1): 52.     CrossRef
• Nomogram integrating serological markers and clinical parameters for predicting severe hepatic steatosis in patients with abnormal glucose metabolism
  Ping Hu, Ao Zhong, Yuting Shen, Yinchen Yuan, Qing Jin, Quan Chen
  Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
• Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus
  Shang-Chin Huang, Jia-Horng Kao
  Biomedical Journal.2026; 49(3): 100969.     CrossRef
• Periodontitis and Chronic Liver Disease: Mechanistic Insights Focusing on Porphyromonas gingivalis—A Narrative Review
  Yue Ying, Yuwei Nie, Jiahui Zhao, Qin Dong, Meixian Chen, Aijia Jiang, Nan Liu, Tong Xu, Junchao Liu, Yaping Pan, Li Lin, Dongmei Zhang
  Microorganisms.2026; 14(4): 736.     CrossRef
• Predicting the highly imbalanced hepatitis B virus infection outcome in Chinese middle-aged and older adults using an ensemble machine learning approach
  Chen Sun, Xiaohan Yi, Nyi Nyi Soe, Phyu Mon Latt, Biying Wang, Zhongqun Zhao, Zhen Yu, Xianglong Xu
  Discover Public Health.2026;[Epub]     CrossRef
• The stealthy saboteur: hepatic steatosis and its erosion of APRI and FIB-4 accuracy
  Huaying Zhou, Yuhong Li, Maoping Li, Jing Ma
  Frontiers in Medicine.2026;[Epub]     CrossRef
• Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes
  Qin Lou, Jiarong Cai, Jianhua Yin
  Microorganisms.2026; 14(4): 853.     CrossRef
• Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease
  Chieh Liu, Yi-Fen Shih, Chun-Jen Liu
  Clinical and Molecular Hepatology.2026; 32(2): 565.     CrossRef
• Retrospective analysis of predictors for significant hepatic inflammation in metabolic-associated fatty liver disease with chronic hepatitis B
  Long Hao Xu, Run Yan He, Yan Neng Kang, Heng Hong Lin, Jia En Yang, Hua Xiao Chen, Xue Ting Huang, Xiao Lu Wu, Bao Hui Pei, Chao Zhou, Min Wang
  PeerJ.2026; 14: e21186.     CrossRef
• Diagnosing and defining MASLD in people living with chronic hepatitis B
  Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews
  Communications Medicine.2026;[Epub]     CrossRef
• Limited Utility of Serum Scores vs. Shear Wave Elastography for Graft Fibrosis in Adult and Pediatric Liver Transplant Recipients
  Si-Rui Wang, Shu-Chun Wang, Zhan-Xiong Yi, En-Hui He, Jun-Feng Zhao, Xiang-Dong Hu
  Ultrasound in Medicine & Biology.2026; 52(8): 1671.     CrossRef
• The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
  Shang-Chin Huang, Tai-Chung Tseng
  Gut and Liver.2026; 20(3): 350.     CrossRef
• Knowledge, attitude, and practice towards fatty liver disease among the general population in Shanghai, China: a community-based cross-sectional study
  Xue Yang, Hui Chang, Limei Feng, Bin Wang
  Frontiers in Public Health.2026;[Epub]     CrossRef
• What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol
  Emily Martyn, Jessica Carter, Maeve Barlow, Flora Olcott, Indrajit Ghosh, Elizabeth Waddilove, Alejandro Arenas-Pinto, Richard Gilson, Stuart Flanagan, WD Francois Venter, Jennifer Manne-Goehler, Sally Hargreaves, Emmanouil Tsochatizis, Douglas MacDonald,
  Wellcome Open Research.2026; 11: 285.     CrossRef
• Coexistent Hepatitis B Virus and Metabolic Dysfunction-Associated Steatotic Liver Disease Under the New Definition: A New Era for Established Diseases
  Ahmed Tawheed, Abdulla A. Mahmoud, Hussein Hassan Aly, Mohamed El-Kassas
  Livers.2026; 6(3): 44.     CrossRef
• Beyond fibrosis: The imperative for dual steatosis and fibrosis assessment in chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease co-pathology
  Francesco Giangregorio, Elisa Civaschi, Samanta Mazzocchi, Davide Romano, Paolo Clini, Esther Centenara, Umberto Casale, Davide Catucci
  World Journal of Hepatology.2026;[Epub]     CrossRef
• Aloe emodin isolated from Cassiae semen upregulates IFITM1 to suppress hepatitis B virus replication via the interferon signaling pathway
  Xin Wen, Xincan Yu, Yuxin Hu, Jiamin Chen, Dongwei Zhang, Yalin Hou, Shui Liu, Xuemeng Shi, Jun Xu, Felicia Goodrum
  mSphere.2026;[Epub]     CrossRef
• Metabolic dysfunction-associated fatty liver disease in chronic hepatitis B: dual effects on hepatocarcinogenesis and evolving strategies for risk prediction
  Huihui Tao, Yuxin Duan, Guoyang Yu, Wei Yan, Jianhua Yin
  Frontiers in Immunology.2026;[Epub]     CrossRef
• The coexistence of MAFLD increases fibrosis burden in patients with chronic hepatitis B
  Alaa Mohamed Mostafa, Yasser Fouad, Nadia Abdelaaty Abdelkader, Omar Magdy, Nehal Refaat Raouf, Mohammed Eslam
  Scientific Reports.2026;[Epub]     CrossRef
• Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B
  Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Sih-Han Liao, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
  American Journal of Gastroenterology.2025; 120(2): 401.     CrossRef
• Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29‐year follow‐up
  Ming‐Whei Yu, Wan‐Jung Wu, Chih‐Lin Lin, Chun‐Jen Liu, Wei‐Ya Peng, Pin‐Yu Huang, Yi‐Wen Huang, Jui‐Ting Hu, Hung‐Chuen Chang, Jyh‐Ming Liou
  Hepatology Research.2025; 55(1): 46.     CrossRef
• All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease
  Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
  Journal of Hepatology.2025; 83(1): 43.     CrossRef
• Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction
  Ammara A Majeed, Amna S Butt
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Impact of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis
  Qingyan Kong, Diao Kong, Bei Li, Wei Peng, Zheyu Chen
  Academic Radiology.2025; 32(11): 6514.     CrossRef
• Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana
  Ho Soo Chun, Minjong Lee
  Clinical and Molecular Hepatology.2025; 31(1): 261.     CrossRef
• Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China
  Di Shen, Xintian Cai, Junli Hu, Shuaiwei Song, Qing Zhu, Huimin Ma, Yingying Zhang, Rui Ma, Pan Zhou, Wenbo Yang, Jing Hong, Delian Zhang, Nanfang Li
  Journal of Inflammation Research.2025; Volume 18: 1623.     CrossRef
• Divergent roles of MASLD components in chronic hepatitis B: A double-edged sword
  Shang-Chin Huang, Tung-Hung Su
  Journal of Hepatology.2025; 83(1): e34.     CrossRef
• Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
  Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
  Cells.2025; 14(6): 428.     CrossRef
• Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection
  Chih-Jan Ko
  American Journal of Cancer Research.2025; 15(2): 737.     CrossRef
• Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B
  Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
  Clinical and Molecular Hepatology.2025; 31(Suppl): S182.     CrossRef
• SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B
  Huiying Yu, Bin Li, Huili Guo, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao
  The Journal of Infectious Diseases.2025; 232(2): 474.     CrossRef
• Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis
  Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
  Hepatology International.2025; 19(4): 959.     CrossRef
• Non-invasive Assessment of Advanced Fibrosis and Steatosis in Chronic Hepatitis B Patients with Comorbid NAFLD
  Zhenhua Zhou, Feng Chen, Rongrong Zou, Qianhui Li, Xiaomin Xu
  Hepatitis Monthly.2025;[Epub]     CrossRef
• Study on Ultrasound-Assisted Diagnosis of CHB Complicated with NAFLD Hepatic Fibrosis Based on Deep Learning
  Xiuling Huang, Shan Huang, Changfeng Dong, Nuo Chen, Yuxuan Wang, Changmiao Wang, Yongquan Zhang, Cheng Feng
  Journal of Imaging Informatics in Medicine.2025; 38(6): 4349.     CrossRef
• Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
  Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
  Health Science Reports.2025;[Epub]     CrossRef
• Molecular mechanisms of pyroptosis in non-alcoholic steatohepatitis and feasible diagnosis and treatment strategies
  Dong-fang Shang, Wen-qian Xu, Qing Zhao, Chen-lu Zhao, Si-ying Wang, Yong-li Han, He-guo Li, Ming-hao Liu, Wen-xia Zhao
  Pharmacological Research.2025; 216: 107754.     CrossRef
• Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine
  Yaru Shi, Rong Fan
  Interdisciplinary Medicine.2025;[Epub]     CrossRef
• The Associations of Serum Folate Forms with Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Fibrosis: A Nationwide Cross-Sectional Study
  Hai Zhao, Wei Fan, Yan Yan, Yuxing Liu, Xuejun Kang
  Metabolites.2025; 15(6): 370.     CrossRef
• Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review
  Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya
  Preventive Medicine: Research & Reviews.2025; 2(4): 183.     CrossRef
• Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens
  Mei Huang, Dongyao Wang, Jiao Huang, An-Na Bae, Yun Xia, Xutu Zhao, Mahsa Mortaja, Marjan Azin, Michael R. Collier, Yevgeniy R. Semenov, Jong Ho Park, Shadmehr Demehri
  Nature Communications.2025;[Epub]     CrossRef
• Natural active botanical metabolites: targeting AMPK signaling pathway to treat metabolic dysfunction-associated fatty liver disease
  Hualing Wang, Xinyu Liu, Chunyi Wang, Shishuang Yu, Xiuli Yang, Xiyu Cao, Maocai Luo, Shiwei Liu, Chuantao Zhang
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• The Role of Chinese Medicine in the Treatment of Chronic Hepatitis B
  Shihao Zheng, Qiuyue Wang, Wenying Qi, Jinchi Xie, Xiaobin Zao, Xiaoke Li, Peng Zhang, Yongan Ye
  The American Journal of Chinese Medicine.2025; 53(05): 1285.     CrossRef
• Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B
  Tyng‐Yuan Jang, Chih‐Wen Wang, Po‐Cheng Liang, Yu‐Ju Wei, Ming‐Lun Yeh, Yi‐Hung Lin, Chao‐Kuan Huang, Pei‐Chien Tsai, Yu‐Min Ko, Yi‐Shan Tsai, Kuan‐Yu Chen, Ching‐Chih Lin, Zu‐Yau Lin, Jee‐Fu Huang, Chia‐Yen Dai, Chung‐Feng Huang, Wan‐Long Chuang, Ming‐Lu
  Journal of Gastroenterology and Hepatology.2025; 40(9): 2290.     CrossRef
• Association between dietary inflammatory index and hepatic steatosis: cross-sectional evidence from the NHANES 2007–2020
  Zhounan Wu, Yuhang Liang, Li Zeng, Jiayi Fang, Jinshen He
  Journal of Health, Population and Nutrition.2025;[Epub]     CrossRef
• HBV and host metabolic crosstalk: Reprogramming pathways for viral replication and pathogenesis
  YanYing Yan, Zhiqiang Wei, Min Zheng, Mengji Lu, Xueyu Wang
  Virologica Sinica.2025; 40(5): 685.     CrossRef
• Predictive Value of Hepatic Steatosis for Postoperative Recurrence in Hepatitis B-Related Hepatocellular Carcinoma: Development of a Machine Learning-Based Prognostic Model
  Aoyun Hao, Changlei Li, Ruitao Sun, Bin Tan, Guanming Shao, Kun Li, Na Li, Weiyu Hu, Chao Qu, Jingyu Cao
  Journal of Hepatocellular Carcinoma.2025; Volume 12: 2459.     CrossRef
• Identification and Validation of Lipid Metabolism-Related Biomarkers GPD1 and CEBPD in Metabolic Dysfunction-Associated Steatohepatitis
  Jianyu Zhou, Chunying Xiao, Bin Huang, Fenfang Chen
  Journal of Inflammation Research.2025; Volume 18: 14805.     CrossRef
• Knowledge, attitudes, and practices toward fatty liver disease in patients with hepatitis B combined fatty liver disease
  Qian Li, Yongping Qiu, Lang Xiao, Lijian Ran, Hongli Deng, Xin Lu, Shilian Li, Yan Guo, Maolan Fu, Xuqing Zhang, Jie Xia, Huimin Liu
  Scientific Reports.2025;[Epub]     CrossRef
• Effects of Non-Alcoholic Fatty Liver Disease on Baseline Histology and 96-Week Entecavir Response in Treatment-Naïve Chronic Hepatitis B
  Xiaohui Gu, Weiguang Yang, Yue Hu, Yixin Li, Liwei Zheng, Bei Jiang
  Infection and Drug Resistance.2025; Volume 18: 6817.     CrossRef
• Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study
  Seong Hee Kang, Jimi Choi, Hyung Joon Yim, Young Kul Jung, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
  Cancers.2025; 18(1): 120.     CrossRef
• Usefulness of the Fibrosis‐4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients
  Jun Inoue, Takehiro Akahane, Tomoo Kobayashi, Osamu Kimura, Kosuke Sato, Masashi Ninomiya, Tomoaki Iwata, Satoshi Takai, Norihiro Kisara, Toshihiro Sato, Futoshi Nagasaki, Masahito Miura, Takuya Nakamura, Teruyuki Umetsu, Akitoshi Sano, Mio Tsuruoka, Masa
  Hepatology Research.2024; 54(2): 131.     CrossRef
• The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review
  Shang‐Chin Huang, Jia‐Horng Kao
  The Kaohsiung Journal of Medical Sciences.2024; 40(1): 6.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion
  Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chi-Ling Chen, Shih-Jer Hsu, Chen-Hua Liu, Sih-Han Liao, Chun-Ming Hong, Ting-Yuan Lan, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
  Clinical Gastroenterology and Hepatology.2024; 22(3): 581.     CrossRef
• Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality
  Sung Won Lee, Daniel Q. Huang, Ricki Bettencourt, Veeral Ajmera, Monica Tincopa, Nabil Noureddin, Maral Amangurbanova, Harris Siddiqi, Egbert Madamba, Abdul M. Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Masato Yoneda, Ramzan I
  Alimentary Pharmacology & Therapeutics.2024; 59(1): 80.     CrossRef
• Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case–control study and serological comparison
  Zheng Lin, Yue-yi Shi, Lu-yan Yu, Chen-xi Ma, Si-yi Pan, Yuan Dou, Qiu-jun Zhou, Yi Cao
  Frontiers in Medicine.2024;[Epub]     CrossRef
• The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area
  Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu
  Journal of Gastroenterology and Hepatology.2024; 39(1): 193.     CrossRef
• High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare
  Ta-Jen Wang, Mei-Yen Chen, Yu-Chih Lin, Wen-Nan Chiu, Tung-Jung Huang, Hsu-Huei Weng
  BMC Public Health.2024;[Epub]     CrossRef
• Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC
  Mei-Hsuan Lee, Yi-Ting Chen, Yu-Han Huang, Sheng-Nan Lu, Tsai-Hsuan Yang, Jee-Fu Huang, Szu-Ching Yin, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu, Hwai-I Yang, Hsuan-Yu Chen, Chien-Jen Chen
  Clinical Gastroenterology and Hepatology.2024; 22(6): 1275.     CrossRef
• Reply
  Shang-Chin Huang, Tung-Hung Su, Jia-Horng Kao
  Clinical Gastroenterology and Hepatology.2024; 22(9): 1957.     CrossRef
• Current perspectives of viral hepatitis
  Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
  World Journal of Gastroenterology.2024; 30(18): 2402.     CrossRef
• Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma
  Xin Cai, Shi Peng, Xuan Xiao, Zhaoyang Huang, Pingan Zhang
  Scientific Reports.2024;[Epub]     CrossRef
• The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
  María Hernández‐Pérez, Daniel Riado, Eva Pena, Carmen Méndez, Fernando Pinedo, Paloma Ramos, Pilar Castillo, Miriam Romero, Conrado Fernández‐Rodríguez, Antonio Olveira
  Alimentary Pharmacology & Therapeutics.2024; 60(5): 613.     CrossRef
• Hepatitis B surface antigen loss in chronic hepatitis B patients with low‐viral‐load
  Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai
  Journal of Gastroenterology and Hepatology.2024; 39(11): 2327.     CrossRef
• Response to the letter of HEPI-D-24–00252
  Shang-Chin Huang, Tung-Hung Su, Jia-Horng Kao
  Hepatology International.2024; 18(4): 1340.     CrossRef
• Functional cure of chronic hepatitis B encounters resmetirom
  Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng
  Clinical and Molecular Hepatology.2024; 30(3): 580.     CrossRef
• Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation
  Jun Wang, Hongzhou Lu, Qian Li
  Frontiers in Immunology.2024;[Epub]     CrossRef
• Outcome of bariatric surgery in patients with unexpected liver cirrhosis: A multicenter study from China
  Xia Sun, Libin Yao, Xing Kang, Weihua Yu, Fidele Kakule Kitaghenda, Mohammad Sajjad Ibn Rashid, Angeline Nogue Taguemkam, Jian Hong, Zhiyong Dong, Xitai Sun, Xiaocheng Zhu
  Liver Research.2024; 8(3): 172.     CrossRef
• Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
  Lung-Yi Mak
  Journal of Liver Cancer.2024; 24(2): 145.     CrossRef
• Comparison of Non-invasive Biochemical Fibrosis Markers According to Obesity-Based Metabolic Profile in Chronic Liver Disease with Chronic Hepatitis B Etiology
  Sedat Çiftel
  Ağrı Tıp Fakültesi Dergisi.2024; 2(3): 113.     CrossRef
• Effect of dyslipidemia on HBsAg clearance in nucleos(t)ide analogues-experienced chronic hepatitis B patients treated with peginterferon alfa
  Kaimin Song, Lan Ren, Yunyun Qian, Huitong Wang, Zhixiang Guo, Huatang Zhang, Yijie Lin, Yijuan Zheng, Dawu Zeng, Yongjun Zhou, Zhijun Su, Xueping Yu
  BMC Infectious Diseases.2024;[Epub]     CrossRef
• Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B
  Qingyan Kong, Qianqian Gao, Wenjie Li, Zheyu Chen
  Asian Journal of Surgery.2024; 47(11): 4725.     CrossRef
• Retrospective cohort evaluation study in terms of cardiovascular and metabolic diseases in chronic hepatitis B patients
  Aysun Yakut
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review
  Sanjay Bandyopadhyay, Shambo Samrat Samajdar, Sirshendu Chaudhuri, Saibal Das
  Hospital Practice.2024; 52(4-5): 123.     CrossRef
• Impact of concurrent MASLD on early-stage HCC following curative resection in chronic hepatitis B
  Cao-Ngoc Huynh
  American Journal of Cancer Research.2024; 14(9): 4567.     CrossRef
• Obesity and risk for liver disease: a two-sample Mendelian randomisation study
  Wen An, Jing Luo, Zhe Yu, Mengqi Li, Herui Wei, Aqian Song, Yuanpeng Mao, Hao Bian, Lingling He, Fan Xiao, Hongshan Wei
  British Journal of Nutrition.2024; 132(10): 1403.     CrossRef
• Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
  Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao
  Scientific Reports.2024;[Epub]     CrossRef
• Revolutionizing the understanding of liver disease: Metabolism, function and future
  Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez
  World Journal of Hepatology.2024; 16(12): 1365.     CrossRef
• Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
  Eileen Laurel Yoon, Dae Won Jun
  Clinical and Molecular Hepatology.2023; 29(2): 371.     CrossRef
• Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B
  Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chi-Ling Chen, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Ting-Yuan Lan, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
  Hepatology International.2023; 17(5): 1139.     CrossRef
• Reply to: ‘A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?’
  Hyun Yang, Ji Hoon Kim, Ji Won Han, Soon Kyu Lee, Jeong Won Jang
  Journal of Hepatology.2023; 79(4): e155.     CrossRef
• Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients
  Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Xuehong Zhang, Sang Hoon Ahn
  International Journal of Cancer.2023; 153(8): 1448.     CrossRef

Citations

Citations to this article as recorded by  

• Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
  Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi
  Saudi Journal of Gastroenterology.2026; 32(2): 104.     CrossRef
• Deep learning-enhanced quantitative evaluation of hepatic ischemia–reperfusion injury and steatosis via near-infrared hyperspectral imaging
  Zichen Wang, Zhan Qu, Chen Chen, Jian Du, Jian Zhang, Tao Li, Jianhua Shi, Chun Zhang, Jianwen Lu, Min Tian, Lu Lu, Boyan Tian, Zhen Zhao, Fan Mu, Lexuan Xu, Xin Zhang, Yimeng Wang, Cuiping Yao, Hao Sun, Yi Lyu, Bo Wang, Liangshuo Hu
  International Journal of Surgery.2026; 112(5): 11274.     CrossRef
• Rehabilitation challenges and enablers for exercise in post-liver transplant patients with metabolic syndrome: a qualitative study
  Mingyan Shen, Zuxin Shi, Yanping Shen, Pengxia Wan, Xiaoxiao Zhu
  BMC Nursing.2026;[Epub]     CrossRef
• Effectiveness of nutrition education program and omega-3 supplementation on body weight, liver enzyme, lipid profile among non-alcoholic fatty liver disease patients
  Dilkhosh Shamal Ramadhan, Ibrahim Hasan Mustafa
  BMC Nutrition.2026;[Epub]     CrossRef
• Liver transplantation in Japan: Achievements, limitations, and future perspectives
  Yasuhiko Sugawara
  BioScience Trends.2026;[Epub]     CrossRef
• Engineering Immunoregenerative Therapy via an Immunomodulatory Binary Pharmacology Hydrogel Depot for Prolonged Allograft Survival
  Ning Wang, Ruiqi Sun, Yang Fu, Zhonghan Wu, Xinyu Tong, Hong Tang, Wentao Zhao, Zhi Liang, Jintao Zheng, Yanan Guan, Ke Zhou, Penghong Song, Shusen Zheng, Hangxiang Wang, Haiyang Xie
  Advanced Science.2026;[Epub]     CrossRef
• Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019
  Jacob Romano, Jessica Burnside, Giada Sebastiani, Alnoor Ramji, Keyur Patel, Mark Swain, Sahar Saeed
  Annals of Hepatology.2025; 30(1): 101757.     CrossRef
• Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease—the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression
  Sinéad M Mullin, Aidan J Kelly, Méabh B Ní Chathail, Suzanne Norris, Christopher E Shannon, Helen M Roche
  Advances in Nutrition.2025; 16(3): 100375.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
  Vlad Alexandru Ionescu, Gina Gheorghe, Nicolae Bacalbasa, Camelia Cristina Diaconu
  Biomolecules.2025; 15(2): 163.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease correlates with higher lower graft survival in liver transplant recipients with hepatocellular carcinoma
  Marwan Alsaqa, Leandro Sierra, Ana Marenco-Flores, Ximena Parraga, Romelia Barba, Daniela Goyes, N. Begum Ozturk, Michael P. Curry, Alan Bonder, Behnam Saberi
  European Journal of Gastroenterology & Hepatology.2025; 37(4): 497.     CrossRef
• Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study
  Javier Díaz Carnicero, Inma Saurí-Ferrer, Josep Redon, Jorge Navarro, Gonzalo Fernández, Carlos Hurtado, Karine Ferreira, Carolina Alvarez-Ortega, Antón Gómez, Carlos J. Martos-Rodríguez, David Martí-Aguado, Desamparados Escudero, Marta Cedenilla
  Journal of Clinical Medicine.2025; 14(7): 2441.     CrossRef
• MASLD or MAFLD: fatty liver by any name will pose the same challenge
  Anil Chandra Anand, Dibyalochan Praharaj
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Cardiac Remodeling and Arrhythmic Burden in Pre-Transplant Cirrhotic Patients: Pathophysiological Mechanisms and Management Strategies
  Charilila-Loukia Ververeli, Yannis Dimitroglou, Stergios Soulaidopoulos, Evangelos Cholongitas, Constantina Aggeli, Konstantinos Tsioufis, Dimitris Tousoulis
  Biomedicines.2025; 13(4): 812.     CrossRef
• Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
  Soon Kyu Lee, Jong Young Choi
  Clinical and Molecular Hepatology.2025; 31(2): e212.     CrossRef
• Risk Factors Related to the Development of Nonalcoholic Fatty Liver: A Systematic Review
  Omaira Valencia, Carolina López, Esteban Vanegas-Duarte, Carolina Fillizola, Diana Fernanda Bejarano Ramírez, Nicolás Andrés Cortés Mejía, Alonso Vera Torres, Kevork M. Peltekian
  Canadian Journal of Gastroenterology and Hepatology.2025;[Epub]     CrossRef
• Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidates
  Carme Ginard, Giulia Pagano, Salvatore Brugaletta, Annabel Blasi, Marta Sánchez-Ric, Ander Regueiro, Roger Pujol, Sergio Rodriguez-Tajes, Pablo Ruiz, Jordi Colmenero, Gonzalo Crespo
  JHEP Reports.2025; 7(7): 101428.     CrossRef
• The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort
  Qi Feng, Chioma N Izzi-Engbeaya, Andrea D Branch, Benjamin H Mullish, Pinelopi Manousou, Mark Woodward
  The Journal of Clinical Endocrinology & Metabolism.2025; 111(1): e58.     CrossRef
• MAFLD as a Cardiovascular Risk Factor: An Extended Retrospective Study with a Control Group
  Małgorzata Szymala-Pędzik, Marcin Piersiak, Maciej Pachana, Karolina Lindner-Pawłowicz, Wioletta Szczepaniak, Małgorzata Sobieszczańska
  Journal of Clinical Medicine.2025; 14(12): 4181.     CrossRef
• Metabolic-associated fatty liver disease: Noninvasive diagnosis and assessment of liver fibrosis
  O. O. Karshina, I. S. Sabirov
  Meditsinskiy sovet = Medical Council.2025; (8): 72.     CrossRef
• Are we standing on the shifting sands of post-transplant metabolic-associated steatotic liver disease?
  Renata Zatta, Luana S da Silva, Guilherme Felga, Carolina FMG Pimentel
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
  Marika Hancock, Cayden Beyer, Michael Fuchs, Mukesh Harisinghani, Prasun Jalal, Michael Ndaa, Niharika Samala, Jose D. Vargas, Arjun Jayaswal
  Journal of Medical Economics.2025; 28(1): 1370.     CrossRef
• Integrated Genomic Analysis Reveals the Synergistic Role of PNPLA3 and ABCC8 Variants in Diabetic MASLD in Pakistan
  Asma Shabbir, Ambrina Khatoon, Zaigham Abbas, Sucheta Srivastava, Talat Mirza
  Medical Sciences.2025; 13(3): 178.     CrossRef
• Sex-Stratified Prediction Models for 5-Year Nonalcoholic Fatty Liver Disease Risk in Thyroid Cancer Patients: A Nationwide Cohort Study
  Young Bin Cho, Kyoung Sik Park
  Biomedicines.2025; 13(9): 2250.     CrossRef
• Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention
  Leonardo Leal-Mercado, Arturo Panduro, Alexis José-Abrego, Sonia Roman
  International Journal of Molecular Sciences.2025; 26(18): 8977.     CrossRef
• Validation of MELD 3.0 and ReMELD-Na scoring systems: a German clinical cohort study
  Aghnia J. Putri, Decan Jiang, Zoltan Czigany, Arianeb Mehrabi, Markus Wolfgang Buechler, Uta Merle, Christoph Michalski, Peri Husen
  Langenbeck's Archives of Surgery.2025;[Epub]     CrossRef
• A Multi-Modal Deep Fusion Network: Enhancing Graft Survival Prediction in Non-Alcoholic Fatty Liver Disease Patients Prior to Liver Transplantation
  Devi Rajeev, S Remya, Anand Nayyar
  IEEE MultiMedia.2025; 32(4): 68.     CrossRef
• Investigating the Effect of Two Types of Aerobic Exercise on SIRT1 and AMPK Gene Expression Regulation in an Animal Model of Non-Alcoholic Fatty Liver Disease
  Masoumeh Sadat Foroughi Rahaghi, Lida Moradi, Bahram Abedi, Mohammad Ali Azarbaijani
  Journal of Shahrekord University of Medical Sciences.2025; 27(4): 192.     CrossRef
• How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey
  Jeannette Widmer, Janina Eden, Fariba Abbassi, Roberta Angelico, Fabian Rössler, Beat Müllhaupt, Philipp Dutkowski, Marco Bueter, Andrea Schlegel
  Liver International.2024; 44(2): 566.     CrossRef
• Exploring the effects of epigallocatechin gallate on lipid metabolism in the rat steatotic liver during normothermic machine perfusion: Insights from lipidomics and RNA sequencing
  Shuxuan Li, Yao Zhi, Wentao Mu, Mingqian Li, Guoyue Lv
  European Journal of Pharmacology.2024; 964: 176300.     CrossRef
• Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
  Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo
  Biomedicines.2024; 12(2): 397.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
  Arghya Samanta, Moinak Sen Sarma
  World Journal of Hepatology.2024; 16(4): 511.     CrossRef
• Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
  David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, Nathalie Sturm, Hélène Borges, Salomé Biennier, Marie Courçon, Marc de Saint Loup, Victoria Mignot, Charlotte Costentin, Thomas Burger, Yohann Couté, Christophe Bru
  Biomarker Research.2024;[Epub]     CrossRef
• Cardiac abnormalities pre- and post-liver transplantation for metabolic dysfunction-associated steatohepatitis – Evidence and special considerations
  Steven M. Elzein, Elizabeth W. Brombosz, Sudha Kodali
  Journal of Liver Transplantation.2024; 15: 100228.     CrossRef
• Serum Creatinine as an Independent Predictor of Moderate to Severe Fibrosis in Chinese American Non-obese Metabolic Dysfunction-Associated Steatotic Liver Disease
  Michael Sun, Vincent J Yao, Aivi A Rahman, Kevin Liu, Saud Rehman, Amber Sun, Alan C Yao
  Cureus.2024;[Epub]     CrossRef
• Recent trends and new developments in liver transplantation
  Yasuhiko Sugawara, Taizo Hibi
  BioScience Trends.2024; 18(3): 206.     CrossRef
• Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice
  Guanliang Chen, Yanwen Yu, Yuqin Zhu, Mayumi Nagashimada, Yajiao Wang, Naoto Nagata, Liang Xu
  Endocrinology.2024;[Epub]     CrossRef
• Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
  Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan
  Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
• The interrelation of cardiometabolic risk factors and metabolic dysfunction-associated steatotic liver disease subtypes
  A. Yu. Ishchenko, M. Yu. Galushko, I. G. Bakulin
  Meditsinskiy sovet = Medical Council.2024; (15): 146.     CrossRef
• Cardio-metabolic disorders in a patient with non-alcoholic fatty liver disease and normal body weight
  Svetlana V. Turkina, Mikhail E. Statsenko, Irina A. Tyshchenko, Marina N. Titarenko, Marina A. Kosivtsova, Elena E. Gorbacheva
  Journal of Volgograd State Medical University.2024; 21(3): 109.     CrossRef
• Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire
  Samah Al Tawil, Mohamad Abdelkhalik, Adam El Fouani, Nour Allakiss, Lama Mattar, Wissam H. Faour, Rajaa Chatila
  Heliyon.2024; 10(22): e40217.     CrossRef
• Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study
  José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente
  Nutrients.2024; 16(22): 3857.     CrossRef
• Liver transplantation for alcohol-related liver disease in Korea: The need for patient management guidelines
  Soon Kyu Lee
  Annals of Liver Transplantation.2024; 4(2): 40.     CrossRef
• Post-transplant complications in alcohol- and metabolic-associated steatotic liver disease
  Shekhar Singh Jadaun, Sanjiv Saigal
  Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
• How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
  Byeong Geun Song, Dong Hyun Sinn
  Clinical and Molecular Hepatology.2023; 29(2): 411.     CrossRef
• Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
  Qingfu Dong, Haolin Bao, Jiangang Wang, Wujiang Shi, Xinlei Zou, Jialin Sheng, Jianjun Gao, Canghai Guan, Haoming Xia, Jinglin Li, Pengcheng Kang, Yi Xu, Yunfu Cui, Xiangyu Zhong
  Frontiers in Medicine.2023;[Epub]     CrossRef
• Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patients
  Simone Di Cola, Giulia Cusi, Lucia Lapenna, Jakub Gazda, Stefano Fonte, Marco Mattana, Gianluca Mennini, Patrizio Pasqualetti, Manuela Merli, Xingshun Qi
  Canadian Journal of Gastroenterology and Hepatology.2023; 2023: 1.     CrossRef
• Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases
  Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, María José Domper-Arnal, Sandra García-Mateo, Alberto Lué
  Nutrients.2023; 15(15): 3487.     CrossRef
• New Developments and Challenges in Liver Transplantation
  Amjad Khalil, Alberto Quaglia, Pierre Gélat, Nader Saffari, Hassan Rashidi, Brian Davidson
  Journal of Clinical Medicine.2023; 12(17): 5586.     CrossRef
• Outcomes in elderly patients undergoing hepatic resection compared to liver transplant for hepatocellular carcinoma
  Sameer A. Khan, Fasih A. Ahmed, Muhammad S. Hafeez, Lawrence R. Feng, Abhinav Seth, Yong K. Kwon, Hassan Aziz
  Journal of Surgical Oncology.2023; 128(8): 1320.     CrossRef